

Profiles
June 11, 2015

Ross J. Baldessarini, M.D.

P U B L I C A T I O N S

(Total = 2,194, including 1018 Abstracts & Brief Reports)

ORIGINAL REPORTS in JOURNALS

1. Baldessarini RJ, Kopin IJ: Assay of tissue levels of *S*-adenosyl-L-methionine. *Analyt.Biochem* 1963; 6: 289–292.
2. Baldessarini RJ, Carbone PP: Adenosylmethionine elevation in leukemic white blood cells. *Science* 1965; 149: 644–645.
3. Baldessarini, RJ, Snyder, SH: Schizophrenia: a critique of recent genetic-biochemical formulations. *Nature* 1965; 206: 1111–1112.
4. Park LC, Baldessarini RJ, Kety SS: Methionine effects on chronic schizophrenics. *Arch Gen Psychiatry* 1965; 12: 346–351.
5. Baldessarini RJ: *S*-adenosyl-L-methionine. *Biochem Pharmacol* 1966; 15: 741–748.
6. Baldessarini RJ, Bell W: Methionine activating enzyme and catechol-O-methyltransferase activity in normal and leukemic white blood cells. *Nature* 1966; 209: 78–79.
7. Baldessarini RJ, Kopin IJ: *S*-adenosyl-L-methionine in brain and other tissues. *J Neurochem* 1966; 13: 769–777.
8. Baldessarini R J, Kopin IJ: Tritiated norepinephrine: Release from brain slices by electrical stimulation. *Science* 1966; 152: 1630–1631.
9. Snyder SH, Baldessarini RJ, Axelrod J: A sensitive and specific enzymatic isotopic assay for tissue histamine. *J Pharmacol Exptl Ther* 1966; 153: 544–549.
10. Baldessarini RJ, Fischer JE: *S*-adenosyl-L-methionine in the liver following portacaval anastomosis. *Surgery* 1967; 62: 311–318.
11. Baldessarini RJ, Kopin IJ: The effect of drugs on the release of [³H]-norepinephrine from central nervous system tissues by electrical stimulation in vitro. *J Pharmacol Exptl Ther* 1967; 156: 31–38.
12. Baldessarini RJ, Willmuth RL: Psychotic reactions during amitriptyline therapy. *Can Psychiatr Assoc J* 1968; 13: 571–573.
13. Baldessarini RJ: Frequency of diagnoses of schizophrenia vs. affective psychoses from 1944 to 1968. *Am J Psychiatry* 1970; 127: 759–763.
14. Baldessarini RJ, Stephens J: Lithium carbonate for affective disorder: Clinical pharmacology and toxicology. *Arch Gen Psychiatry* 1970; 22: 72–77.
15. Baldessarini, RJ, Yorke C: Effects of lithium and of pH on synaptosomal metabolism of noradrenaline. *Nature* 1970; 228: 1301–1303.
16. Wurtman R, Rose C, Matthyse S, Stephenson J, Baldessarini RJ: L-DOPA: Effect on *S*-adenosyl-L-methionine in brain. *Science* 1970; 169: 395–396.
17. Baldessarini RJ: Compounds antagonistic to norepinephrine retention by rat brain homogenates. *Biochem Pharmacol* 1971; 20: 1769–1780.
18. Baldessarini RJ: Release of aromatic amines from brain tissues of the rat in vitro. *J Neurochem* 1971; 18: 2509–2518.
19. Baldessarini RJ, Vogt M: Uptake and release of norepinephrine by rat brain tissue fractions prepared by ultrafiltration. *J Neurochem* 1971; 18: 951–962.
20. Baldessarini RJ, Vogt M: The uptake and subcellular distribution of aromatic amines in the brain of the rat. *J Neurochem* 1971; 18: 2519–2533.
21. Chalmers JP, Baldessarini RJ, Wurtman RJ: Effects of L-DOPA on norepinephrine metabolism in the brain. *Proc Natl Acad Sci USA* 1971; 68: 662–666.

22. Fischer JE, Baldessarini RJ: False neurotransmitters and hepatic failure. *Lancet* 1971; 2: 75–80.
23. Fischer JE, Baldessarini RJ: Renal changes in hepatic failure. *Lancet* 1971; 2: 769–770.
24. Baldessarini RJ: Inhibition of catechol-O-methyl transferase by L-DOPA and decarboxylase inhibitors. *J Pharm Pharmacol* 1972; 24: 78–80.
25. Baldessarini RJ: Interactions of drugs and amines in the brain. *N Engl J Med* 1972; 286: 542–543.
26. Baldessarini RJ, Chace KV: Metabolism of L-DOPA after inhibition of catechol-O-methyl transferase. *Eur J Pharmacol* 1972; 17: 163–166.
27. Baldessarini RJ, Karobath M: Effects of L-DOPA and L-3-O-methyl-DOPA on uptake of [³H]-L-methionine by synaptosomes. *Neuropharmacology* 1972; 11: 715–720.
28. Baldessarini RJ, Lipinski JF, Chace KV: Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. *Biochem Pharmacol* 1972; 21: 77–87.
29. Baldessarini RJ, Vogt M: Regional release of aromatic amines from tissues of the rat brain in vitro. *J Neurochem* 1972; 19: 755–761.
30. Fischer JE, James JH, Baldessarini RJ: Changes in brain amines following portal flow diversion and acute hepatic coma: Effects of levodopa (L-DOPA) *Surg Forum* 1972; 23: 348–350.
31. Fischer JE, Snyder SH, James JH, Baldessarini RJ: Histamine and serotonin metabolism following massive small bowel resection. *Ann Surgery* 1972; 175: 260–267.
32. Karobath M, Baldessarini RJ: Formation of catechol compounds from phenylalanine and tyrosine with isolated nerve endings. *Nature* 1972; 36: 206–208.
33. Matthysse S, Baldessarini RJ: S-adenosyl-L-methionine and catechol-O-methyl transferase in schizophrenia. *Am J Psychiatry* 1972; 128: 1310–1312.
34. Baldessarini RJ, Fischer JE: Serotonin metabolism of rat brain after surgical diversion of the portal venous circulation. *Nature–New Biology* 1973; 245: 25–27.
35. Baldessarini RJ, Gerson S: Effects of 5,6-dihydroxytryptamine on the metabolism of 5-hydroxytryptamine in the central nervous system of the rat. *J Pharm Pharmacol* 1973; 25: 647–648.
36. Baldessarini RJ, Greiner E: Inhibition of catechol-O-methyl transferase by catechols and polyphenols. *Biochem Pharmacol* 1973; 22: 247–256.
37. Ebert M, Baldessarini RJ, Lipinski JF, Berv K: Effects of electroconvulsive seizures on amine metabolism in the rat brain. *Arch Gen Psychiatry* 1973; 29: 387–401.
38. Harris JE, Baldessarini RJ: Amphetamine-induced inhibition of tyrosine hydroxylation in homogenates of rat corpus striatum. *J Pharm Pharmacol* 1973; 25: 755–757.
39. Harris JE, Baldessarini RJ: Uptake of [³H]catecholamines by homogenates of rat corpus striatum and cerebral cortex: Effects of amphetamine analogues. *Neuropharmacology* 1973; 12: 669–679.
40. Harris JE, Baldessarini RJ: The uptake of [³H]-dopamine by homogenates of rat corpus striatum: Effects of cations. *Life Sciences* 1973; 13: 303–312.
41. Lipinski JF, Schaumburg HH, Baldessarini RJ: Regional distribution of histamine in human brain. *Brain Research* 1973; 52: 403–408.
42. Tarsy D, Baldessarini RJ: Pharmacologically induced behavioural supersensitivity to apomorphine. *Nature* 1973; 245: 262–263.
43. Baldessarini RJ: Tardive dyskinesia: An evaluation of the etiological association with neuroleptic therapy. *Can Psychiatr Assoc J* 1974; 19: 551–554.
44. Baldessarini RJ, Harris JE: Effects of amphetamines on the metabolism of catecholamines in the rat brain. *J Psychiatr Research* 1974; 11: 41–43.
45. Baldessarini RJ, Yorke C: Uptake and release of possible false transmitter amino acids by rat brain tissue. *J Neurochem* 1974; 23: 839–848.
46. Gerson S, Baldessarini RJ: Nonspecific actions of dihydroxylated tryptamines in the central nervous system of the rat. *J Pharm Pharmacol* 1974; 26: 71–73.
47. Gerson S, Baldessarini RJ, Wheeler SC: Biochemical effects of dihydroxytryptamines on the central indoleamine neurons. *Neuropharmacology* 1974; 13: 987–1004.
48. Harris JE, Morgenroth VH III, Roth RH, Baldessarini RJ: Regulation of catecholamine synthesis in the rat brain in vitro by cyclic-AMP. *Nature* 1974; 252: 156–158, 1974.
49. Jacobson G, Baldessarini RJ, Manschreck TC: Tardive and withdrawal dyskinesia associated with haloperidol. *Am J Psychiatry* 1974; 131: 910–912.

50. Quinn J, Baldessarini RJ: Literary technique and psychological effect in Hawthorne's "The Minister's Black Veil." *Lit Psychology* 1974; 24: 115–123.
51. Tarsy D, Baldessarini RJ: Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. *Neuropharmacology* 1974; 13: 927–940.
52. Baldessarini RJ: Biological transmethylation involving *S*-adenosylmethionine: Development of assay methods and implications for neuropsychiatry. *Intl Rev Neurobiology* 1975; 18: 41–67.
53. Baldessarini RJ, Amatruda T III, Griffith FF, Gerson SC: Differential effects of serotonin on turning and stereotypy induced by apomorphine. *Brain Research* 1975; 93: 158–163.
54. Baldessarini RJ, Walton KG, Borgman RJ: Esters of apomorphine and *N,N*-dimethyldopamine as agonists of dopamine receptors in the rat brain in vivo. *Neuropharmacology* 1975; 14: 725–731.
55. Fischer JE, Baldessarini RJ: Neurotransmitter metabolism in hepatic encephalopathy. *N Engl J Med* 1975; 293: 1152–1153.
56. Gerson S, Baldessarini RJ: Selective destruction of serotonin terminals in rat forebrain by high doses of 5,7-dihydroxytryptamine. *Brain Research* 1975; 85: 140–145.
57. Granacher RP Jr, Baldessarini RJ: Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. *Arch Gen Psychiatry* 1975; 32: 375–380.
58. Granacher RP Jr, Baldessarini RJ, Cole JO: Cholinergic mechanisms in tardive dyskinesia. *N Engl J Med* 1975; 292: 926–927.
59. Harris JE, Baldessarini RJ, Morgenroth VH III, Roth, RH: Activation by cyclic 3',5'-adenosine monophosphate of tyrosine hydroxylase in the rat brain. *Proc Natl Acad Sci USA* 1975; 72: 789–793.
60. Harris JE, Baldessarini RJ, Roth RH: Amphetamine-induced inhibition of tyrosine hydroxylation in homogenates of rat corpus striatum. *Neuropharmacology* 1975; 14: 457–471.
61. Baldessarini RJ, Griffith F: Acute increases by *p*-chlorophenylalanine of apomorphine-induced stereotyped behavior in the rat. *Psychopharmacology* 1976; 48: 91–95.
62. Baldessarini RJ, Walton KG, Borgman RJ: Prolonged apomorphine-like behavioral effects of apomorphine esters. *Neuropharmacology* 1976; 15: 471–478.
63. Borgman RJ, Baldessarini RJ, Walton KG: Diester derivatives as apomorphine prodrugs. *J Med Chem* 1976; 19: 717–719.
64. Harris JE, Karobath M, Baldessarini RJ: Characteristics of tyrosine hydroxylation in isolated nerve endings. *Biochem Pharmacol* 1976; 25: 91–93.
65. Stewart RM, Growdon JH, Cancian D, Baldessarini RJ: 5-Hydroxytryptophan-induced myoclonus: increased sensitivity to serotonin after intracranial 5,7-dihydroxytryptamine in the adult rat. *Neuropharmacology* 1976; 15: 449–455.
66. Stewart RM, Growdon JH, Cancian D, Baldessarini RJ: Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system. *Neurology* 1976; 26: 690–692.
67. Stewart RM, Martuza RL, Baldessarini RJ, Kornblith PL: Glutamate accumulation by human gliomas and meningiomas in tissue culture. *Brain Research* 1976; 118: 441–452.
68. Walton KG, Baldessarini RJ: Effects of Mn^{2+} and other divalent cations on adenylate cyclase activity in rat brain. *J Neurochem* 1976; 27: 557–564.
69. Baldessarini RJ, Fischer JE: Substitute and alternative neurotransmitters in neuropsychiatric illness. *Arch Gen Psychiatry* 1977; 34: 958–964.
70. Baldessarini RJ, Kula NS, Walton KG, Borgman RJ: Behavioral effects of apomorphine and di-isobutyrylapomorphine in the mouse. *Psychopharmacology* 1977; 53: 45–53.
71. Baldessarini RJ, Kula NS, Walton KG: Hydrolysis of diester prodrugs of apomorphine. *Biochem Pharmacol* 1977; 26: 1749–1756.
72. Ducomb L, Baldessarini RJ: Timing and risk of bone marrow depression by psychotropic drugs. *Am J Psychiatry* 1977; 134: 1294–1295.
73. Fischer JE, Baldessarini RJ: Biochemistry of hepatic coma, in *Proc Intl Conf. on Hepatic Coma*, Munich, Germany, November, 1974, Janssen Symposien Series, Janssen GmbH, Dusseldorf, 1977, pp 180–225.
74. Groshong R, Gibson DA, Baldessarini RJ: Monoamine oxidase activity in cultured human skin fibroblasts. *Clin Chim Acta* 1977; 80: 113–120.
75. Sperk G, Baldessarini RJ: Stabilizing effect of sucrose on leakage of cytoplasm from rat brain synaptosomes in saline media. *J Neurochem* 1977; 28: 1403–1405.
76. Baldessarini RJ, Fischer JE: Trace amines and alternative neurotransmitters in the central nervous system. *Biochem Pharmacol* 1978; 27: 621–626.

77. Baldessarini RJ, Lipinski JF: Monoamine oxidase in schizophrenia. *N Engl J Med* 1978; 298: 1150–1151.
78. Groshong R, Baldessarini RJ, Gibson DA, Lipinski JF, Axelrod D, Pope HA Jr: Activities of types A and B MAO and catechol-O-methyl transferase in blood cells and skin fibroblasts of normal and chronic schizophrenic subjects. *Arch Gen Psychiatry* 1978; 35: 1198–1205.
79. Noon JP, Rice, PJ, Baldessarini RJ: Calcium leakage as a cause of the high resting tension in vascular smooth muscle from the spontaneously hypertensive rat. *Proc Natl Acad Sci USA* 1978; 75: 1605–1607.
80. Sperk G, Stewart RM, Campbell A, Baldessarini RJ: Inhibition of 5,7-dihydroxytryptamine induced supersensitivity to 5-hydroxytryptophan in mice by treatment with cycloheximide. *Brain Research* 1978; 159: 183–194.
81. Stramentinoli G, Baldessarini RJ: Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung in vivo by methionine or S-adenosyl-L-methionine. *J Neurochem* 1978; 31: 1015–1020.
82. Walton KG, Liepmann P, Baldessarini RJ: Inhibition of dopamine-stimulated adenylate cyclase activity by phenoxybenzamine. *Eur J Pharmacol* 1978; 52: 231–234.
83. Warbritton JD III, Stewart RM, Baldessarini RJ: Decreased locomotor activity and attenuation of amphetamine hyperactivity with intraventricular infusion of serotonin in the rat. *Brain Research* 1978; 143: 373–382.
84. Baldessarini RJ: Therapy and genetic counseling in schizophrenia. *N Engl J Med* 1979; 298: 345–346.
85. Baldessarini RJ, Boyd AE III, Kula NS, Borgman RJ: Prolonged decrease of serum prolactin in rat by an ester prodrug of apomorphine. *Psychoneuroendocrinology* 1979; 4: 173–175.
86. Baldessarini RJ, Kula NS, Walton KG: Effects of alternative transmitter amines on cyclic-AMP formation in rat brain tissue. *Eur J Pharmacol* 1979; 56: 167–171.
87. Baldessarini RJ, Stramentinoli G, Lipinski JF: Methylation hypothesis. *Arch. Gen. Psychiatry* 1979; 36: 303–307.
88. Herschel M, Baldessarini RJ: Evidence for two types of binding of [³H]-GABA and [³H]-muscimol in rat cerebral cortex and cerebellum. *Life Sciences* 1979; 24: 1849–1854.
89. Smith RV, Wilcox RE, Soine RH, Riffie WH, Baldessarini RJ, Kula NS: Plasma levels of apomorphine following intravenous intraperitoneal and oral administration to mice and rats. *Res Comm Chem Pathol Pharmacol* 1979; 24: 483–499.
90. Stewart RM, Campbell A, Sperk G, Baldessarini RJ: Receptor mechanisms in increased sensitivity to serotonin agonists after di-hydroxytryptamine shown by electronic monitoring of muscle twitches in the rat. *Psychopharmacology* 1979; 60: 281–289.
91. Walton KG, Miller E, Baldessarini RJ: Prenatal and early postnatal beta-adrenergic receptor-mediated increase of cyclic AMP in slices of rat brain. *Brain Research* 1979; 177: 515–522.
92. Baldessarini RJ, Davis JM: What is the best maintenance dose of neuroleptics in schizophrenia? *Psychiatry Research* 1980; 3: 115–122.
93. Baldessarini RJ, Kula NS, Arana GW, Neumeyer JL, Law S-J: Chloroethylnorapomorphine, a proposed long-acting dopamine antagonist: Interactions with dopamine receptors of mammalian forebrain in vitro. *Eur J Pharmacol* 1980; 67: 105–110.
94. Campbell A, Baldessarini RJ, Kula NS: Oral bioavailability of apomorphine in the rat with a portacaval anastomosis. *Eur J Pharmacol* 1980; 67: 139–142.
95. Campbell A, Herschel M, Cohen BM, Baldessarini RJ: Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. *Life Sciences* 1980; 27: 633–640.
96. Cohen BM, Herschel M, Miller B, Mayberg H, Baldessarini RJ: Radioreceptor assay of haloperidol in the rat. *Neuropharmacology* 1980; 19: 663–668.
98. Gerson SC, Baldessarini RJ: Motor effects of serotonin in the central nervous system. *Life Sciences* 1980; 27: 1435–1451.
99. Majocha R, Baldessarini, RJ: Effects of repeated administration of muscarinic antagonists and agonists on receptor binding of [³H]-quinuclidinyl benzilate. *Eur J Pharmacol* 1980; 67: 327–328.
100. Mandel MR, Madsen J, Miller AL, Baldessarini RJ: Intoxication associated with lithium and ECT. *Am J Psychiatry* 1980; 137: 1107–1109.
101. Neumeyer JL, Law S-J, Baldessarini RJ, Kula NS: Aporphines 30: (–)N-2-chloroethyl-10,11-dihydroxynoraporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist. *J Med Chem* 1980; 23: 594–595.
102. Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with age. *Arch Gen Psychiatry* 1980; 37: 1368–1373.

103. Warbritton JD III, Stewart RM, Baldessarini RJ: Increased sensitivity to intracerebroventricular infusion of serotonin and deaminated indoles after lesioning rat with 5,7-dihydroxytryptamine. *Brain Research* 1980; 183: 355–366.
104. Arana GW, Baldessarini RJ, Harding M: Binding of [³H]-apomorphine: Pharmacology. *Biochem Pharmacol* 1981; 30: 3171–3179.
105. Arana GW, Baldessarini RJ, Herschel M, Fava M: Improved high-affinity binding of [³H]-apomorphine with a subcellular membrane fraction of mammalian brain tissue. *Life Sciences* 1981; 29: 121–133.
106. Baldessarini RJ, Campbell A, Madsen J, Herschel M, Finklestein S, Smith, JM, Majocha R, Arana GW: Chronopsychopharmacology. *Psychopharmacology Bull* 1981; 17: 112–113.
107. Campbell A, Baldessarini RJ: Effects of maturation and aging on behavioral responses to haloperidol in the rat. *Psychopharmacology* 1981; 73: 219–222.
108. Campbell A, Baldessarini RJ: Tolerance of behavioral effects of prolonged administration of haloperidol. *Life Sciences* 1981; 29: 1341–1346.
109. Cohen BM, Baldessarini RJ: Haloperidol levels and clinical response. *Am J Psychiatry* 1981; 138: 1513–1514.
110. Madsen JR., Campbell A, Baldessarini RJ: Effects of prenatal treatment of rats with haloperidol due to altered drug distribution in neonatal brain. *Neuropharmacology* 1981; 20: 931–939.
111. Neumeyer JL, Arana GW, Law S-J, Lamont JS, Kula NS, Baldessarini RJ: Dopamine receptor interactions of trihydroxyaporphines: Synthesis, radioreceptor binding and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines. *J Med Chem* 1981; 24: 1440–1445.
112. Quinn J, Baldessarini RJ: Literary and psychological analysis of Hawthorne's "The Birthmark." *Hartford Studies Literature* 1981; 13: 91–98.
113. Wolfe BB, Augustyn DH, Majocha RB, Dibner MD, Molinoff PB, Baldessarini RJ, Walton KG: Effects of isoproterenol on the development of beta-adrenergic receptors in brain cell aggregates. *Brain Research* 1981; 207: 174–177.
114. Arana GW, Baldessarini RJ, Kula NS: Differential effects of sodium ascorbate and EDTA on high-affinity binding of [³H]-apomorphine and ³H-ADTN to calf caudate membranes. *Neuropharmacology* 1982; 21: 601–604.
115. Baldessarini RJ: Update on the clinical interpretation of the dexamethasone suppression test (DST). *McLean Hospital J* 1982; 7: 99–101.
116. Baldessarini RJ, Neumeyer JL, Campbell A, Sperk G, Ram VJ, Arana GW, Kula NS: An orally effective, long-acting dopaminergic prodrug: R(-)10,11-methylenedioxy-N-n-propylnoraporphine. *Eur J Pharmacol* 1982; 77: 87–88.
117. Campbell A, Baldessarini RJ: Circadian changes in behavioral effects of haloperidol in rat. *Psychopharmacology* 1982; 77: 150–155.
118. Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL: Behavioral effects of (-)10,11-methylenedioxy-N-n-propyl-noraporphine, an orally effective, long-acting agent active at central dopamine receptors, and analogous aporphines. *Neuropharmacology* 1982; 21: 953–961.
119. Campbell A, Herschel M, Madsen JR, Sommer B, Cohen BM, Baldessarini RJ: Circadian changes in the distribution and effects of haloperidol in rat. *Neuropharmacology* 1982; 21: 663–669.
120. Finklestein SP, Benowitz LI, Baldessarini RJ, Arana GW, Levine D, Woo E, Bear D, Moya K, Stoll AL: Mood, vegetative disturbance, and dexamethasone suppression test after stroke. *Ann Neurology* 1982; 12: 463–468.
121. Law S-J, Morgan, JM, Masten LW, Borne RF, Arana GW, Kula NS, Baldessarini RJ: Rigid analogues of dopamine: Synthesis and interactions of 6-exo and 6-endo-3',4'-dihydroxyphenyl-2-azabicyclo-(2.2.2)-octanes with dopamine receptors. *J Med Chem* 1982; 25: 213–216.
122. Neumeyer JL, Arana GW, Ram VJ, Kula NS, Baldessarini RJ: Synthesis, dopamine receptor binding and pharmacological activity of (R)-(-) and (S)-(+)-2-hydroxyapomorphine. *J Med Chem* 1982; 25: 990–992.
123. Sperk G, Campbell A, Baldessarini RJ, Stoll A, Neumeyer JL: Tissue levels of N-n-propylnorapomorphine after treatment with (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally long-acting prodrug active at central dopamine receptors. *Neuropharmacology* 1982; 21: 1311–1316.
124. Akiskal H, Arana GW, Baldessarini RJ, Barreira P: Thymoleptic-responsive atypical paranoid psychoses. *Am J Psychiatry* 1983; 140: 1187–1190.
125. Arana GW, Baldessarini RJ: Dexamethasone suppression test. *J Clin Psychiatry* 1983; 44: 116–117.
126. Arana GW, Baldessarini RJ, Lamont JS, Amlicke D, Neumeyer JL: Pharmacology of high-affinity binding of [³H]-(+)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) to bovine caudate nucleus fractions. *Biochem Pharmacology* 1983; 32: 2873–2880.

127. Arana GW, Baldessarini RJ, Neumeyer JL: Structure-activity characteristics for high-affinity binding at central dopamine receptors. *Acta Pharm Suec* 1983; (Suppl Vol 2): 25-36.
128. Arana GW, Barreira P, Wilens T, Baldessarini RJ, Cohen BM, Lipinski JF: Clinical studies of the dexamethasone suppression test in psychotic illness. *Psychopharmacol Bull* 1983; 19: 630-633.
129. Baldessarini RJ, Finklestein S, Arana GW: The predictive power of diagnostic tests and the effect of prevalence of illness. *Arch Gen Psychiatry* 1983; 40: 569-573.
130. Baldessarini RJ, Finklestein S, Arana GW: Predictive power of diagnostic tests. *Directions in Psychiatry* 1983; 2: 1-7.
131. Baldessarini RJ, Kula NS: Irreversible binding of [³H]-chloroethylnorapomorphine to mammalian brain tissue. *Life Sciences* 1983; 33: 769-778.
132. Finklestein SP, Baldessarini RJ: Mood disorders following brain injury. *Integrative Psychiatry* 1983; 1: 39-40.
133. Finklestein SP, Campbell A, Stoll L, Baldessarini RJ, Stinus L, Paskevich PA, Domesick VB: Changes in cortical and subcortical levels of monoamines and their metabolites following unilateral ventrolateral cortical lesions in the rat. *Brain Research* 1983; 271: 279-288.
134. Neumeyer JL, Arana GW, Ram VJ, Baldessarini RJ: Synthesis and structure-activity relationships of aporphines at central dopamine receptors. *Acta Pharm Suec* 1983; (Suppl Vol. 2): 11-24.
135. Neumeyer JL, Reischig D, Arana GW, Campbell A, Baldessarini RJ, Kula NS, Watling KJ: Aporphines 48. Enantioselectivity of (R)(-) and (S)(+)-N-n-propylnorapomorphine on dopamine receptors. *J Med Chem* 1983; 26: 516-521.
136. Wilens TB, Arana GW, Baldessarini RJ, Cremens C: Comparison of solid-phase radioimmunoassay and a competitive protein binding method for post-dexamethasone cortisol levels in psychiatric patients. *Psychiatry Research* 1983; 8: 199-206.
137. Arana GW, Lamont JS, Baldessarini RJ, Teicher M, Cohen BM: Binding of [³H]apomorphine to an aporphine binding site as well as to dopamine sites in bovine caudate nucleus tissue. *Neuropharmacology* 1984; 23: 885-892.
138. Arana GW, Workman RJ, Baldessarini RJ: Association between low plasma levels of dexamethasone and elevated levels of cortisol in psychiatric patients given dexamethasone. *Am J Psychiatry* 1984; 141: 1619-1620.
139. Baldessarini RJ, Katz B, Cotton P: Dissimilar dosing with high-potency and low-potency neuroleptics. *Am J Psychiatry* 1984; 141: 748-752.
140. Campbell A, Baldessarini RJ, Stoll A, Teicher MH, Maynard P: Effect of age on behavioral responses and tissue levels of apomorphine in rat. *Neuropharmacology* 1984; 23: 725-730.
141. Kula NS, Baldessarini RJ, Campbell A, Finklestein S, Ram, VJ, Neumeyer JL: Effects of N-substituted phenylhydro-pyridines on the uptake of dopamine and other amines in several mammalian species. *Life Sciences* 1984; 34: 2567-2575.
142. Majocha R, Baldessarini RJ: Tolerance to an anticholinergic agent is paralleled by increased binding to muscarinic receptors in rat brain and increased behavioral response to a centrally active cholinomimetic. *Life Sciences* 1984; 35: 2247-2255.
143. Shashoua VE, Jacob JN, Ridge R, Campbell A, Baldessarini RJ: GABA esters 1: Synthesis, brain uptake, and pharmacological studies of γ -aminobutyric acid. *J Med Chem* 1984; 27: 659-664.
144. Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP: Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. *J Chromatog Biomed Applic* 1984; 307: 457-463.
145. Arana GW, Baldessarini RJ, Workman RJ: Dexamethasone plasma levels contribute to the outcome of the DST in major depression. *Am J Psychiatry* 1985; 142: 1124-1125.
146. Arana GW, Baldessarini RJ, Ornstein M: The dexamethasone suppression test for diagnosis and prognosis in psychiatry. *Arch Gen Psychiatry* 1985; 42: 1193-1204.
147. Arana GW, Wilens TE, Baldessarini, RJ: Plasma corticosterone and cortisol following dexamethasone in psychiatric patients. *Psychoneuroendocrinology* 1985; 10: 49-60.
148. Campbell A, Baldessarini RJ: Prolonged pharmacologic activity of neuroleptics. *Arch Gen Psychiatry* 1985; 42: 637-638.
149. Campbell A, Baldessarini RJ, Kula NS: Prolonged antidopamine actions of single doses of butyrophenones in the rat. *Psychopharmacology* 1985; 87: 161-166.
150. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL: S(+)-aporphines: Selective inhibition of excitatory effects of dopamine injected into rat limbic system. *Neuropharmacology* 1985; 24: 391-399.

151. Cohen BM, Baldessarini RJ: Tolerance to therapeutic effects of antidepressants. *Am J Psychiatry* 1985; 142: 489–490.
152. Teicher M, Baldessarini RJ: Selection of neuroleptic dosage. *Arch Gen Psychiatry* 1985; 42: 636–637.
153. Jacob JN, Shashoua VE, Campbell A, Baldessarini RJ: GABA esters 2. Synthesis, brain uptake and pharmacological properties of lipid esters of gamma-aminobutyric acid. *J Med Chem* 1985; 28: 106–110.
154. Finklestein SP, Campbell A, Baldessarini RJ, Moya KL, Haber SN: Late changes in cerebral monoamine metabolism following focal ventrolateral cerebral cortical lesions in rats. *Brain Research* 1985; 344: 205–210.
155. Kula NS, Baldessarini RJ, Bromley S, Neumeyer JL: Effects of isomers of aporphines on dopamine receptors in striatal and limbic tissue of rat brain. *Life Sciences* 1985; 37: 1051–1057.
156. Biederman J, Baldessarini RJ, Harmatz JS, Rivinus TM, Arana GW, Herzog DB, Schildkraut JJ: Evidence of heterogeneity in anorexia nervosa. *Biol Psychiatry* 1986; 21: 213–216.
157. Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL: Behavioral effects of apomorphine isomers in the rat: Selective locomotor-inhibitory effects of S(+)-N-n-propylnorapomorphine. *Psychopharmacology* 1986; 88: 158–164.
158. Baldessarini RJ, Kula NS, Francoeur D, Finklestein SP: Antioxidants fail to inhibit depletion of striatal dopamine by MPTP. *Neurology* 1986; 36: 735–736.
159. Baldessarini RJ, Kula NS, Francoeur D, Finklestein SP, Murphy F, Neumeyer JL: Effects of substituted phenylpiperidines on uptake, storage and release of dopamine in mouse striatum. *Life Sciences* 1986; 29: 1765–1777.
160. Baldessarini RJ, Neumeyer JL: Lack of dopamine depleting effect of phenylpiperidine analgesics. *N Engl J Med* 1986; 314: 649–650.
161. Froimowitz M, Neumeyer JL, Baldessarini RJ: A stereochemical explanation of the dopamine agonist and antagonist activity of stereoisomeric pairs. *J Med Chem* 1986; 29: 1570–1573.
162. Teicher MH, Barber NI, Reichheld J, Baldessarini RJ: Selective depletion of cerebral norepinephrine with 6-hydroxydopamine and GBR-12909 in rat. *Dev Brain Research* 1986; 30: 124–128.
163. Teicher MH, Lawrence JM, Barber NI, Finklestein SP, Lieberman H, Baldessarini RJ: Altered locomotor activity in neuropsychiatric patients. *Prog Neuro-Psychopharmacol Biol Psychiatry* 1986; 10: 755–761.
164. Baldessarini RJ: Neuropharmacology of S-adenosyl-L-methionine. *Am J Medicine* 1987; 83 (Suppl 5A): 95–103.
165. Campbell A, Baldessarini RJ, Kula NS, Ram VJ, Neumeyer JL: S(+)-methylenedioxy-N-n-propylnorapomorphine: An orally active inhibitor of dopamine selective for rat limbic system. *Brain Research* 1987; 403: 393–397.
166. Finklestein SP, Weintraub RJ, Karamouz N, Askinasi C, Baldessarini RJ: Current use of antidepressants in post-stroke depression. *Arch Phys Med Rehab* 1987; 68: 772–776.
167. Froimowitz M, Baldessarini RJ: A stereochemical and conformational model of dopaminergic agonist and antagonist activity: Further evaluation. *J Pharm Science* 1987; 76: 557–564.
168. Lamont JS, Kula NS, Baldessarini RJ: Effects of cations on high-affinity binding of ³H-ADTN to dopaminergic sites in calf caudate tissue. *Neuropharmacology* 1987; 26: 637–639.
169. Arana GW, Goff D, Baldessarini RJ: Efficacy of anticholinergic prophylaxis of neuroleptic-induced acute dystonia. *Am J Psychiatry* 1988; 145: 993–996.
170. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry* 1988; 45: 79–91.
171. Baldessarini RJ, Teicher MH, Cassidy JW, Stein M: Anticonvulsant cotreatment may increase toxic metabolites of tricyclic antidepressants and other psychotropic drugs. *J Clin Psychopharmacology* 1988; 8: 381–382.
172. Baldessarini RJ, Vogt M: Release of [³H]-dopamine and analogous monoamines from rat striatal tissue. *Cell Mol Neurobiology* 1988; 8: 205–216.
173. Campbell A, Baldessarini RJ, Cremens MC: Dose-catalepsy response to haloperidol in rat: Effects of gender and strain. *Neuropharmacology* 1988; 11: 1197–1199.
174. Campbell A, Baldessarini RJ, Teicher MH: Decreasing sensitivity to phenothiazine and butyrophenone neuroleptics given intracerebrally or systemically to developing rats. *Psychopharmacology* 1988; 94: 46–51.
175. Cohen BM, Babb S, Campbell A, Baldessarini RJ: Persistence of haloperidol in brain. *Arch Gen Psychiatry* 1988; 45: 879–880.
176. Gao Y, Zong R, Campbell A, Kula NS, Baldessarini RJ, Neumeyer JL: Synthesis and dopamine agonist and antagonist effects of R(-) and S(+)-11-hydroxy-N-n-propylnorapomorphine. *J Med Chem* 1988; 31: 1392–1396.

177. Gutierrez-Esteinou R, Baldessarini RJ, Cremens MC, Campbell A, Teicher MH: Clinical interactions of bromocriptine and cocaine. *Am J Psychiatry* 1988; 145: 1173–1174.
178. Kula NS, Baldessarini RJ, Neumeyer JL: Substituted phenylpiperidines and phenylpyridines as selective inhibitors of monoamine oxidase, types A and B. *Biochem Pharmacol* 1988; 37: 763–766.
179. Lampen P, Neumeyer JL, Baldessarini RJ: Liquid chromatographic separation and electrochemical or spectrophotometric determination of R(-)-N-n-propylnorapomorphine and R(-)-10,11-methylenedioxy-N-n-propylnorapomorphine in primate plasma. *J Chromatography* 1988; 426: 283–294.
180. Neumeyer JL, Froimowitz M, Baldessarini RJ, Campbell A, Gao Y: Neuropharmacology and stereochemistry of dopamine receptor agonist and antagonist enantiomeric pairs. *J. Receptor Research* 1988; 8: 83–96.
181. Svendsen C, Froimowitz M, Hrbek C, Campbell A, Kula N, Baldessarini RJ, Cohen BM, Babb S, Teicher MH, Bird E: Neuropharmacology of the optical isomers of thioridazine. *Neuropharmacology* 1988; 27: 1117–1124.
182. Teicher MH, Barber NI, Baldessarini RJ, Shaywitz BA: Amphetamine accelerates and attenuates ultradian activity rhythms in preweanling rats. *Pharmacol Biochem Behavior* 1988; 29: 517–523.
183. Teicher MH, Cohen BM, Baldessarini RJ, Cole JO: Severe daytime somnolence in patients treated with an MAO inhibitor. *Am J Psychiatry* 1988; 145: 1552–1556.
184. Teicher MH, Lawrence JM, Barber NI, Finklestein SP, Lieberman HR, Baldessarini RJ: Increased activity and phase delay in circadian motility rhythms in geriatric patients with major depression. *Arch Gen Psychiatry* 1988; 45: 913–918.
185. Trainor TM, Vouros P, Lampen P, Neumeyer JL, Baldessarini RJ, Kula NS: Determination of *N-n*-propylnorapomorphine in serum and brain tissue by gas chromatography–negative ion chemical ionization mass spectrometry. *J Chromatography* 1988; 457: 257–266.
186. Barber NI, Teicher MH, Baldessarini RJ: Effects of selective monoaminergic reuptake blockade on activity rhythms in developing rats. *Psychopharmacology* 1989; 97: 343–348.
187. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. *J Am Acad Child Adolesc Psychiatry* 1989; 28: 777–784.
188. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz J, Goldblatt A: A double-blind placebo controlled study of desipramine in the treatment of ADD: II. Serum drug levels and cardiovascular findings. *J Am Acad Child Adolesc Psychiatry* 1989; 28: 903–911.
189. Campbell A, Baldessarini RJ, Cremens C, Teicher MH, Marsh ER: Bromocriptine antagonizes behavioral effects of cocaine in the rat. *Neuropsychopharmacology* 1989; 2: 209–224.
190. Cohen BM, Baldessarini RJ, Campbell A, Tsuneizumi T, Babb S: Persistence of antipsychotic drug effects and tissue levels. *Schizophrenia Research* 1989; 2: 198–199.
191. Cohen BM, Benes FM, Baldessarini RJ: Atypical neuroleptics: Dose-response relationships, and treatment-resistant psychosis. *Arch Gen Psychiatry* 1989; 46: 381–383.
192. Faedda G, Kula NS, Baldessarini RJ: Pharmacology of binding of ³H-SCH-23390, a ligand selective for D₁ dopamine receptor sites, in rat brain tissue. *Biochem Pharmacol* 1989; 38: 473–480.
193. Gelbard HA, Teicher MH, Faedda G, Baldessarini RJ: Postnatal development of dopamine D₁ and D₂ receptor sites in rat striatum. *Dev Brain Research* 1989; 49: 123–136.
194. Keck PB, Cohen BM, Baldessarini RJ, McElroy SL: Time course of antipsychotic effects of neuroleptic drugs. *Am J Psychiatry* 1989; 146: 1289–1292.
195. Teicher MH, Barber NI, Gelbard HA, Brasher CA, Gallitano AL, Marsh ER, Campbell A, Baldessarini RJ: Developmental differences in regional dopamine turnover in response to haloperidol. *Schizophrenia Research* 1989; 2: 175–176.
196. Baldessarini RJ, Marsh ER, Kula NS, Zong R, Gao Y, Neumeyer JL: Effects of isomers of hydroxyaporphines on dopamine metabolism in rat brain regions. *Biochem Pharmacol* 1990; 40: 417–423.
197. Baldessarini RJ, Marsh ER: Fluoxetine and side effects. *Arch Gen Psychiatry* 1990; 47: 191–192.
198. Booth RG, Baldessarini RJ: Adenosine A₂ stimulation of tyrosine hydroxylase activity in rat striatal minces is reversed by D₂ autoreceptor activation. *Eur J Pharmacol* 1990; 185: 217–221.
199. Booth R, Baldessarini RJ, Kula NS, Gao Y, Zong R, Neumeyer JL: Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines. *Mol Pharmacol* 1990; 38: 92–101.
200. Booth R, Baldessarini RJ, Kula NS, Neumeyer JL: Stereochemical effects of mono- and dihydroxyaporphines on presynaptic inhibition of dopamine synthesis in vitro. *Ann NY Acad Sci* 1990; 604: 592–595.

201. Campbell A, Baldessarini RJ, Gao Y, Ram VJ, Neumeyer JL: R(-) and S(+) stereoisomers of 11-hydroxy- and 11-methoxy-N-n-propylnoraporphine: Central dopaminergic behavioral activity in the rat. *Neuropharmacology* 1990; 29: 527–536.
202. Gao Y, Baldessarini RJ, Kula NS, Neumeyer JL: Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. *J Med Chem* 1990; 33: 1800–1805.
203. Gao Y, Ram VJ, Campbell A, Kula NS, Baldessarini RJ, Neumeyer JL: Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D₁, D₂, and agonist receptor sites in rat brain. *J Med Chem* 1990; 33: 39–44.
204. Gelbard H, Teicher, MH, Gallitano A, Marsh ER, Zorc J, Faedda GL, Baldessarini RJ: Dopamine D₁ receptor development depends on endogenous dopamine. *Dev Brain Research* 1990; 56: 137–140.
205. Gelenberg AJ, Wojcik JD, Falk WE, Baldessarini RJ, Zeisel SH, Schoenfeld D, Mok GS: Tyrosine for depression: A double-blind trial. *J Affective Disorders* 1990; 19:125–132.
206. Neumeyer JL, Gao Y, Kula NS, Campbell A, Baldessarini RJ: Synthesis and dopamine receptor affinity of R(-)-2-fluoro-N-n-propylnorapomorphine: A potent and highly selective dopamine D₂ agonist, and other 2-substituted aporphines. *J Med Chem* 1990; 33: 3122–3124.
207. Baldessarini RJ, Frankenburg FR: Clozapine—a novel antipsychotic agent. *N Engl J Med* 1991; 324: 746–754.
208. Baldessarini RJ, Kula NS, Gao Y, Campbell A, Neumeyer JL: R(-)-2-Fluoro-N-n-propylnorapomorphine: A potent and selective D₂ agonist. *Neuropharmacology* 1991; 30: 93–95.
209. Booth RG, Baldessarini RJ: (+)-6,7-Benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue. *Brain Research* 1991; 557: 349–352.
210. Booth RG, Baldessarini RJ, Campbell A: Inhibition of dopamine synthesis in rat striatal minces: Evidence of dopamine autoreceptor supersensitivity to S(+) but not R(-) N-n-propylnorapomorphine after pretreatment with fluphenazine. *Biochem Pharmacol* 1991; 41: 2040–2043.
211. Campbell A, Yeghiayan S, Baldessarini RJ, Neumeyer JL: Selective antidopaminergic effects of S(+) N-n-propylnoraporphines in limbic vs. extrapyramidal sites in rat brain: Comparisons with typical and atypical antipsychotic agents. *Psychopharmacology* 1991; 103: 323–329.
212. Gelbard HA, Teicher MH, Beers, NB, Gallitano A, Baldessarini RJ: Neonatal depletion of dopamine decreases D₁ and forskolin binding sites in rat striatum. *Posters in Neuroscience* 1991; 1: 9–11.
213. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C: Episode sequence in bipolar disorder and response to lithium treatment. *Am J Psychiatry* 1991; 148: 1237–1239.
214. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ: Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. *Am J Psychiatry* 1991; 148: 790–792.
215. Kula NS, Baldessarini RJ: Lack of increase in dopamine transporter binding or function in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. *Neuropharmacology* 1991; 30: 89–92.
216. Nemeroff CB, Kilts CD, Levant B, Bissette G, Campbell A, Baldessarini RJ: Effects of aporphine isomers and haloperidol on regional concentrations of neurotensin in rat brain. *Neuropsychopharmacology* 1991; 4: 27–33.
217. Neumeyer JL, Gao Y, Kula NS, Baldessarini RJ: R and S-enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: Synthesis and affinity for dopamine receptors in rat brain tissue. *J Med Chem* 1991; 34: 24–28.
218. Satlin A, Teicher MH, Lieberman HR, Baldessarini RJ, Volicer L, Rheume Y: Circadian locomotor activity rhythms in Alzheimer's disease. *Neuropsychopharmacology* 1991; 5: 115–126.
219. Suppes T, Baldessarini RJ, Faedda GL, Tohen M: Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. *Arch Gen Psychiatry* 1991; 48: 1082–1088.
220. Teicher MH, Gallitano AL, Gelbard HA, Evans HK, Marsh ER, Booth RG, Baldessarini RJ: Dopamine D₁ autoreceptor function: Possible expression in developing rat prefrontal cerebral cortex and striatum. *Dev Brain Research* 1991; 63: 229–235.
221. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh, E, Cohen BM: Do antiadrenergic actions contribute to the atypical properties of clozapine? *Br J. Psychiatry* 1992; 160 (17S): 12–16.
222. Baldessarini RJ, Kula NS, Campbell A, Bakthavachalam V, Yuan J, Neumeyer, JL: Prolonged D₂ antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. *Mol Pharmacol* 1992; 42: 856–863.
223. Baldessarini RJ, Marsh ER, Kula NS: Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. *Brain Research* 1992; 579: 152–156.
224. Campbell A, Baldessarini RJ, Yeghiayan S: Antagonism of limbic and extrapyramidal actions of intracerebrally injected dopamine by aporphines with partial D₂-agonist activity in the rat. *Brain Research* 1992; 592: 348–352.

225. Wyrick SD, Booth RG, Myers AM, Kula NS, Baldessarini RJ: Synthesis of [N-C³H₃]-racemic-trans-1-phenyl-3-dimethylamino-6-chloro-7-hydroxy-1,2,3,4-tetrahydronaphthalene (PAT-6). *J Labeled Compds Radiopharmaceuticals* 1992; 31:871–874.
226. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb S: Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. *Psychopharmacology* 1992; 108:338–344.
227. Kula NS, George T, Baldessarini RJ: Rate of recovery of D₁ and D₂ dopaminergic receptors in young vs. adult rat striatal tissue following alkylation with ethoxycarbonyl-ethoxy-dihydroquinoline (EEDQ). *Dev Brain Research* 1992; 66: 286–289.
228. Neumeyer JL, Baidur N, Bakthavachalam V, Yuan J, Madras BK, Kula NS, Campbell A, Baldessarini RJ: Selective probes for characterization of dopamine D₁ and D₂ receptors. *Neurochem International* 1992; 20(S): 63–68.
229. Neumeyer JL, Kula NS, Baldessarini RJ, Baidur N: Stereoisomeric probes for the D₁ dopamine receptor: Synthesis and characterization of R-(+) and S-(–) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. *J Med Chem* 1992; 35: 1466–1471.
230. Morin I, Gao Y, Kula NS, Baldessarini RJ, Neumeyer, JL: Synthesis and affinity to dopamine receptors of N-monofluoroalkylnoraporphines. *Med Chem Res* 1992; 2: 354–360.
231. Stoll AL, Tohen M, Baldessarini RJ: Increasing diagnostic frequency of obsessive-compulsive disorder. *Am J Psychiatry* 1992; 149: 638–640.
232. Wilens T, Biederman J, Baldessarini RJ, McDermott SP, Puopolo P, Flood JG: Fluoxetine inhibits desipramine metabolism. *Arch Gen Psychiatry* 1992; 49: 752–753.
233. Wilens TE, Biederman J, Baldessarini RJ, Puopolo P, Flood JG: Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. *J Am Acad Child Adolesc Psychiatry* 1992; 31: 691–698.
234. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM: Tissue concentrations of clozapine and its metabolites in the rat. *Neuropsychopharmacology* 1993; 9: 117–124.
235. Baldessarini RJ, Kula NS, McGrath C, Keabian JW, Neumeyer JL: Isomeric selectivity of D₃ dopamine receptors. *Eur J Pharmacol* 1993; 239: 269–270.
236. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S: A double-blind, placebo-controlled study of desipramine in the treatment of attention deficit disorder: III. Lack of impact of comorbidity and family–genetic factors in clinical responses. *J Am Acad Child Adolesc Psychiatry* 1993; 32: 199–204.
237. Biederman J, Baldessarini RJ, Goldblatt A, Lapey K, Doyle A, Husslein PS: A naturalistic study of 24-hour electro-cardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. *J Am Acad Child Adolesc Psychiatry* 1993; 32: 805–813.
238. Booth RG, Wyrick SD, Baldessarini RJ, Kula NS, Myers AM, Mailman RB: A new sigma-like receptor recognized by novel phenylaminotetralins. *Mol Pharmacol* 1993; 44: 1232–1239.
239. Campbell A, Baldessarini, RJ, Neumeyer JL: Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. *Psychopharmacology* 1993; 111: 351–358.
240. Faedda GL, Tondo L, Teicher MH, Baldessarini RJ, Gelbard HA, Floris GF: Seasonal mood disorders: Patterns of seasonal recurrence in major affective disorder. *Arch Gen Psychiatry* 1993; 50: 17–23.
241. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M: Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar mood disorders. *Arch Gen Psychiatry* 1993; 50: 448–455.
242. Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein S, Katz S, Geenens D, Swinson RP, Goethe JW, McGlashan T: Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972–1988. *Am J Psychiatry* 1993; 150:1668–1673.
243. Suppes T, Baldessarini RJ, Faedda GL, Tondo, L, Tohen M: Discontinuing maintenance treatment in bipolar manic-depression: Risks and implications. *Harv Rev Psychiatry* 1993; 1: 131–144.
244. Teicher MH, Barber NI, Gelbard HA, Gallitano AL, Campbell A, Marsh ER, Baldessarini RJ: Developmental changes in acute nigrostriatal and mesocorticolimbic system response to haloperidol. *Neuropsychopharmacology* 1993; 9: 147–156.
245. Volpicelli S, Centorrino F, Puopolo P, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG: Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. *Clin. Chem* 1993; 39: 1656–1659.
246. Wilens TE, Biederman J, Baldessarini RJ, Puopolo P, Flood JG: Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents and adults treated with desipramine. *J Am Acad Child Adolesc Psychiatry* 1993; 32:798–804.

247. Wyrick SD, Booth RG, Myers AM, Owens C, Kula NS, Baldessarini RJ, McPhail AT, Mailman RB: Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel neuromodulatory sigma-like receptor. *J Med Chem* 1993; 36: 2542–2551.
248. Baldessarini RJ, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer JL: Effects of aporphine isomers on rat prolactin. *Neurosci Letters* 1994; 176: 269–271.
249. Baldessarini RJ, Kula NS, Zong R, Neumeyer JL: Receptor affinities of aporphine enantiomers in rat brain tissue. *Eur J Pharmacol* 1994; 254:199–203.
250. Baldessarini RJ, Marsh ER, Huston-Lyons D: Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain. *Biochem Pharmacol* 1994; 47: 1917–1919.
251. Booth RG, Baldessarini RJ, Marsh ER: Actions of (\pm)-7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of rat brain. *Brain Research* 1994; 662: 283–288.
252. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Flood JG: Clozapine and metabolites: Serum concentrations and clinical findings during treatment of chronically psychotic patients. *J Clin Psychopharmacology* 1994; 14: 119–125.
253. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG: Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with clozapine and fluoxetine or valproate. *Am J Psychiatry* 1994; 151: 123–125.
254. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux CM, Oepen G: One hundred years of schizophrenia: A meta-analysis of the outcome literature. *Am. J. Psychiatry* 1994; 151: 1409–1416.
255. Kula NS, Baldessarini RJ, Keabian JW, Neumeyer JL: S(+)aporphines are not selective for human D₃ dopamine receptors. *Cell Mol Neurobiology* 1994; 14:185–191.
256. Myers AM, Wyrick SD, Charifson PS, Booth RG, Owens CE, Kula NS, Baldessarini RJ, McPhail AT: Conformational analyses, pharmacophore identification, and comparative molecular field analyses of ligands for the neuromodulatory σ_3 receptor. *J Med Chem* 1994; 37: 4109–4117.
257. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB: N- ω -fluoroalkyl analogs of (1R)-2 β -carboxy-3- β -(4-iodophenyl)tropane (β -CIT): Radiotracers for PET and SPECT imaging of dopamine transporters. *J Med Chem* 1994; 37: 1558–1561.
258. Wyrick SD, Myers AM, Booth RG, Kula NS, Baldessarini RJ, Mailman RB: Synthesis of [N -C³H₃]-trans-(1R,3S)-1-phenyl-3-N,N-dimethylamino-1,2,3,4-tetrahydronaphthalene (H₂-PAT). *J Labeled Compds Radiopharmaceuticals* 1994; 34: 131–134.
259. Baldessarini RJ, Centorrino F, Flood JG, Frankenburg FR, Kando J, Winkelman JW: Effects of fluoxetine on serum clozapine levels: relationship to epileptic seizures. *Am J Psychiatry* 1995; 152: 473–474.
260. Baldessarini RJ, Kando JC, Centorrino F: Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length-of-stay. *Am J Psychiatry* 1995; 152: 1038–1044.
261. Baldessarini RJ, Viguera AC: Neuroleptic withdrawal in schizophrenic patients. *Arch Gen Psychiatry* 1995; 52: 189–192.
262. Centorrino F, Baldessarini RJ, Flood JG, Kando J, Frankenburg FR: Relation of leukocyte counts during clozapine treatment to serum concentration of clozapine and metabolites. *Am J Psychiatry* 1995; 152: 610–612.
263. Tohen M, Castillo J, Baldessarini RJ, Zarate CA Jr, Kando JR: Blood dyscrasias during treatment with carbamazepine and valproate vs. antidepressants: A pharmacoepidemiological study of 2,228 patients at risk. *Am. J. Psychiatry* 1995; 152: 413–418.
264. Aravagiri M, Marder SR, Yuwiler A, Midha KK, Kula NS, Baldessarini RJ: Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. *Neuropsychopharmacology* 1995; 13: 235–248.
265. Baldessarini RJ, Gardner DM, Garver DL: Conversions from clozapine to other antipsychotics. *Arch Gen Psychiatry* 1995; 52: 1071–1072.
266. Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz D: Pediatric-onset bipolar disorder: A neglected clinical and public health problem. *Harv Rev Psychiatry* 1995; 3: 171–195.
267. Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine therapy in severe mood disorders. *J Clin Psychiatry* 1995; 56: 411–417.
268. Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz, EC, Hooper PE, Kula NS, Baldessarini RJ, Mailman RB: 1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and congeners as ligands for the neuromodulatory σ_3 receptor: Further structure-activity relationships. *J Med Chem* 1995; 38:3857–3864.
269. Baldessarini RJ, Suppes T, Tondo L: Lithium withdrawal in bipolar disorder: Implications for clinical practice and experimental therapeutics research. *Am J Therapeutics* 1996; 3: 492–496.
270. Baldessarini RJ, Tondo L, Faedda G, Floris G, Suppes T, Rudas N: Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. *J Clin Psychiatry* 1996; 57: 441–448.

271. Centorrino F, Baldessarini RJ, Frankenburg FR., Volpicelli SA, Flood JG, Kando J: Serotonin reuptake inhibitors alter metabolism of clozapine. *Am J Psychiatry* 1996; 153: 820–822.
272. Meyer M, Baldessarini RJ, Goff D, Centorrino F: Clinically significant interactions of psychotropic drugs with antipsychotic agents. *Drug Safety* 1996; 15: 333–346.
273. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Baldessarini RJ: N-substituted analogs of 2 β -carbomethoxy-3 β -(4-iodophenyl)tropane (β -CIT): Synthesis and binding affinity to monoamine transporters in rat forebrain. *J Med Chem* 1996; 39: 543–548.
274. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 1996; 35: 1491–1501.
275. Yeghiayan SK, Campbell A, Puopolo P, Flood J, Baldessarini RJ: Lethal potentiation of barbiturate anesthesia by fluoxetine in the rat. *Pharmaceut Sci* 1996; 2: 111–113.
276. Baldessarini RJ, Hegarty JD, Bird ED, Benes FM: Postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia: A meta-analysis. *Am J Psychiatry* 1997; 54: 861–863.
277. Baldessarini RJ, Tarazi FI, Kula NS, Gardner DM: Supersensitivity of D₄ receptors induced by clozapine. *Arch Gen Psychiatry* 1997; 45: 761–762.
278. Baldessarini RJ, Tondo L, Floris G, Rudas N: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. *Am J Psychiatry* 1997; 154: 551–553.
279. Biederman J, Faraone SV, Baldessarini RJ, Flood J, Meyer M, Wilens T, Spencer T, Chen L, Weber W: Predicting desipramine levels in children and adolescents: A naturalistic clinical study. *J Am Acad Child Adolesc Psychiatry* 1997; 36: 384–389.
280. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ: Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. *J Clin Psychiatry* 1997; 58: 137–145.
281. Campbell A, Villavicencio AT, Yeghiayan SK, Balikian R, Baldessarini RJ: Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of the rat forebrain. *Brain Research* 1997; 771: 55–62.
282. Gardner DM, Baldessarini RJ, Benzo J, Zarate CA Jr, Tohen M: Switching between clozapine and risperidone. *Can J Psychiatry* 1997; 42: 430–431.
283. Kula NS, Baldessarini RJ, Keabian JW, Bakthavachalam V, Xu L: RBI-257: A highly potent D₄-selective dopamine receptor ligand. *Eur J Pharmacol* 1997; 331: 333–336.
284. Tamagnan G, Gao Y, Wang S, Kula NS, Baldessarini RJ, Neumeyer JL: N-phthalimidoalkyl derivatives of 2 β -carbomethoxy-3 β -(4-iodophenyl)tropane (β -CIT): Brain monoamine transporter affinity. *Bioorg Med Chem Lett* 1997; 7: 337–340.
285. Tarazi FI, Kula NS, Baldessarini RJ: Regional distribution of dopamine D₄ receptors in rat forebrain regions. *NeuroReport* 1997; 8: 3423–3426.
286. Tarazi F, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL: Long-term effects of S(+)-N-n-propylnorapomorphine compared with typical and atypical antipsychotics: Differential increases of cerebrocortical D₂-like and striatolimbic D₄-like dopamine receptors. *Neuropsychopharmacology* 1997; 17: 186–196.
287. Tondo L, Baldessarini RJ, Floris G, Rudas N: Effectiveness of restarting lithium after its discontinuation in bipolar I and II disorders. *Am J Psychiatry* 1997; 154: 548–550.
288. Tondo L, Jamison KR, Baldessarini RJ: Antisucide effects of lithium. *Ann NY Acad Sci* 1997; 836: 339–351.
289. Viguera AC, Baldessarini RJ, Hegarty JM, Van Kammen D, Tohen M: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. *Arch Gen Psychiatry* 1997; 54: 49–55.
290. Yeghiayan SK, Andersen SL, Baldessarini RJ: Lack of effect of chronic clorgyline or selegiline on dopamine and serotonin transporters in rat caudate-putamen or nucleus accumbens septi. *Neurosci Letters* 1997; 236: 147–150.
291. Yeghiayan SK, Kelley AE, Kula NS, Campbell A, Baldessarini RJ: Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. *Pharmacol Biochem Behav* 1997; 56: 251–259.
292. Zarate CA Jr, Baldessarini RJ, Siegel A, Nakamura A, McDonald J, Muir-Hutchinson LA, Cherkerzian T, Tohen M: Risperidone in the elderly: a pharmacoepidemiological study. *J Clin Psychiatry* 1997; 58: 311–317.
293. Zarate CA Jr, Tohen M, Baraibar G, Zarate SB, Baldessarini RJ: Shifts in hospital diagnostic frequencies: Bipolar disorder subtypes, 1981–1993. *J Affect Disord* 1997; 43: 79–84.
294. Baldessarini RJ, Tondo L: Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. *Clin Drug Investigation* 1998; 15: 337–351.

295. Baldessarini EJ, Tondo L, Hennen J: The antisuicidal effects of lithium. *McLean Hosp Psychiatric Update* 1998; 1: 1–2.
296. George T, Innamorato L, Sernyak MJ, Baldessarini RJ, Centorrino F: Leukopenia with addition of paroxetine to clozapine. *J Clin Psychiatry* 1998; 59: 31–32.
297. Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD: Neuropharmacological assessment of potential dopamine D₄ receptor-selective radioligands. *Eur J Pharmacol* 198; 367: 139–142.
298. Tarazi FI, Campbell A, Baldessarini RJ: Effects of hippocampal kainic acid lesions on striatolimbic dopamine D₁-, D₂-, and D₄-like receptors. *Neuroscience* 1998; 87: 1–4.
299. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ: Localization of dopamine receptor subtypes in caudate-putamen and nucleus accumbens septi of rat brain: Comparison of D₁-, D₂-, and D₄-like receptors. *Neuroscience* 1998; 83: 169–176.
300. Tarazi FI, Yeghiayan SK, Neumeyer JL, Baldessarini RJ: Medial prefrontal cortical D₂ and striatolimbic D₄ dopamine receptors: Common targets for typical and atypical antipsychotic drugs. *Prog. Neuro-Psychopharmacol. Biol Psychiatry* 1998; 22: 693–707.
301. Tondo L, Baldessarini RJ: Rapid cycling in women and men with bipolar manic-depressive disorders. *Am. J. Psychiatry* 1998; 155: 1434–1436.
302. Tondo L, Baldessarini RJ, Floris G, Rudas N: Effectiveness of restarting lithium treatment after its discontinuation in bipolar disorders. *Psychiatry Digest* 1998; 3: 27–27.
303. Tondo L, Baldessarini RJ, Hennen J, Floris G: Lithium maintenance treatment: Depression and mania in bipolar I and II disorders. *Am J Psychiatry* 1998; 155:638–645.
304. Viguera AC, Baldessarini RJ, Friedberg J: Risks of interrupting continuation or maintenance treatment with antidepressants in major depressive disorders. *Harv Rev Psychiatry* 1998; 5: 293–306.
305. Tarazi FI, Campbell A, Baldessarini RJ: Effects of hippocampal lesions on striatolimbic ionotropic glutamatergic receptors. *Neurosci Letters* 1998; 250: 13–16.
306. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ: Localization of ionotropic glutamate receptors in rat caudate-putamen and nucleus accumbens septi: Comparison of NMDA, AMPA and kainate subtypes. *Synapse* 1998; 30: 227–235.
307. Tarazi FI, Tomasini EC, Baldessarini RJ: Postnatal development of D₄-like receptors in rat forebrain: Comparison with D₂-like receptors. *Devel Brain Research* 1998; 110: 227–233.
308. Tarazi FI, Tomasini EC, Baldessarini RJ: Postnatal development of dopamine and serotonin transporters in rat brain. *Neurosci Letters* 1998; 254: 21–24.
309. Teicher MH, Andersen SL, Campbell A, Gelbard HA, Baldessarini RJ: Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats. *Neurosci Letters* 1998; 247: 99–102.
310. Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. *J Clin Psychiatry* 1998; 59: 405–414.
311. Yeghiayan SK, Gongwer M, Baldessarini RJ, Kula NS, Zong R, Neumeyer JL: Local injection of alkylating and nonalkylating dopamine receptor antagonists into rat basal forebrain: Autoradiographic assessment of D₂-like and D₃ sites. *Brain Research* 1998; 792: 324–326.
312. Baldessarini RJ, Tondo L, Floris G, Hennen J: Latency and episodes before starting treatment, and response to lithium maintenance in bipolar I and II disorders. *Bipolar Disorders* 1999; 2: 91–97.
313. Baldessarini RJ, Tondo L, Hennen J: Antisuicidal effects of lithium in manic-depressive disorders. *J Clin Psychiatry* 1999; 60 (Suppl. 2): 77–84.
314. Baldessarini RJ, Tondo L, Viguera AC: Effects of discontinuing lithium maintenance treatment. *Bipolar Disorder* 1999; 1: 17–24.
315. Baldessarini RJ, Tondo L, Viguera AC: Discontinuing psychotropic agents. *J Psychopharmacology* 1999; 13: 292–293.
316. Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, Neumeyer JL. [³H]β-CIT: A radioligand for dopamine transporters in rat brain tissue. *Eur J Pharmacol* 1999; 385: 291–294.
317. Tarazi FI, Baldessarini RJ: Brain dopamine D₄ receptors: Basic and clinical status. *Intl J Neuropsychopharmacology* 1999; 2: 41–58.
318. Tarazi FI, Baldessarini RJ: Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. *J Neurosci Res* 1999; 55: 401–410.
319. Tarazi FI, Baldessarini RJ: The dopamine D₄ receptor: Significance for molecular psychiatry at the millennium. *Mol Psychiatry* 1999; 4: 529–538.

320. Tarazi FI, Tomasini EC, Baldessarini RJ: Postnatal development of dopamine D₁-like receptors in rat cortical and striatolimbic brain regions: An autoradiographic study. *Dev Neurosci* 1999; 21: 43–49.
321. Tondo L, Baldessarini RJ, Hennen J, Minnai GP, Salis P, Scamonatti L, Masia M, Ghiani C, Mannu P: Suicide attempts in major affective disorder patients with comorbid substance use disorders. *J Clin Psychiatry* 1999; 60 (Suppl 2): 63–69.
322. Tondo L, Baldessarini RJ, Hennen J: Lithium and suicide risk in bipolar disorder. *Primary Psychiatry* 1999; 6: 51–56.
323. Zhang K, Tarazi FI, Kula NS, Baldessarini RJ, Neumeyer JL: Selective alkylation of dopamine D₂ and D₄ receptors in rat brain by N-(p-isothiocyanatophenethyl)piperone. *Neurosci Letters* 1999; 274: 155–158.
324. Zhang K, Weiss NT, Tarazi FI, Kula NS, Baldessarini RJ: Effects of alkylating agents on dopamine D₃ receptors in rat brain: Selective protection by dopamine. *Brain Res* 1999; 847: 32–37.
325. Jacobs DG, Jamison KR, Baldessarini RJ, Fawcett JA, Hendin H, Gutheil TG: Suicide: Clinical risk management issues for psychiatrists. *CNS Spectrums* 2000; 5 (2: Suppl 1): 32–54.
326. Tondo L, Baldessarini RJ, Hennen J: Lithium and suicide risk in bipolar disorder. *CNS Spectrums* 2000; 5 (2: Suppl 1): 6–11.
327. Baldessarini RJ: A plea for integrity of the bipolar disorder concept. *Bipolar Disord* 2000; 2: 3–7.
328. Baldessarini RJ, Tohen M, Tondo L: Maintenance treatment in bipolar disorder. *Arch Gen Psychiatry* 2000; 57: 490–492.
329. Baldessarini RJ, Tondo L: Does lithium still work? Evidence of stable responses over three decades. *Arch Gen Psychiatry* 2000; 57: 187–190.
330. Centorrino F, Baldessarini RJ: Treatment of bipolar disorder (Introduction). *Noös–Aggiornamenti in Psichiatria (Rome)* 2000; 6: 5–8.
331. Centorrino F, Baldessarini RJ: Bipolar disorder: Pharmacological treatment of acute mania and long-term maintenance treatment. *Noös–Aggiornamenti in Psichiatria (Rome)* 2000; 6: 31–76.
332. Huxley NA, Parikh SV, Baldessarini RJ: Effectiveness of psychosocial treatments in bipolar disorder: State of the evidence. *Harv Rev Psychiatry* 2000; 8: 126–140.
333. Huxley NA, Parikh SV, Baldessarini RJ: Summary of the current state of psychotherapies in bipolar disorder. *Nóos: Aggiornamenti in Psichiatria (Rome)* 2000; 6: 77–101.
334. Tamagnan G, Baldwin RM, Kula NS, Baldessarini RJ, Innis RB: Synthesis and monoamine transporter affinity of 2 β -carbomethoxy-3 β -phenyl(4'-phenyl-substituted) diphenyltropanes. *Bioorg Med Chem Lett* 2000; 10: 1783–1785.
335. Tarazi FI, Baldessarini RJ: Dopamine D₄ receptors: Neuropsychiatric implications. *The Economics of Neuroscience (TEN)* 2000; 2: 54–58.
336. Tarazi FI, Kula NS, Zhang K, Baldessarini RJ: Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. *Neuropharmacology* 2000; 39: 2133–2138.
337. Tarazi FI, Zhang K, Baldessarini RJ: Olanzapine, quetiapine, and risperidone: Long-term effects on monoamine transporters in rat forebrain. *Neurosci Letters* 2000; 287: 81–84.
338. Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. *Brain Research* 2000; 881: 69–72.
339. Tohen M, Strakowski SM, Hennen J, Zarate CA Jr, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ: The McLean-Harvard First Episode Project: Six-month symptomatic and functional outcome in affective and nonaffective psychoses. *Biol Psychiatry* 2000; 48: 467–476.
340. Tamagnan G, Baldwin RM, Kula NS, Baldessarini RJ, Innis RB: Cyclopentadienyltricarbonyl-rheniumbenzazepines: Synthesis and binding affinity. *Bioorg Med Chem Lett* 2000; 10: 1113–1115.
341. Tarazi FI, Baldessarini RJ: Comparative postnatal development of dopamine D₁, D₂ and D₄ receptors in rat forebrain regions. *Int J Dev Neurosci* 2000; 18: 29–37.
342. Tondo L, Baldessarini RJ: Reduced suicide risk during lithium maintenance treatment. *J Clin Psychiatry* 2000; 61 (Suppl 9): 97–104.
343. Tohen M, Hennen J, Zarate CA Jr, Baldessarini RJ, Strakowski SM, Stoll AL, Faedda GL, Suppes T, Gebre-Medhin P, Cohen BM: The McLean First Episode Project: Two-year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. *Am J Psychiatry* 2000; 157: 220–228.
344. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ: Risk of discontinuing lithium maintenance in pregnant vs. nonpregnant women with bipolar disorders. *Am J Psychiatry* 2000; 157: 179–184.
345. Viguera AC, Tondo L, Baldessarini RJ: Sex differences in responses to lithium treatment. *Am J Psychiatry* 2000; 157: 1509–1511.

346. Zhang K, Tarazi FI, Baldessarini RJ: Dopamine D₄ receptors in rat forebrain: Unchanged with amphetamine-induced behavioral sensitization. *Neuroscience* 2000; 97: 211–213.
347. Zhang K, Tarazi FI, Campbell A, Baldessarini RJ: GABA_B receptors: Altered coupling to G-proteins in rats sensitized to amphetamine. *Neuroscience* 2000; 101: 5–10.
348. Baldessarini RJ, Tondo L, Hennen J: Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. *J Affect Disord* 2000; 61: 13–22.
349. Baldessarini RJ, Campbell A, Webb NL, Swindell CS, Flood JG, Shashoua VE, Kula NS, Hemamalini S, Bradley MO: Fatty acid derivatives of clozapine: Prolonged antidopaminergic activity of docosahexaenylclozapine in the rat. *Neuropsychopharmacology* 2001; 24: 55–65.
350. Baldessarini RJ, Tondo L: Long-term lithium for bipolar disorder: a re-analysis. *Am J Psychiatry* 2001; 158: 1740–1741.
351. Baldessarini RJ, Tondo L, Hennen J: Reduced suicide risk during long-term treatment with lithium. *Ann NY Acad Sci* 2001; 932: 24–43.
352. Centorrino F, Hernán MA, Drago-Ferrante G, Rendall M, Apicella A, Langer G, Baldessarini RJ: Noncompliance with psychiatric outpatient visits: Associated factors. *Psychiatr Serv* 2001; 52: 378–380.
353. Ghaemi SN, Lenox MS, Baldessarini RJ: Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. *J Clin Psychiatry* 2001; 62: 565–569.
354. Gu X-H, Zong R, Nora S, Kula NS, Baldessarini RJ, Neumeyer JL: Design, synthesis and biological evaluation of novel N- or O-fluoroalkyl tropane derivatives: Potential positron emission tomography (PET) imaging agents for the dopamine transporter. *Bioorg Med Chem Lett* 2001; 11: 3049–3053.
355. Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor subtypes: Implications for antipsychotic drug treatment. *J Pharmacol Exp Ther* 2001; 297: 711–717.
356. Tondo L, Baldessarini RH, Floris G: Long-term effectiveness of lithium maintenance treatment in types I and II bipolar disorders. *Brit J Psychiatry* 2001; 178 (Suppl 40): S184–S190.
357. Tondo L, Hennen J, Baldessarini RJ: Reduced suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. *Acta Psychiatr Scand* 2001; 104: 163–172.
358. Viguera AC, Tondo L, Baldessarini RJ: Comparison of women and men with bipolar disorders. *Bipolar Disord* 2001; 3: 245–252.
359. Zhang K, Tarazi FI, Baldessarini RJ: Nigrostriatal dopaminergic denervation enhances dopamine D₄ receptor binding in rat caudate-putamen. *Pharmacol Biochem Behavior* 2001; 69: 111–116.
360. Zhang K, Tarazi FI, Baldessarini RJ: Role of dopamine D₄ receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. *Neuropsychopharmacology* 2001; 25: 624–632.
361. Baldessarini RJ: Treatment research in bipolar disorder: Issues and recommendations. *CNS Drugs* 2002; 16: 721–729.
362. Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. *Psychother Psychosomatics* 2002; 71: 177–179.
363. Baldessarini RJ, Tondo L, Hennen J, Viguera AC: Is lithium still worth using? Update of selected recent research. *Harv Rev Psychiatry* 2002; 10: 59–75.
364. Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren JL, Salvatore P, Egli S, Baldessarini RJ: Inpatient antipsychotic drug use in 1998: Comparisons to 1993 and 1989. *Am J Psychiatry* 2002; 159: 1932–1935.
365. Centorrino F, Price BH, Tuttle M, Bahk W-M, Hennen J, Albert M, Baldessarini RJ: Electroencephalographic abnormalities during treatment with typical and atypical antipsychotics. *Am J Psychiatry* 2002; 159: 109–115.
366. Cesati RR III, Tamagnan G, Baldwin RM, Zoghbi SS, Innis RB, Kula NS, Baldessarini RJ: Synthesis of cyclopentadienyltricarbonyl rhenium phenyltropanes by double ligand transfer: Organometallic ligands for the dopamine transporter. *Bioconjugate Chem* 2002; 13: 29–39.
367. Davids E, Zhang K, Baldessarini RJ: Stereoselective effects of methylphenidate on hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. *Psychopharmacology* 2002; 160: 92–98.
368. Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ: Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. *J Pharmacol Exp Ther* 2002; 301: 1097–1102.
369. Fu X, Tan PZ, Kula NS, Baldessarini R, Tamagnan G, Innis RB, Baldwin RM: Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT_{2A} ligands for PET or SPECT brain imaging. *J Med Chem* 2002; 45: 2319–2324.
370. Goodwin FK, Baldessarini RJ, Dunner DL: The use of lithium in treating bipolar disorder. *CNS Spectrums* 2002; 7: 1–12.

371. Kelleher JP, Centorrino F, Baldessarini RJ: New formulations and new atypical antipsychotics: Potential therapeutic advantages. *CNS Drugs* 2002; 16: 249–261.
372. Salvatore P, Baldessarini RJ, Centorrino F, Egli S, Albert M, Gerhard A, Maggini C: Weygandt's, The Manic-Depressive Mixed States: a translation and commentary on its significance in the evolution of the concept of bipolar manic-depressive disorder. *Harv Rev Psychiatry* 2002; 10: 255–275.
373. Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A, and 2C receptors in rat forebrain regions. *Psychopharmacology* 2002; 161: 263–270.
374. Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. *Nitric Oxide: Biol Chemistry* 2002; 7: 297–300.
375. Tarsy D, Baldessarini RJ, Tarazi FI: Atypical antipsychotic agents: Effects on extrapyramidal functions. *CNS Drugs* 2002; 16: 23–45.
376. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R: Managing bipolar disorder in pregnancy: Weighing the risks and benefits. *Can J Psychiatry* 2002; 47: 426–436.
377. Viguera AC, Cohen LS, Bouffard S, Whitfield TH, Baldessarini RJ: Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation. *Am J Psychiatry* 2002; 159: 2102–2104.
378. Zhang K, Davids E, Tarazi FI, Baldessarini RJ: Effects of dopamine D₄ receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. *Psychopharmacology* 2002; 161: 100–106.
379. Zhang K, Davids E, Tarazi FI, Baldessarini RJ: Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: Implications for motor hyperactivity. *Dev Brain Res* 2002; 137: 135–138.
380. Zhang K, Tarazi FI, Davids E, Baldessarini RJ: Plasticity of dopamine D₄ receptors in rat forebrain: Temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. *Neuropsychopharmacology* 2002; 26: 625–633.
381. Zhu M-Y, Kim C-H, Hwang D-Y, Baldessarini RJ, Kim K-S: Effects of desipramine treatment on norepinephrine transporter gene expression in cultured SK-N-BE(2)M17 cells and rat brain tissue. *J Neurochem* 2002; 82: 146–153.
382. Baldessarini RJ: Assessment of treatment response in mania: Commentary and new findings. *Bipolar Disord* 2003; 5: 79–84.
383. Baldessarini RJ: Reducing suicide risk in psychiatric disorders. *Current Psychiatry* 2003; 2: 15–24.
384. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE Jr, McElroy SL, Sachs G, Vieta E, Yatham LN, Zarate CA Jr, Baker RW, Tohen M: Olanzapine vs. placebo in acute mania: Treatment responses in subgroups. *J Clin Psychopharmacol* 2003; 23: 370–376.
385. Baldessarini RJ, Tondo L, Hennen J: Lithium treatment and suicide risk in major affective disorders: Update and new findings. *J Clin Psychiatry* 2003; 64 (Suppl 5): 44–52.
386. Baldessarini RJ, Tondo L, Hennen J: Latency and episodes before treatment: Effects on pretreatment morbidity but not response to maintenance treatment in bipolar I and II disorders. *Bipolar Disord* 2003; 5: 169–179.
387. Baethge C, Baldessarini RJ: Cyclothymia, a Circular Mood Disorder, Classic Text 55 by Ewald Hecker: (translation). *Hist Psychiatry* 2003; 14: 391–399.
388. Baethge C, Baldessarini RJ, Bratti IM, Tondo L: Prophylaxis-latency and outcome in bipolar disorders. *Can J Psychiatry* 2003; 48: 449–457.
389. Baethge C, Salvatore P, Baldessarini RJ: Cyclothymia, a Circular Mood Disorder, Classic Text 55 by Ewald Hecker (introduction and commentary). *Hist Psychiatry* 2003; 14: 377–390.
390. Baethge C, Salvatore P, Baldessarini RJ: On *Cyclic Insanity* (1882) by Karl Ludwig Kahlbaum, MD: Translation and commentary. *Harv Rev Psychiatry* 2003; 11: 78–90.
391. Baldwin RM, Fu X, Kula NS, Baldessarini RJ, Amici L, Innis RB, Tamagnan GD: Synthesis and affinity of a possible by-product of electrophilic radiolabeling of [¹²³I]IBZM. *Biochem. Med. Chem Lett* 2003; 13: 4015–4017.
392. Beresin EV, Baldessarini RJ, Alpert J, Rosenbaum J: Teaching ethics of psychopharmacology research in psychiatric residency training programs. *Psychopharmacology* 2003; 171: 105–111.
393. Bratti IM, Baldessarini RJ, Baethge C, Tondo L: Pretreatment episode count and response to lithium treatment in manic-depressive illness. *Harv Rev Psychiatry* 2003; 11: 245–256.
394. Centorrino F, Albert MJ, Berry JM, Kelleher JP, Fellman V, Line G, Koukopoulos AE, Kidwell JE, Fogarty KV, Baldessarini RJ: Oxcarbazepine: clinical experience with hospitalized psychiatric patients. *Bipolar Disord* 2003; 5: 370–374.

395. Centorrino F, Drago-Ferrante G, Albert M, Drago-Perrante G, Koukopoulos AE, Berry JM, Baldessarini RJ: Delirium during treatment with clozapine: Incidence and associated risk factors. *Pharmacopsychiatry* 2003; 36: 156–160.
396. Centorrino F, Kelleher JP, Berry JM, Salvatore P, Eakin M, Fogarty KV, Fellman V, Baldessarini RJ: Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. *Am J Psychiatry* 2003; 160: 1348–1350.
397. Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ, Piscitelli S, Kim GS, Rapoport, JL: Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. *J Clin Psychopharmacol* 2003; 23: 87–91.
398. Glod C, Lynch A, Flynn E, Berowitz C, Baldessarini RJ: Open trial of bupropion SR in adolescent major depression. *J Child Adolesc Psychiatr Nursing* 2003; 16: 123–130.
399. Joffe, H., Taylor, AE, Hall, JE, Cohen LS, Baldessarini RJ: Valproate and the polycystic ovarian syndrome in women with bipolar disorder. *Harv Rev Psychiatry* 2003; 11: 99–108.
400. Meltzer HY, Baldessarini RJ: Reducing risk for suicide in schizophrenia and affective disorders. *J Clin Psychiatry* 2003; 64: 1122–1129.
401. Neumeyer JL, Bergman J, Kula NS, Baldessarini RJ: Receptor affinities of novel dopamine D₁ receptor-selective phenylbenzazepines. *Eur J Pharmacol* 2003; 474: 137–140.
402. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K: Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. *J Pharmacol Exp Ther* 2003; 306: 1145–1151.
403. Tohen M, Zarate CA Jr, Hennen J, Kaur Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ: The McLean-Harvard First-Episode Mania Study: Prediction of recovery and first recurrence. *Am J Psychiatry* 2003; 160: 2099–2107.
404. Tondo L, Hennen J, Baldessarini RJ: Meta-analysis of treatment responses of rapid-cycling and non-rapid-cycling bipolar disorder patients. *Acta Psychiatr Scand* 2003; 104: 4–14.
405. Tondo L, Isacson G, Baldessarini RJ: Suicide in bipolar disorder: Risk and prevention. *CNS Drugs* 2003; 17: 491–511.
406. Baldessarini RJ, Hennen J: Genetics of suicide: An overview. *Harv Rev Psychiatry* 2004; 12: 1–13.
410. Baethge C, Baldessarini RJ, Freudenthal K, Steeruvitz A, Bschor T: Hallucinations in bipolar disorders: Characteristics and comparison to unipolar depression and schizophrenia. *Bipolar Disord* 2004; 7: 136–145.
407. Baethge C, Glovinsky IP, Baldessarini RJ: Manic-depressive illness in children: An early twentieth-century view by Theodor Ziehen (1862–1950). *History Psychiatry* 2004; 15: 201–212.
408. Baethge C, Glovinsky IP, Baldessarini RJ: Thodor Ziehen on mania, melancholia and periodic psychoses in children: *Classic Text 58* (translation). *History Psychiatry* 2004; 15: 213–226.
409. Bois F, Baldwin RM, Kula NS, Baldessarini RJ, Innis RB, Tamagnan GD: Synthesis and monoamine transporter affinity of 3'-analogs of 2- β -carbomethoxy-3- β -(4'-iodophenyl)tropane (β -CIT). *Bioorg Med Chem Lett* 2004; 14: 2117–2120.
410. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini RJ: Multiple vs. single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks vs. benefits. *Am J Psychiatry* 2004; 161: 700–706.
411. Centorrino F, MacLean E, Salvatore P, Kidwell KE, Fogarty KV, Berry JM, Hennen J, Baldessarini RJ: Ziprasidone: first year of use. *J Psychiatr Practice* 2004; 10: 361–367.
412. Csutoras C, Neumeyer JL, Zhong R, Zhang K, Kula NS, Baldessarini RJ: Synthesis and neuropharmacological evaluation of substituted R-(–) 11-hydroxyaporphines. *Bioorganic Med Chem* 2004; 12-13: 3553–3559.
413. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB: Pediatric bipolar disorder: Phenomenology and course-of-illness. *Bipolar Disorders* 2004; 6: 306–313.
414. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB: Treatment-emergent mania in pediatric bipolar disorder: A retrospective case review. *J Affect Disord* 2004; 82: 149–158.
415. Gan L, Falzone TL, Zhang K, Rubenstein M, Baldessarini RJ, Tarazi FI: Enhanced expression of cerebral dopamine D₁ and glutamate NMDA receptors in dopamine D₄ knock-out mice. *J Mol Neurosci* 2004; 22: 167–177.
416. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ: Antidepressant treatment in bipolar vs unipolar depression. *Am J Psychiatry* 2004; 161: 163–165.
416. Hennen J, Perlis R, Sachs G, Tohen M, Baldessarini RJ: Weight-gain during treatment of bipolar I patients with olanzapine. *J Clin Psychiatry* 2004; 65: 1679–1687.

418. Oepen G, Salvatore P, Baldessarini RJ: On the periodicity of manic-depressive insanity by Eliot Slater (1938): Translation and commentary. *J Affect Disord* 2004; 78: 1–9.
419. Peng X, Zhang A, Kula NS, Baldessarini RJ, Neumeier JL: Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents. *Bioorg Med Chem Lett* 2004; 14: 5635–5639.
420. Tarazi FI, Zhang K, Baldessarini RJ: Dopamine D₄ receptors: Beyond schizophrenia. *J Recept Sig Transduc* 2004; 24: 131–142.
421. Vieta E, Calabrese JR, Hennen J, Yatham L, Colom F, Martinez-Arn A, Baldessarini RJ, Tohen M: Comparison of rapid and non-rapid cycling bipolar I manic patients during treatment with olanzapine. *J Clin Psychiatry* 2004; 65: 1420–1428.
422. Zhang K, Grady CJ, Tsapakis EM, Andersen SL, Tarazi FI, Baldessarini RJ: Regulation of working memory by dopamine D₄ receptor in rats. *Neuropsychopharmacology* 2004; 29: 1648–1655.
423. Baldessarini RJ, Faedda GL, Hennen J: Risk of mania with serotonin reuptake inhibitors vs. tricyclic antidepressants in children, adolescents and young adults. *Arch Pediatr Adolesc Med* 2005; 159: 298–299.
424. Baldessarini RJ, Pompili M, Tondo L, Tsapakis E, Soldani F, Faedda GL, Hennen J: Antidepressants and suicidal behavior: Are we hurting or helping? *Clin Neuropsychiatry* 2005; 2: 73–75.
425. Baethge C, Baldessarini RJ, Khalsa HMK, Hennen J, Salvatore P, Tohen M: Substance abuse in first-episode bipolar I disorder: indications for early intervention. *Am J Psychiatry* 2005; 162: 1008–1010.
426. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghofer A, Muller-Oerlinghausen B, Bschor T, Adli M, Bauer M: Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. *J Clin Psychiatry* 2005; 66: 174–182.
427. Baethge C, Baldessarini RJ, Freudenthal K, Streeruwitz A, Bauer M, Bschor T: Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia. *Bipolar Disord* 2005; 7: 136–145.
428. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cimbolli P, Baldessarini RJ: Antipsychotic drug use: McLean Hospital, 2002. *Hum Psychopharmacol* 2005; 20: 355–358.
429. Centorrino F, Fogarty KV, Cimbolli P, Salvatore P, Thompson T, Sani G, Cincotta SL, Baldessarini RJ: Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. *J Psychiatr Pract* 2005; 11: 241–247.
430. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cincotta SL, Hennen J, Guzzetta F, Talamo A, Saadeh M, Baldessarini RJ: Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. *Hum Psychopharmacology* 2005; 20: 485–492.
431. Chengappa KNR, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M: Recovery and functional outcomes following olanzapine treatment for bipolar I mania. *Bipolar Disord* 2005; 7: 68–76.
432. Grant M, Baldessarini RJ: Tardive dyskinesia and aripiprazole. *Ann Pharmacother* 2005; 39:1–2.
433. Hennen J, Baldessarini RJ: Reduced suicidal risk during treatment with clozapine: A meta-analysis. *Schizophrenia Res* 2005; 73: 139–145.
434. Lasser R, Bossie C, Gharabawi GM, Baldessarini RJ: Clinical improvements in 336 stable, chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. *Intl J Neuropsychopharmacol* 2005; 8: 427–438.
435. Moran-Gates T, Zhang K, Baldessarini RJ, Tarazi FI: Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. *Int J Neuropsychopharmacol* 2005; 8: 439–444.
436. Soldani F, Ghaemi SN, Baldessarini RJ: Research methods in psychiatric treatment studies. Critique and proposals. *Acta Psychiatr Scand* 2005; 112: 1–3.
437. Soldani F, Ghaemi SN, Baldessarini RJ: Research reports on treatments for bipolar disorder: Preliminary assessment of methodological quality. *Acta Psychiatr Scand* 2005; 112: 72–74.
438. Pompili M, Tondo L, Baldessarini RJ: Suicidal risk emerging during antidepressant treatment: Recognition and intervention. *Clin Neuropsychiatry* 2005; 2: 66–72.
439. Tamagnan G, Alagille D, Fu X, Kula NS, Baldessarini RJ, Innis RB, Baldwin RM: Synthesis and Monoamine transporter affinity of new 2 β -carbomethoxy-3 β -[4-(substituted thiophen)]phenyltropanes: Discovery of a selective SERT antagonist with picomolar potency. *Bioorg Med Chem Lett* 2005; 15: 1131–1133.

440. Tondo L, Baldessarini RJ: Suicidal risk in bipolar disorder. *Clin Neuropsychiatry* 2005; 2: 55–65.
441. Tóth M, Berényi S, Csutorás, Kula NS, Zhang K, Baldessarini RJ, Neumeyer JL: Synthesis and dopamine receptor binding of sulfur-containing aporphines. *Bioorg Med Chem* 2005; 14: 1918–1923.
442. Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ: Manic-Depressive Illness: evolution in Kraepelin's Textbook, 1883–1926. *Harv Rev Psychiatry* 2005; 13: 155–178.
443. Zhang A, Neumeyer JL, Kula NS, Zhang K, Baldessarini RJ, Kaufman M, Renshaw PF, Neumeyer JL: Development of polyfluorophenyltropanes: Potential probes for ^{19}F magnetic resonance imaging (MRI) and spectroscopy (MRS) assessments of the dopamine transporter. *Lett Drug Design Discovery* 2005; 2: 302–06.
444. Zhu M-Y, Wang W-P, Baldessarini RJ, Kim K-S: Effects of desipramine treatment on tyrosine hydroxylase gene expression in cultured neuroblastoma cells and rat brain tissue. *Mol Brain Res* 2005; 133 167–175.
445. Acharya N, Rosen AS, Polzer JP, D'Souza DN, Perahia DG, Cavazzoni PA, Baldessarini RJ: Duloxetine: Meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. *J Clin Psychopharmacol* 2006; 26: 587–594.
446. Baldessarini RJ, Pompili M, Tondo L: Suicidal risk in antidepressant trials. *Arch Gen Psychiatry* 2006; 63: 246–248.
447. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. *Bipolar Disord* 2006; 8:625–639.
448. Bois F, Baldwin RM, Kula NS, Baldessarini RJ, Al Tikriti M, Innis RB, Tamagnan G: Synthesis and monoamine transporter affinity of 2 β -(carbomethoxy)-3 β -(4'-*p*-substituted-phenyl)-piperidine-based analogs of cocaine. *Bioorg Med Chem Lett* 2006; 16: 5222–5225.
449. Centorrino F, Hennen J, Mallya G, Egli S, Clark T, Baldessarini RJ: Clinical outcome in patients with bipolar I disorder, obsessive-compulsive disorder, or both. *Hum Psychopharmacol* 2006; 21: 189–193.
450. Centorrino F, Sani G, Fogarty KV, Salvatore P, Talamo A, Cincotta SL, Baldessarini RJ: Combinations of mood-stabilizers with antipsychotics as treatment strategies in hospitalized psychiatric patients. *Clin Neuropsychiatry J Treat Eval* 2006; 3: 322–326.
451. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, Guay DM, Romeling M, Kidwell J, Cincotta SL, Baldessarini RJ: Weight-loss in overweight patients maintained on atypical antipsychotic agents. *Int J Obesity (London)* 2006; 30: 1011–1006.
452. Derenne JL, Baldessarini RJ: Clozapine toxicity associated with smoking cessation. *Am J Therapeutics* 2006; 12: 469–471.
453. Gonzalez-Pinto A, Mosquera F, Alonso M, Lopez P, Ramirez F, Santiago J, Baldessarini RJ: Increased risk of suicide attempts in bipolar-I disorder patients associated with nonadherence with lithium maintenance treatment: A 10-year prospective study. *Bipolar Disord* 2006; 8: 618–624.
454. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ: Reduced suicidality in bipolar-I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. *J Clin Psychiatry* 2006; 67: 1246–1252.
455. Minnai GP, Tondo L, Salis P, Ghiani C, Manfredi A, Paluello MM, Baethge C, Baldessarini RJ: Secular trends in hospitalization for mood disorders with comorbid substance use. *Int J Neuropsychopharmacol* 2006; 9: 319–326.
456. Moran-Gates T, Gan L, Zhang K, Baldessarini RJ, Tarazi FI: Effects of antipsychotic drug treatment and withdrawal on dopamine receptors in juvenile animals. *Synapse* 2006; 59: 92–100.
457. Pantazopoulos H, Lange N, Baldessarini RJ, Berretta S: Parvalbumin neurons in entorhinal cortex subregions of subjects diagnosed with bipolar disorder or schizophrenia. *Biol Psychiatry* 2006; 61: 640–652.
458. Sim K, Lee NB, Chua HC, Mahendran R, Fujii S, Yang S-Y, Chong M-Y, Si T-M, He YL, Chung EK, Chan YH, Shinfuku N, Tan CH, Sartorius N, Baldessarini RJ: Newer antidepressant drug use in East Asian psychiatric treatment settings: Research on East Asia Psychotropic Prescriptions (REAP) Study. *Br J Clin Psychopharmacol* 2006; 63: 431–437.
459. Talamo A, Centorrino F, Tondo L, Demetri A, Hennen J, Baldessarini RJ: Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. *Schizophrenia Res* 2006; 86: 251–255.

460. Tamagnan G, Alagille D, Fu X, Kula NS, Baldessarini RJ, Innis RB, Baldwin RM: Synthesis and monoamine transporter affinity of new 2 β -carbomethoxy-3 β -[aryl or heteroaryl]phenyltropanes *Bioorg Med Chem Lett* 2006; 16: 217–220.
461. Tarsy D, Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? *Movement Disord* 2006; 21: 589–598.
462. Tondo L, Albert M, Baldessarini RJ: Suicide rates in relation to health-care access in the United States. *J Clin Psychiatry* 2006; 67: 517–523.
463. Tóth M, Berényi S, Csutorás, Kula NS, Zhang K, Baldessarini RJ, Neumeyer JL: Synthesis and dopamine receptor binding of sulfur-containing aporphines. *Bioorg Med Chem* 2006; 14: 1918–1923.
464. Baldessarini RJ, Leahy LF, Arcona S, Gause D, Zhang W, Hennen J: Prescribing patterns of psychotropic medicines in the United States for patients diagnosed with bipolar disorders. *Psychiatr Serv* 2007; 58: 85–91.
465. Baldessarini RJ, Tondo L, Baethge C, Lepri B, Bratti IM: Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. *Bipolar Disorders* 2007; 9: 386–393.
466. Baldessarini RJ, Tondo L, Strombom I, Dominguez S, Fawcett J, Oquendo M, Licinio J, Valuck R, Tollefson G, Tohen M: Analysis of ecological studies of relationships between antidepressant utilization and suicidal risk. *Harv Rev Psychiatry* 2007; 15: 133–145.
467. Centorrino F, Meyers AL, Ahl J, Cincotta SL, Zun L, Gulliver AH, Kinon BJ, Houston JP. Observational study of effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. *Hum Psychopharmacol* 2007; 22: 455–462.
468. Centorrino F, Sani G, Fogarty KV, Salvatore P, Talamo A, Cincotta SL, Baldessarini RJ: Combinations of mood-stabilizers with antipsychotics as treatment strategies in hospitalized psychiatric patients. *Clin Neuropsychiatry* 2007; 3: 322–326.
469. Ghaemi SN, Baldessarini RJ: Kraepelin's ghost: Revival of the manic-depressive spectrum. *Psychother Psychosomatics* 2007; 76: 65–69.
470. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ: Lithium treatment reduces suicidal risk in recurrent major depressive disorder. *J Clin Psychiatry* 2007; 68: 380–383.
471. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. *Bipolar Disord* 2007; 9: 183–196.
472. Kyomen HH, Whitfield TH, Baldessarini RJ: Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type. *J Clin Psychopharmacol* 2007; 27: 408–410.
473. Moran-Gates T, Grady C, Park YS, Baldessarini RJ, Tarazi FI: Effects of risperidone on dopamine receptor subtypes in developing rat brain. *Eur Neuropsychopharmacol* 2007; 17: 448–555.
474. Salvatore P, Khalsa HMK, Hennen J, Tohen M, Yurgelun-Todd D, Casolari F, De Panfilis C, Maggini C, Baldessarini RJ: Psychopathology factors in first-episode affective and nonaffective psychotic disorders. *J Psychiatr Res* 2007; 41: 724–736.
475. Salvatore P, Tohen M, Khalsa H-M K, Baethge C, Tondo L, Baldessarini RJ: Longitudinal research on bipolar disorders. *Epidemiol Psychiatr Soc (Rome)* 2007; 16: 109–117.
476. Si Y-G, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL: R-(–)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT_{1A} receptor ligands. *Bioorg Med Chem Lett* 2007; 17: 4128–4130.
477. Talamo A, Centorrino F, Tondo L, Demitri A, Hennen J, Baldessarini RJ: Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms: comments. *Schizophrenia Res* 2007; 90:353–354.
478. Tamagnan G, Brenner E, Alagille D, Haile C, Cosgrove K, Koreen AO, Early M, Baldwin RM, Tarazi FI, Baldessarini RJ, Jarkas N, Goodman MM, Staley JK, Seibyl JP: Development of SPECT imaging agents for the norepinephrine transporter: [¹²³I]INER. *Bioorgan Med Chem Lett* 2007; 17: 533–537.
479. Tondo L, Lepri B, Baldessarini RJ: Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. *Acta Psychiatr Scand* 2007; 116: 419–428.

480. Valuck RJ, Libby AM, Morrato EM, Orton HD, Allen R, Baldessarini RJ: Spillover effects on treatment of adult depression following FDA advisories on suicidal risk during treatment of juvenile patients with serotonin reuptake inhibitors. *Am J Psychiatry* 2007; 164: 1198–1205.
481. Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ: Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. *J Clin Psychiatry* 2007; 68 (Suppl 9): 29–33.
482. Viguera AC, Newport DJ, Ritchie J, Stowe Z, Whitfield T, Mogielnicki J, Baldessarini RJ, Zurick A, Cohen LS: Lithium from breast milk in nursing infants: Clinical implications. *Am J Psychiatry* 2007; 164: 342–345.
483. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Cohen LS: Recurrences of bipolar disorder in pregnancy: prospective study of mood-stabilizer discontinuation. *Am J Psychiatry* 2007; 164: 1817–1824.
484. Baethge C, Hennen J, Khalsa H-MK, Salvatore P, Tohen M, Baldessarini RJ: Sequencing of substance use and mood changes in 166 first-episode bipolar I disorder patients. *Bipolar Disord* 2008; 10: 738–741.
485. Baldessarini RJ, Henk HJ, Sklar AR, Chang J, Leahy LF. Psychotropic medications for bipolar disorder patients in the United States: polytherapy and adherence. *Psychiatr Serv* 2008; 59: 1175–1183.
486. Baldessarini RJ, Perry R, Pike J: Factors associated with treatment nonadherence among US bipolar disorder patients. *Hum Psychopharmacol* 2008; 23: 95–105.
487. Baldessarini RJ, Tondo L: Lithium and suicidal risk. *Bipolar Disord* 2008; 10:114–115.
488. Bois F, Baldwin RM, Amici L, Al-Tikriti M, Kula NS, Baldessarini RJ, Innis RB, Staley JK, Tamagnan GD: Synthesis, neuropharmacology, radiolabeling, and baboon SPECT imaging of 2 β -carbomethoxy-3 β -(3'-[¹²³I]iodophenyl)tropane ([¹²³I]YP256) as a serotonin transporter (SERT) radiotracer. *Nucl Med Biol* 2008; 35: 53–59.
489. Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, Salvatore P, Baldessarini RJ: Hospital use of antipsychotic drugs: polytherapy. *Compr Psychiatry* 2008; 49: 65–69.
490. Frankenburg F, Baldessarini RJ: Neurosyphilis, malaria, and discovery of antipsychotic agents. *Harvard Rev Psychiatry* 2008; 16: 299–307.
491. Ghaemi SN, Wingo AP, Filkowski MA, Goodwin FK, Baldessarini RJ: Effectiveness of long-term antidepressant treatment in bipolar disorder: a meta-analysis. *Acta Psychiatr Scand* 2008;118: 347–356.
492. Khalsa HMK, Salvatore P, Hennen J, Tohen M, Baldessarini RJ: Suicidal events and accidents in 216 first-episode bipolar-I disorder patients: Predictive factors. *J Affect Disord* 2008; 106: 179–184.
493. Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, Pennell PB, Baldessarini RJ: Lamotrigine in bipolar disorder: efficacy during pregnancy. *Bipolar Disord* 2008; 10: 432–436.
494. Salvatore P, Bhuvaneshwar C, Ebert D, Maggini C, Baldessarini RJ: Cycloid psychosis: case reports and historical review. *Harvard Rev Psychiatry* 2008; 16:167–180.
495. Salvatore P, Bhuvaneshwar C, Ebert D, Maggini C, Baldessarini RJ: Yeniden döngüsel psikozlar: olgu bildirimleri, literatür derlemesi ve yorum. *Harvard Rev Psychiatry [Turkish Edition]* 2008; 16: 167–180.
496. Tondo L, Lepri B, Baldessarini RJ: Suicidal status during antidepressant treatment in 789 Sardinian patients with major affective disorder. *Acta Psychiatr Scand* 2008;118: 106–115.
497. Nykiel SA, Baldessarini RJ, Bower MC, Goodwin J, Salvatore P. Psychosis NOS: search for diagnostic clarity. *Harvard Rev Psychiatry* 2008; 16:55–65.
498. Salvatore P, Ghidini S, Zita G, De Panfilis C, Lambertino S, Maggini C, Baldessarini RJ: Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients. *Bipolar Disord* 2008;10:256–265.
499. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL: Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. *Bioorg Med Chem Lett* 2008; 18: 3971–1973.
500. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL: Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D₁ versus D₂ receptor selectivity. *J Med Chem* 2008; 51: 983–987.
501. Talamo A, Baldessarini RJ, Centorrino F. Comparison of mania patients suitable for treatment trials versus clinical treatment. *Hum Psychopharmacol* 2008; 23: 447–454.
502. Tsapakis E, Soldani F, Tondo L, Baldessarini RJ: Efficacy of antidepressants in depressed children and adolescents: a meta-analysis. *Br J Psychiatry* 2008;193:10–17.
503. Baethge C, Tondo L, Lepri B, Baldessarini RJ: Coffee and cigarette use: association with suicidal acts in 352 bipolar disorder patients. *Bipolar Disord* 2009; 11: 494–503.

504. Baldessarini RJ, Tondo L: Meta-analytic comparison of antisuicidal effects of lithium versus anticonvulsants. *Pharmacopsychiatry* 2009; 42: 72–75.
505. Bhuvaneshwar C, Alpert J, Harsh V, Baldessarini RJ: Adverse endocrine and metabolic effects of psychotropic drugs. *CNS Drugs* 2009; 23: 1003–1021.
506. Fawcett J, Baldessarini RJ, Coryell W, Stein BD, Silverman MM. Recognition and management of suicidality in psychiatric patients (review and panel discussion). *J Clin Psychopedia*. Memphis, TN: Physicians' Press. May 2009, 3 pp.
507. Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Tatarelli R, Baldessarini RJ. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants by dissimilar methods. *Hum Psychopharmacol* 2009; 24:177–190.
508. Salvatore P, Baldessarini RJ, Tohen M, Khalsa H-M, Sanchez-Toledo JP, Zarate CA Jr, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. *J Clin Psychiatry* 2009; 70:458–466.
509. Si Y.G, Choi Y, Garner MP, Tarazi DFI, Baldessarini RJ, Neumeyer JL. Synthesis and neuropharmacological evaluation of esters of *R*-(-)-*N*-alkyl-11-hydroxy-2-methoxynoraporphines. *Bioorg Med Chem Lett* 2009; 19:51–53.
510. Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Tsang HY, Shinfuku N, Kua EH, Tan CH, Baldessarini RJ. Low doses of antipsychotic drugs for hospitalized schizophrenia patients in East Asia: 2004 vs. 2001. *Int J Neuropsychopharmacol* 2009; 18:117–123.
511. Tondo L, Baldessarini RJ: Prevenzione medica del suicidio [Medical prevention of suicide]. Chapt 9 in Tatarelli R, Pompili M, Girardi P, editors: *Il Suicidio e la Sua Prevenzione [Suicide and Its Prevention]*, Rome: Fioriti, 2009, pp 131–144.
512. Trede K, Viguera AC, Bottéro A, Baldessarini RJ: Treatise on Insanity in Pregnant, Postpartum, and Lactating Women by Louis-Victor Marcé (1858): Commentary. *Harvard Rev Psychiatry* 2009; 17: 157–165.
513. Trede K, Viguera AC, Bottéro A, Baldessarini RJ: Treatise on Insanity in Pregnant, Postpartum, and Lactating Women by Louis-Victor Marcé (1858): Commentary. *Harv Rev Psychiatry Greek Edition* 2009; 17: 106–115.
514. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. To prescribe or not to prescribe? *Br J Psychiatry* 2009; 194:189–190.
515. Wingo AP, Harvey PD, Baldessarini RJ: Cognitive impairment in euthymic bipolar disorder patients: functional implications. *Bipolar Disord* 2009; 11: 113–125.
516. Baldessarini RJ, Bolzani L, Cruz N, Jones PB, Lai M, Lepri B, Pérez J, Salvatore P, Tohen M, Tondo L, Vieta E. Onset-age of bipolar disorders at six international sites. *J Affect Dis* 2010; 121: 143–146.
517. Baldessarini RJ, Salvatore P, Khalsa HM, Gebre-Medhin P, Imaz H, González-Pinto A, Pérez J, Cruz N, Maggini C, Tohen M. Morbidity in 303 first-episode bipolar I disorder patients. *Bipolar Disord* 2010; 12: 264–270.
518. Baldessarini RJ, Tondo L, Lepri B. Empirical test of a basic assumption underlying survival analysis as applied to experimental therapeutics in psychopharmacology. *J Clin Psychopharmacol*; 2010; 30:72–75.
519. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ: Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. *Hum Psychopharmacol* 2010; 25:179–186.
520. Booth RG, Neumeyer JL, Baldessarini RJ. Therapeutic and diagnostic agents for Parkinson's disease. Chapter 15, vol 9, in Donald J. Abraham DJ, eds. New York: John Wiley & Sons. *Burger's Medicinal Chemistry, Drug Discovery and Development*, 7th edition, 2010, pp 529-568.
521. Gross A, Altman M, Salvatore P, Baldessarini RJ, Chanoff M, Powers JF. Atypical, chronic psychotic disorder in a 55-year old man. *Harv Rev Psychiatry* 2009; 17: 329–343.
522. Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ: Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. *J Affect Disord* 2009; 119: 22–27.
523. Vigo D, Baldessarini RJ: Anticonvulsants in the treatment of major depressive disorder patients: an overview. *Harvard Rev Psychiatry* 2009; 17: 231–141.

524. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ: Effects of lithium on cognitive performance: meta-analysis. *J Clin Psychiatry* 2009; 70: 1588–1597.
525. Baldessarini RJ. Reflections of suicide prevention: challenges for modern psychiatry. Chapt 6 in Pompili M, editor: *Suicide in the Words of Suicidologists*. Hauppauge, NY: Nova Science Publishers, 2010; pp 35–39.
526. Baldessarini RJ. Commentary: the Bipolar Affective Disorder: Lithium/Anticonvulsant Evaluation (BALANCE) study. *Bipolar Disord* 2010; 12:667–668.
527. Baldessarini RJ, Bolzani L, Cruz N, Jones PB, Lai M, Lepri B, Pérez J, Salvatore P, Tohen M, Tondo L, Vieta E. Onset-age of bipolar disorders at six international sites. *J Affect Disord* 2010; 12 1:143–146.
528. Baldessarini RJ, Salvatore P, Khalsa H-MK, Tohen M. Dissimilar morbidity following initial mania vs. mixed-states in type-I bipolar disorder. *J Affect Disord* 2010; 126:299–302.
529. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Discontinuation rate vs. recurrence risk following long-term antidepressant treatment in major depressive disorder patients. *Am J Psychiatry* 2010; 167:934–941. [Selected among Journal Watch Top Stories 2010: <http://psychiatry.jwatch.org/top_stories/editors_choice2010.dt>].
530. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. *Harvard Rev Psychiatry* 2010; 18:143–157.
531. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. *Hum Psychopharmacol* 2010; 25:179–186.
532. Gardner D, Murphy A, Centorrino F, Baldessarini RJ. Equivalent doses of antipsychotic agents: findings from an international Delphi survey. International consensus study of antipsychotic dosing. *Am J Psychiatry* 2010; 167:686–693.
533. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, Filkowski MM, Hennen J, Sachs GS, Goodwin FK, Baldessarini RJ. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. *J Clin Psychiatry* 2010; 71:372–380.
534. Girardi P, Serafini G, Pompili M, Innamorati M, Tatarelli R, Baldessarini RJ. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. *Pharmacopsychiatry* 2010; 43:66–72.
535. Harvey PD, Wingo AP, Burdick K, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. *Bipolar Disord* 2010; 12:364–375.
536. Pompili M, Baldessarini RJ. Suicidal risk associated with antiepileptic drug treatment. *Nature Rev Neurology* 2010; 6:651–653.
537. Pompili M, Baldessarini RJ, Tondo L, Cecchitelli C, Olivieri C, De Pisa E, Mosticoni S, Girardi P, Tatarelli R. Response to intravenous antidepressant treatment by suicidal major affective disorder patients. *J Affect Disord* 2010; 122: 154–158.
538. Pompili M, Tatarelli R, Girardi P, Tondo L, Baldessarini RJ. Suicide risk during anticonvulsant treatment. *Pharmacoepidemiol Drug Safety* 2010; 19:525–528.
539. Tondo L, Lepri B, Cruz N, Baldessarini RJ. Age at onset in 3014 Sardinian bipolar and major depressive disorder patients. *Acta Psychiatr Scand* 2010; 121:446–452.
540. Tondo L, Vázquez GH, Baldessarini RJ. Mania associated with antidepressant-treatment: comprehensive meta-analytic review. *Acta Psychiatr Scand* 2010; 121:404–414.
541. Viguera AC, Cohen LE, Whitfield T, Reminick AM, Bromfield R, Baldessarini RJ. Perinatal use of anticonvulsants: differences in attitudes and recommendations among neurologists and psychiatrists. *Arch Women's Ment Health* 2010; 13:175–178.
542. Vincenti A, Ventriglio A, Baldessarini RJ, Talamo A, Fitzmaurice G, Centorrino F. Characteristics and clinical changes during hospitalization in bipolar and psychotic disorder patients with versus without substance-use disorders. *Pharmacopsychiatry* 2010; 43:225–232.
543. Wingo AP, Baldessarini RJ, Compton MT, Harvey PD. Correlates of recovery of social functioning in types I and II bipolar disorder patients. *Psychiatry Res*; 2010; 177:131–134.
544. Wingo AP, Baldessarini RJ, Holtzheimer PE, Harvey PD. Factors associated with functional recovery in bipolar disorder patients. *Bipolar Disord* 2010; 12:319–326.
545. Alphas L, Samad N, Baldessarini RJ, Berlin J, Feltner D, Ferziger R, Lindenmayer J-P, Radhakrishnan R, Ramey T, Sachs G, Siu C, Stang P, Vanderburg D. Commentary on a draft report of the US Agency for

- Healthcare Research and Quality (AHRQ): *Antipsychotics in Adults: Comparative Effectiveness of First-Generation versus Second-Generation Medications*. Washington, DC: International Society for CNS Clinical Trials and Methodology (ICSTM), 2011, 15 pp.
546. Baldessarini RJ: Reflections on suicide prevention: challenges for modern psychiatry. Chapt 6 in Pompili M, editor: *Suicide in the Words of Suicidologists*. Hauppauge, NY: Nova Science Publishers, 2011, pp 35–39.
547. Baldessarini RJ, Gardner D. Incidence of extrapyramidal syndromes and tardive dyskinesia. *J Clin Psychopharmacol* 2011; 31: 382–384.
548. Indic P, Salvatore P, Baldessarini RJ, Murray G, Ferraro G, Ghidini S, Maggini C. Scaling human activity rhythms to develop a novel biomarker for bipolar disorder. *PLoS One* 2011; 6(51 e20650): 1–8.
549. Leiderman EA, Lolich M, Vázquez GH, Baldessarini RJ. Depression: point-prevalence and sociodemographic correlates in a Buenos Aires community sample of 1335 persons. *J Affect Disord* 2011; 136:1154–1158.
550. Pérez J, Baldessarini RJ, Cruz N, Salvatore P, Vieta E. Andrés Piquer-Arrufat (1711–1772): contributions of an eighteenth-century Spanish physician to the concept of manic-depressive illness. *Harvard Rev Psychiatry* 2011; 19:68–77.
551. Pompili M, Baldessarini RJ, Berman AL, Lester DL, Wasserman D, DeLeo D, Girardi P. Integration of suicidology with general medicine: an obligation to society. *Patient Ed Counseling* 2011; 85:127–128.
552. Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate CA Jr, Vieta E, Maggini C. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. *J Clin Psychiatry* 2011; 72: 183–193.
553. Sim K, Fujii S, Yang S-Y, Chong M-Y, Ungvari GS, Tianmei S, Si T, He YL, Cheng EK, Trivedi J, Udomratn P, Shinfuku N, Chan YH, Kuo EH, Tan CH, Baldessarini RJ. Adjunctive mood-stabilizer treatment for hospitalized schizophrenia patients: Asia Psychotropic Prescription Study (2001–2008). *Int J Neuropsychopharmacol* 2011; 14:1157–1164.
554. Tondo L, Lepri B, Baldessarini RJ. Reproduction in women and men with major mood disorders. *Acta Psychiatr Scand* 2011; 123: 283–289. .
555. Tor P-C, Ng TP, Yong KH, Sim K, Xiang Y-T, Wang C-Y, Lee EHM, Fujii S, Yang S-Y, Chong M-Y, Ungvari GS, Si T, He YL, Cheng EK, Chee KY, Trivedi J, Udomratn P, Shinuku N, Kua EH, Tan CH, Sartorius N, Baldessarini RJ. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patient in Asia from 2001 to 2008. *Int J Neuropsychopharmacol* 2011; 14: 735–745.
556. Vázquez GH, Baldessarini RJ, Yildiz A, Tamayo J, Tondo L, Salvatore P. Multi-site international collaborative clinical trials in mania: commentary. *Int J Neuropsychopharmacol* 2011; 14:1013–1016.
557. Vázquez GH, Lolich M, Leiderman EA, Tondo L, Baldessarini RJ. Age-at-onset in 68 patients with major affective disorders: clinical and prognostic implications. *Mind Brain J Psychiatry* 2011; 1:1–7.
558. Vázquez GH, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. *Pharmacopsychiatry* 2011; 44:21–26.
559. Ventriglio A, Vincenti A, Centorrino F, Talamo A, Fitzmaurice G, Baldessarini RJ. Use of mood-stabilizers for hospitalized adult psychotic and bipolar disorder patients. *Int Clin Psychopharmacol* 2011; 26 88–95.
560. Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2252 pregnancies and postpartum periods. *Am J Psychiatry* 2011; 168:1179–1185.
561. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. *Neuropsychopharmacology* 2011; 36:375–389.
562. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. *Int J Neuropsychopharmacol* 2011; 14:863–875.
563. Baldessarini RJ Salvatore P, Imaz-Etxeberria H, Khalsa H-MK, Gonzalés-Pinto A, Tohen M: Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients. *J Affect Disord* 2012; 136:149–154.
564. Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, Khalsa HMK, Pepri B, Ha TH, Chang HS, Tohen M, Vieta E. Predominant recurrence polarity among 928 adult international bipolar-I disorder patients. *Acta Psychiatr Scand* 2012; 125:293–302.
565. Baldessarini RJ, Tondo L, Vázquez GH, Bolzani L, Khalsa H-MK, Lai M, Lepri B, Lolich M, Maffei PM, Salvatore P, Tohen M. International study of functional and symptomatic outcome versus onset-age in 1437 bipolar-I disorder patients. *World Psychiatry* 2012; 11:40–46.

566. Centorrino F, Masters G, Baldessarini RJ, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. *Hum Psychopharmacol* 2012; 27: 521–526.
567. Indic P, Murray G, Maggini C, Amore A, Meschi T, Borghi L, Baldessarini RJ, Salvatore P. Multi-scale motility amplitude associated with suicidal thoughts in major depression. *PLoS One* 2012; 7(6: e38761):1–7.
568. Kelleher J, Centorrino F, Huxley NA, Bates JA, Kidwell J, Egli S, Baldessarini RJ. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment: a pilot controlled trial. *Eur Neuropsychopharmacol* 2012; 22:415–418.
569. Lorenzo LS, Vázquez GH, Zaratiegui RM, Baldessarini RJ. Characteristics of bipolar disorder patients given antidepressants. *Hum Psychopharmacol* 2012; 27: 486–491.
570. Newport DJ, Baldessarini RJ, Knight BT, Fernandez SV, Morris NJ, Viguera AC, Stowe ZN. Comparison of women with confirmed versus presumably misdiagnosed bipolar disorder. *J Clin Psychiatry* 2012; 73:242–246.
571. Pérez J, Baldessarini RJ, Undurraga J. Origins of psychiatric hospitalization in medieval Spain. *Psychiatr Quart* 2012; 83: 419–430.
572. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. *Bipolar Disord* 2012; 14:573–584.
573. Tohen M, Khalsa H-MK, Salvatore P, Vieta E, Ravichandran C, Baldessarini RJ. Two-year outcomes in first-episode psychotic depression: McLean-Harvard first episode project. *J Affect Disord* 2012; 136:1–8.
574. Undurraga J, Baldessarini RJ. A 30-year meta-analytic review of antidepressant efficacy in acute major depression. *Neuropsychopharmacology* 2012; 37:851–864.
575. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Tondo L, Vázquez GH, Vieta E. Bipolar depression: clinical correlates of receiving antidepressants. *J Affect Disord* 2012; 139: 89–93.
576. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E. Suicidal risk factors in bipolar I and II disorder patients. *J Clin Psychiatry* 2012; 73:778–782.
577. Vázquez GH, Lolic M, Leiderman EA, Tondo L, Baldessarini RJ. Age-at-onset of 648 patients with major affective disorders: clinical and prognostic implications. *Mind Brain J Psychiatry* 2012; 3:1–7.
578. Baethge C, Assall OP, Baldessarini RJ. Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000–2010. *Psychother Psychosom* 2013; 82:152–160.
579. Baldessarini RJ, Faedda GL, Offidani E, Vázquez GH, Marangoni C, Serra G, Tondo L. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. *J Affect Disord* 2013; 148:129–135.
580. Baldessarini RJ, Selle V, Vigo D. Enduring pain: II. treatment (Spanish). *VERTEX Rev Argentin Psiquiatría (Buenos Aires)* 2013; 24:345–350.
581. Baldessarini RJ, Selle V, Vigo D. Enduring pain: II. treatment (English version on-line). *VERTEX Rev Argentin Psiquiatría (Buenos Aires)* 2013; 24:345–350.
582. Koukopoulos A, Reginaldi D, Tondo L, Visioli C, Baldessarini RJ. Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias. *J Affect Disord* 2013; 151:105–110.
583. Lim CS, Baldessarini RJ, Vieta E, Yucil M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. *Neurosci Biobehav Rev* 2013; 37:418–435.
584. Offidani E, Fava GA, Tomba E, Baldessarini RJ. Excessive mood-elevation with juvenile antidepressant treatment in depressive versus anxiety disorders: systematic review. *Psychother Psychosom* 2013; 82:132–141.
585. Pagel T, Baldessarini RJ, Franklin J, Baethge C. Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. *Bipolar Disord* 2013; 15: 229–239.
586. Pagel T, Baldessarini RJ, Franklin J, Baethge C. Heterogeneity of schizoaffective disorder compared with schizophrenia and bipolar disorder. *Acta Psychiatr Scand* 2013; 128:238–250.
587. Pérez J, Faedda GL, Baldessarini RJ. Electricity rendered useful for mental illness: tribute to Richard Lovett (1692–1780). *Br J Psychiatry* 2013; 203:241–242.
588. Pérez J, Undurraga J, Baldessarini RJ. The lions of Granada maristan. *Am J Psychiatry* 2013; 170:152–153.
589. Reginaldi D, Koukopoulos A, Baldessarini RJ, Fredda GL, G, Kotzadilis G, Manfredi G, Raja M, Sani G, Serra G, Tondo L. Transitions: Athanasios Koukopoulos, MD (1931–2013). *Aretaeus News* 2013; 9:1–3.

-
590. Reginaldi D, Koukopoulos A, Baldessarini RJ, Fredda GL, Fazzari G, Girardi P, Kotzadilis G, Manfredi G, Minnai G, Pacchiarotti I, Raja M, Sani G, Serra G, Tondo L. Transitions: Athanasios Koukopoulos [Αθανάσιος Κουκόπουλος], M.D. (1931–2013). *Int J Bipolar Disord* 2013; 1:17.
591. Salvatore P, Baldessarini RJ, Khalsa H-MK, Amore M, DiVittorio C, Ferraro G, Maggini C, Tohen M. Predicting diagnostic change among first-episode patients diagnosed with DSM-IV major depression with psychotic features. *J Clin Psychiatry*; 2013: 74:723–731.
592. Salvatore P, Baldessarini RJ, Khalsa HM, Indic P, Maggini C, Tohen M. Negative affective features in 516 cases of first psychotic disorder episodes: relationship to suicidal risk. *J Depress Anxiety* 2013; 2:131–136.
593. Salvatore P, Indic P, Murray G, Baldessarini RJ. Biological rhythms and mood disorders. *Dialog Clin Neurosci* 2013; 14:369–379.
594. Tondo L, Baldessarini RJ. Fertility rates in mood disorder patients in Sweden and Sardinia. *JAMA-Psychiatry* 2013; 70:1115–1116.
595. Tondo L, Baldessarini RJ, Vázquez GH, Lepri B, Visioli C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. *Acta Psychiatr Scand* 2013; 127:355–364.
596. Undurraga J, Tondo L, Schalkwijk S, Vieta E, Baldessarini RJ. Re-analysis of the earliest controlled trials of imipramine. *J Affect Disord* 2013; 147:451–454.
597. Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment in bipolar depression: critical commentary. *Intl J Neuropsychopharmacol* 2013; 16:1673–1685.
598. Vigo D, Selle V, Baldessarini RJ. Enduring pain: nosology and epidemiology (Spanish). *VERTEX Rev Argentín Psiquiatría (Buenos Aires)* 2013; 24(111):345–350.
599. Vigo D, Selle V, Baldessarini RJ. Enduring pain: nosology and epidemiology (English version, on-line). *VERTEX Rev Argentín Psiquiatría (Buenos Aires)* 2013; 24(111):345–350.
600. Baldessarini RJ. The impact of psychopharmacology on contemporary psychiatry. *Can J Psychiatry* 2014; 59:401–405.
601. Baldessarini RJ, Tondo L. Are renal tumors associated with lithium treatment? *Intl J Bipolar Disord* 2014; 2:6–7.
602. Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: predictive associations with later illness. *Acta Psychiatr Scand* 2014; 129: 383–392.
603. Faedda GL, Serra G, Marangoni C, Salvatore P, Sani G, Vázquez GH, Tondo L, Girardi P, Baldessarini RJ, Koukopoulos A. Clinical risk factors for bipolar disorders: systematic review of prospective studies. *J Affect Disord* 2014; 168:314–321.
604. Masters G, Baldessarini RJ, Öngür D, Centorrino F. Factors associated with length of psychiatric hospitalization. *Compr Psychiatry* 2014; 55:681–687.
605. Salvatore P, Baldessarini RJ, Khalsa H-MK, Vázquez GH, Pérez J, Maggini C, Tohen M. McLean-Harvard International First Psychotic episode study: antecedents in 263 bipolar I disorder patients. *Acta Psychiatr Scand*; 2014; 129: 275–285.
606. Salvatore P, Bhuvanesar C, Baldessarini RJ, Khalsa HMK, Tohen M, Maggini C. Capgras delusional misidentification syndrome in first-episode psychotic disorder patients. *Psychopathology* 2014; 47:261–269.
607. Schalkwijk S, Undurraga J, Tondo L, Baldessarini RJ. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. *Intl J Neuropsychopharmacol* 2014; 17:1343–1352.
608. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analysis of placebo-controlled monotherapy trials of lithium, anticonvulsants, and antipsychotics. *Pharmacopsychiatry* 2014;47:43–52.
609. Serra G, Koukopoulos A, De Chiara L, Napolitano F, Koukopoulos AE, Curto M, Manfredi G, Faedda GL, Girardi P, Baldessarini RJ. Features preceding diagnosis of bipolar versus major depressive disorders. *J Affect Disord* 2015; 173:134–142.
610. Tondo L, Vazquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. *Curr Psychiatry Rep* 2014; 16:431–437.
610. Tondo L, Visioli C, Preti A, Baldessarini RJ. Bipolar disorders following initial depression: modeling predictive clinical factors. *J Affect Disord* 2014; 167:44–49.

612. Vázquez GH, Tondo L, Undurraga J, Zaratiegui R, Baldessarini RJ. Pharmacological treatment for bipolar depression. *Adv Psychiatr Treatment* 2014; 20:193–201.
613. Ventriglio A, Baldessarini RJ, Iuso S, La Torre A, D’Onghia A, La Salandra M, Mazza M, Bellomo A. Language-proficiency among hospitalized immigrant psychiatric patients in Italy. *Intl J Soc Psychiatry* 2014; 50:299–303.
614. Ventriglio A, Gentile A, Baldessarini RJ, Martone S, Vitrani G, La Marca A, Bellomo A. Improvements in metabolic abnormalities in overweight bipolar disorder and schizophrenia patients. *Eur Psychiatry* 2014; 29:402–407.
615. Yildiz A, Vieta E, Nikodem M, Correll CU, Baldessarini RJ. Critical issues on the use of network meta-analysis in psychiatry. *Harv Rev Psychiatry* 2014; 22:367–372.
616. Yildiz A, Vieta E, Nikodem M, Correll CU, Baldessarini RJ. Updated meta-analytic review of antimania treatment trials. *Psychol Med* 2015; 45:299–317.
617. Balda MV, Garay OU, Papale RM, Bologna VG, Brandolini A, Prokopez CR, Balasini JI, Baldessarini RJ, Daray FM. Clozapine-induced neutropenia and agranulocytosis in Argentina between 2007 and 2012. *Int Clin Psychopharmacol*; 2015; 30(2):109–114.
618. Baldessarini RJ. Risks in discontinuation trials with antidepressants. *J Clin Psychiatry* 2015; in press.
619. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent relapse of major depression. *J Clin Psychopharmacol* 2015; in press.
620. Dickstein L, Viguera A, Nowacki A, Thompson N, Griffith S, Baldessarini RJ, Katzan I. Thoughts of death and self-harm in patients with epilepsy or multiple sclerosis in a tertiary-care center. *Psychosomatics* 2015; 56:44–51.
621. Çamsarı U, Viguera AC, Ralston L, Baldessarini RJ, Cohen LS. Prevalence of atypical antipsychotic use in psychiatric outpatients: comparison of women of childbearing age with men. *Arch Women’s Ment Health* 2014; 17:583–586.
622. Serra G, Koukopoulos A, De Chiara L, Koukopoulos AE, Tondo L, Girardi P, Baldessarini RJ, Serra G. Three-year, open, mirror-image, add-on trial of memantine for 30 treatment-resistant bipolar disorder patients. *J Clin Psychiatry* 2015; 76(1):e91–e97.
623. Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment of bipolar depression. *Focus: Journal of Lifelong Learning in Psychiatry* 2015; 13(1):102–111s
624. Baldessarini RJ. Bipolar depression: an orphan syndrome? *Düşünen Adam: J Psychiatry Neurol Sci (Istanbul)* 2015; in press.
625. Tohen M, Khalsa H-MK, Salvatore P, Zarate CA Jr, Strakowski SM, Pérez J, Ravichandran C, Baldessarini RJ. The McLean-Harvard First-Episode Project: early course in 114 cases of first-episode nonaffective psychoses. *J Clin Psychiatry* 2015; in press.
626. Ventriglio A, Gentile A, Baldessarini RJ, Bellomo A. Impact of early life stress on psychiatric disorders: searching new biomarkers and innovative pharmacological targets. *Curr Ther Design* 2015; 21: in press.
627. Ventriglio A, Lepore A, Baldessarini RJ, Mafalda-Patella R, Borelli A, Bellomo A. Cognitive functioning in outpatients diagnosed with schizophrenia, with and without co-morbid alcohol abuse. *J Psychopathol* 2014; in press.
628. Wingo AP, Baldessarini RJ, Windle M. Coping styles: Longitudinal development from ages 17 to 33 and associations with psychiatric disorders. *Psychiatry Res* 2015; in press.
629. Arefian H, Hagel S, Heublein S, Rissner F, Schjerag A, Brunkhorst FM, Baldessarini RJ, Hartmann M. Extra length of stay and costs due to healthcare-associated infections at a German university hospital. *Infect Control Hosp Epidemiol* 2014; in review.
630. Curto M, Centorrino F, Masters GA, Baldessarini RJ. Factors associated with costs of hospitalization of severe mentally ill patients. *J Ment Health Policy Econ* 2014; in review.
631. Faedda GL, Baldessarini RJ, Marangoni C, Pérez J, Koukopoulos A. Giovanni Aldini and studies of postmortem effects of electrical stimulation on newly executed prisoners at Newgate Prison, London. *J Hist Neurosci*; in review.

632. Forte A, Baldessarini RJ, Tondo L, Vázquez G, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and major depressive disorders. *J Affect Disord* 2015; in press.
633. Serra G, Koukopoulos A, De Chiara L, Napoletano D, Faedda GL, Girardi P, Baldessarini RJ. Child and adolescent clinical features preceding suicide attempts. *Acta Psychiatr Scand* 2014; in review.
634. Sim K, Baldessarini RJ. Treatments aimed at reducing risk of relapse and recurrences in major depression. *Lancet-Psychiatry* 2014; in review.
635. Viguera AC, Baldessarini RJ, Whitfield T, Koukopoulos A, Cohen LS. Clinical outcomes and predictors of antidepressant exposure among pregnant women with bipolar disorder. *J Affect Disord* 2014; in review.
636. Salvatore P, Baldessarini RJ, Khalsa H-MK, Tohen M. Antecedents among 516 first-episode patients diagnosed with DSM-IV psychotic disorders; in preparation.

ORIGINAL RESEARCH IN PUBLISHED PROCEEDINGS

1. Baldessarini RJ: Factors influencing S-adenosyl-L-methionine levels in mammalian tissues. In Himwich HE, Kety SS, Smythies JR, editors. *Amines and Schizophrenia*, Oxford Press, New York, 1966, pp 199–206.
2. Baldessarini RJ: Metabolic effects of L-DOPA. In de la Fuente F, editor. *Proceedings Seminario Internacional de Neurologia Experimental y Psicofarmacologia*, Autonomous University of Mexico, Mexico City, November, 1970, pp 150–155.
3. Baldessarini RJ: Aspects of the clinical and biochemical pharmacology of lithium salts. In de la Fuente F, editor. *Proceedings Seminario Internacional de Neurologia Experimental y Psicofarmacologia*, Autonomous University of Mexico, Mexico City; November, 1970, pp 160–164.
4. Kopin IJ, Baldessarini R: Assay of tissue levels of S-adenosyl-L-methionine. In Tabor H, Tabor CW, editors: *Methods in Enzymology*, Vol 17B, *Metabolism of Amino Acids and Amines*, Academic Press, New York, NY, 1971, pp 397–400.
5. Baldessarini RJ, Fischer JE: False neurochemical transmitters and disordered function of the CNS. In de la Fuente R, Weissman MM, editors. *Proc. Fifth World Congress of Psychiatry*, Mexico City, November, 1971, *Excerpta Medica*, Amsterdam, 1973, pp. 871–876.
6. Baldessarini RJ, Fischer JE: Biological models in the study of false neurochemical synaptic transmitters. In Schien H, Ingle D, editors. *Biological Models in Psychiatric Research*, MIT Press, Cambridge, MA, 1975, pp 51–79.
7. Baldessarini RJ, Harris JE: Effects of amphetamines on the metabolism of catecholamines in the rat brain. In Kety SS, Matthysse S, editors. *Proc Intl Symposium on Catecholamines and Schizophrenia*, Strasbourg, France, Pergamon Press, Oxford, 1975, pp 41–43.
8. Stewart RM, Baldessarini RJ: An animal model of myoclonus related to central serotonergic neurons. In Hanin I, Usdin E, editors. *Animal Models in Psychiatry and Neurology*, Pergamon Press, Oxford, 1977, pp 431–439.
9. Baldessarini RJ: On the development and utilization of assays for biological transmethylation involving S-adenosyl-L-methionine, In Andreoli VM, Agnoli A, Fazio C, editors. *Transmethylations and the Central Nervous System*. Springer-Verlag, Berlin, 1978, pp 31–48.
10. Stewart RM, Gerson SC, Sperk G, Campbell A, Baldessarini RJ: Biochemical behavioral, and pharmacologic studies of the effects of dihydroxytryptamines in the rodent brain. In Jacoby JH, Lytle LE, editors. *Serotonin Neurotoxins*. *Ann NY Acad Sci* 1978; 305: 198–207.
11. Baldessarini RJ: Apomorphine prodrug derivatives as long-acting dopamine receptor active agents with potential clinical utility. In Usdin E, Kopin IJ, Barchas JD, editors. *Proc Fourth Intl Catecholamine Symposium*. Pergamon Press, Oxford, 1979, pp 1596–1598.
12. Baldessarini RJ, Stramentinoli G, Lipinski JF: Methylation in schizophrenia: An old hypothesis revisited. In Zappia V, Usdin E, Salvatore F, editors. *Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System*. Pergamon Press, Oxford, 1979, pp 127–140.

13. Noon JP, Rice PJ, Baldessarini RJ: Alpha-adrenergic receptors in rat aortic smooth muscle: Evidence for two cooperatively interacting populations. In Usdin E, Kopin IJ, Barchas JD, editors. *Proceedings Fourth Intl Catecholamine Symposium*. Pergamon Press, New York, 1979, pp 411–413.
14. Baldessarini RJ: Uptake, release, and postsynaptic effects of aromatic amines in mammalian brain. Chapt 1 in Mosnaim AD, Wolf ME, editors. *Non-catecholic Phenethylamines, Part 2, Phenylethanolamine, Tyramines and Octopamine*, M Dekker, New York, 1980, pp 1–19.
15. Baldessarini RJ, Arana GW, Kula NS, Campbell A, Harding M: Preclinical studies of the pharmacology of aporphines. In Corsini GU, Gessa G, editors. *Apomorphine and Other Dopaminomimetics, Vol 1, Basic Pharmacology*, Raven Press, New York, 1981, pp 219–228.
16. Neumeyer JL, Baldessarini RJ, Arana GW, Cohen SA, Campbell A: Aporphines as stereochemical probes for central dopamine receptors. In Melchoirre C, Gianella M, editors. *Highlights in Receptor Chemistry*, Elsevier Press, Amsterdam, Holland, 1984, pp 49–74.
17. Neumeyer JL, Baldessarini RJ, Arana GW, Campbell A: Aporphines as dopamine receptor agonists and antagonists at central dopamine receptors. In Makriyannis A, editor. *New Methods in Drug Research, Vol. 1, JR Prous Science Publishers, Barcelona, Spain, 1985, pp 153–166.*
18. Baldessarini RJ: Epidemiology of tardive dyskinesia. In Berner P, Editor. *Proceedings of the Sixth World Congress of Psychiatry*, Plenum Press, New York, 1986, pp 120–124.
19. Baldessarini RJ, Tohen M: Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? In Casey DE, Christensen AV, editors. *Psychopharmacology: Current Trends*, Springer-Verlag, Heidelberg, 1988, pp 130–139.
20. Gelbard HA, Teicher MH, Baldessarini RJ, Gallitano A, Marsh ER, Zorc J., Faedda G: Development of the dopamine D₁ receptor system depends on endogenous dopamine. *Proc Eighth World Congress of Psychiatry, Athens, Greece, October 1989, pp 100–104.*
21. Teicher MH, Barber NI, Lawrence JM, Baldessarini RJ: Motor activity and antidepressant drugs. A proposed approach to categorizing depression syndromes and their animal models, Chapt. 8 in *Animal Models of Depression*. Birkhauser Press, Boston, 1989, pp 135–161.
22. Gelbard JA, Teicher MH, Baldessarini RJ, Gallitano A, Marsh ER, Zorc J, Faedda GL: Development of the dopamine D₁ receptor system depends on endogenous dopamine. In CN Stefanis, CR Soldatas, AD Rabavailas, editors. *Psychiatry, A World Perspective Volume, Vol. 2. Elsevier Science, Amsterdam, Netherlands, 1990, pp 651–658.*
23. Gelbard HA, Teicher MH, Beers NB, Gallitano A, Baldessarini RJ: Neonatal depletion of dopamine decreases D₁ and forskolin binding sites in rat striatum. In Spano DF, editor. *Dopamine-90: Proc Satellite Symposium to Eleventh Intl Union of Pharmacology (IUPHAR) Congress in Como, Italy, July, 1990.*
24. Baldessarini RJ, Campbell A, Yeghiayan S, Neumeyer JL: Limbic-selective antidopaminergic effects of S(+)-aporphines compared to typical and atypical antipsychotic agents in the rat. In Racagni G, Brunello N, Fukuda T, editors. *Biological Psychiatry (Proc Fifth World Congress of Biological Psychiatry in Florence)*, vol 2. Amsterdam: Excerpta Medica, 1991, pp 837–840.
25. Baldessarini RJ, Campbell A, Yeghiayan S, Neumeyer JL: Limbic-selective antidopaminergic effects of S(+)-aporphines compared to typical and atypical antipsychotic agents in the rat. In Racagni G, Brunello N, Fukuda T, editors. *Biological Psychiatry (Proc Fifth World Congress of Biological Psychiatry, Florence)*, vol 2. Amsterdam: Excerpta Medica, 1991, pp 837–840.
26. Cohen BM, Baldessarini RJ, Campbell A, Tsuneizumi T, Babb S: Persistence of antipsychotic drug effects and tissue levels, Chapt. 27 in *Advances in Neuropsychiatry and Psychopharmacology: vol. 2, Schizophrenia Research*, Schulz SC, Tamminga CA, editors. Raven Press, New York, 1991, pp 277–284.
27. Neumeyer JL, Baidur N, Bakthavachalam V, Yuan J, Kula NS, Campbell A, Baldessarini RJ: Stereoisomeric, photoaffinity, and fluorescent probes for characterization of dopamine D₁ and D₂ receptors. In Angeli P, Gulini U, Quaglia W, editors. *Trends in Receptor Research*, Amsterdam, Elsevier Science, Amsterdam, pp 175–183, 1992.

28. Quinn J, Baldessarini RJ: A psychological reading of Hawthorne's "The Birthmark". In Meyer M, Darion E, Francis C, Phillips A, Repp J, editors. *The Compact Bedford Introduction to Literature: Reading, Thinking, and Writing* (Third Edition). Bedford–St. Martin's Press, Boston, 1994, pp 245–257.
29. Baldessarini RJ: Treatment of bipolar disorders with lithium: Overview of recent research findings from the International Consortium for Bipolar Disorders Research. *Proceedings of the American Society for Clinical Psychopharmacology*, Barbados, February, 1997, pp 120–148.
30. Neumeyer JL, Baldessarini RJ, Kula NS, Tamagnan G: Novel phenyltropanes: Affinity to monoamine transporters in rat forebrain (Chapt. 105). In Fisher A, Hanin I, Yoshida M, editors. *Advances in Behavioral Biology*, Vol. 49, *Progress in Alzheimer's and Parkinson's Diseases*. Plenum Press, New York, 1998, pp 739–745.
31. Tamagnan G., Gao Y, Xu L, Kula NS, Baldessarini RJ, Neumeyer JL: Nonisotopic surrogates for technetium as ligands for monoamine transporters. In: Stern G, editor. *Advances in Neurology*, Vol. 80, *Parkinson's Disease*. Lippincott-Raven Press, Philadelphia, 1999, pp 99–103.
32. Tamagnan G, Zoghbi SS, Kula NS, Gao P, Gao Y, Baldessarini RJ, Innis RB, Baldwin RM: Cyclopentadienyltricarbonylrhenium complexes for dopamine and serotonin receptors. In Mazzi U, editor. *Technetium and Rhenium in Chemistry and Nuclear Medicine*, Vol. 5. SGEEditori, Padova, Italy, 1999, pp 485–490.
33. Tondo L, Baldessarini RJ: Clinical effectiveness of long-term lithium treatment in bipolar disorder. *Proceedings of the Stanley Foundation Bipolar Disorder Symposium*, London, UK, 1999.
34. Baldessarini RJ: Lithium and suicide risk in bipolar disorder. *Medical Education Resources*, Monmouth Junction, NJ, 2000, pp 1–10.
35. Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. *Yearbook of Psychiatry and Applied Mental Health*, Talbott JA, editors. Mosby Press, St. Louis, 2001, pp 360–362.
36. Baldessarini RJ: Recent advances in the pharmacological prevention of suicide. In Cote PJ Jr (editor): *Taking Action, Saving Lives: Suicide Prevention Across the Lifespan*. Boston, MA: Massachusetts Department of Health, September, 2005, pp 62–70.

REVIEWS, CHAPTERS & SYLLABI

1. Glowinski J, Baldessarini RJ: The metabolism of norepinephrine in the central nervous system. *Pharmacol. Reviews* 1966; 18: 1201–1238.
2. Baldessarini RJ, Lambdin, K: *Treatment facilities for adolescent psychiatric patients: A guide for psychiatric practitioners*. Department of Psychiatry, Johns Hopkins Hospital, Baltimore, MD, 1968, 25 pp.
3. Baldessarini RJ, Levy B: *The use of lithium carbonate in affective disorders: A practical review for medical and psychiatric practitioners*. Department of Psychiatry, Johns Hopkins Hospital, Baltimore, MD, 1968 12 pp.
4. Mountcastle VB, Baldessarini RJ: Synaptic transmission. Chapt 58 in *Medical Physiology*, Vol II, 12th edition, Mountcastle VB (ed). Mosby Co., St. Louis, MO, 1968, pp 1231–1274.
5. Baldessarini RJ: Biogenic amines and behavior. *Ann Rev Medicine* 1972; 23: 343–354.
6. Baldessarini RJ: Pharmacology of the amphetamines. *Pediatrics* 1972; 49: 694–701.
7. Baldessarini RJ: Reporter's Notes, First Session. In Usdin E, Snyder S, editors. *Frontiers in Catecholamine Research*, Pergamon Press, Oxford, 1973, pp 619–621.
8. Baldessarini RJ, Karobath M: Biochemical physiology of central synapses. *Ann Rev Physiology* 1973; 35: 273–304.
9. Baldessarini RJ, Lipinski JF: Risks vs. benefits of antipsychotic drugs. *N Engl J Med* 1973; 289: 427–428.
10. Baldessarini RJ: The schizophrenia syndrome and related psychoses. Chapt 342 in Wintrobe M, Thorn GW, Adams, RD, Brunwald E, Isselbacher K, Petersdorf RG, editors. *Harrison's Principles of Internal Medicine*, seventh edition, MacMillan Co., New York, 1974, pp 1896–1903.
11. Baldessarini RJ, Mandel MR, editors. *Hospital Formulary for the Erich Lindemann Mental Health Center*. Massachusetts Department of Mental Hygiene, Boston, 1974, 30 pp.
12. Mountcastle VB, Baldessarini RJ: Synaptic transmission. In Mountcastle VB, editor. *Medical Physiology*, 13th edition, Mosby Co., St. Louis, MO, 1974, pp 182–223.

13. Baldessarini RJ (Consultant): On blocking a blockade buster. *Emergency Medicine* 1975; 7: 91–92.
14. Baldessarini RJ: Overview of the basis for amine hypotheses in affective illness. In Mendels J, editor. *Psychobiology of Depression*. Spectrum Co., New York, 1975, pp 69–83.
15. Baldessarini RJ: Antipsychotic drugs. In *Reference Handbook of the Medical Letter on Drugs and Therapeutics*. The Medical Letter, Inc., New Rochelle, NY, 1975, pp 57–59.
16. Baldessarini RJ: Biogenic amine hypotheses in affective disorders. In Flach FF, Draghi S, editors. *The Nature and Treatment of Depression*. John Wiley & Sons, New York, 1975, pp 347–385.
17. Baldessarini RJ: Release of catecholamines. In Iversen LL, Iversen SD, Snyder SH, editors. *Handbook of Psychopharmacology*, Vol 2, Plenum Press, New York, 1975, pp 37–137.
18. Baldessarini RJ: Basis of amine hypotheses in affective disorders. *Arch Gen Psychiatry* 1975; 32: 1087–1093.
19. Baldessarini RJ, Lipinski JF: Lithium salts: 1970–1975. *Ann Int Med* 1975; 83: 527–533.
20. Marsden CD, Tarsy D, Baldessarini RJ: Spontaneous and drug-induced movement disorders in psychotic patients. In Benson DF, Blumer D, editors. *Psychiatric Aspects of Neurologic Disease*. Grune and Stratton, New York, 1975, pp 219–265.
21. Baldessarini RJ: Basis for amine hypotheses in the affective disorders (text for educational film). American Psychiatric Association Symposium, Miami, FL, May, 1976, 12 pp.
22. Baldessarini RJ: Metabolic hypotheses in schizophrenia. *Guidelines to Metabolic Therapy* 1976; 5: 1–2.
23. Baldessarini RJ: Sviluppo ed applicazione dei metodi per la determinazione delle transmetilazioni biologiche S-adenosilmetionina dipendenti. In Fazio C, editor. *Transmetilazioni e Sistema Nervoso Centrale*. Edizioni Minerva Medica, Rome, Italy, 1976, pp 51–75.
24. Baldessarini RJ: The use of antipsychotic chemicals. *Tribuna Medica (Madrid)* 1976; 6: 3–19.
25. Baldessarini RJ, Lipinski JF: Lithium salts, 1970–1975. In Klein DF, Gittelman-Klein R, editors. *Progress in Psychiatric Drug Treatment*. Brunner/Mazel, New York, 1976, pp 159–173.
26. Baldessarini RJ, Lipinski JF: Toxicity and side-effects of antipsychotic, antimanic, and antidepressant medications. *Psychiatric Annals* 1976; 6: 52–68.
27. Baldessarini RJ, Lipinski JF: Use of lithium salts in psychiatry. *Harbor Area Psychiatric Newsletter (Boston)* 1976; 1 (Suppl.): 1–2.
28. Baldessarini RJ, Tarsy D: Mechanisms of underlying tardive dyskinesia. In *The Basal Ganglia*, Yahr M (ed), Association for Research in Nervous and Mental Diseases (ARNMD) Series, Vol. 55. Raven Press, New York, 1976, pp 433–446.
29. Fischer JE, Baldessarini RJ: Pathogenesis and therapy of hepatic coma. In Schaffner F, Popper H, editors. *Progress in Liver Diseases*, Vol. 5. Grune and Stratton, New York, 1976, pp 363–397.
30. Granacher RP, Baldessarini RJ: Physostigmine: Use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. In Klein DF, Gittelman-Klein R, editors. *Progress in Psychiatric Drug Treatment*, Brunner/Mazel, New York, 1976, pp. 625–638.
31. Granacher RP, Baldessarini RJ: The usefulness of physostigmine in neurology and psychiatry. In Klawans H, editor. *Handbook of Clinical Neuropharmacology*, Vol. 1, Raven Press, New York, 1976, pp 63–79.
32. Granacher RP, Baldessarini RJ, Messner E: Physostigmine treatment of delirium induced by anticholinergics. *Am Family Physician* 1976; 13: 99–103.
33. Tarsy D, Baldessarini RJ: The tardive dyskinesia syndrome. In Klawans H, editor. *Clinical Neuropharmacology*, Vol. 1, Raven Press, New York, 1976, pp 29–61.
34. Baldessarini RJ: Schizophrenia. *N Engl J Med* 1977; 297: 988–995.
35. Baldessarini RJ: Interactions of psychopharmaceuticals with other agents. *MGH Harbor Area Somatic Therapy Newsletter* 1977; 3 (6): 2–4.
36. Baldessarini RJ, Fischer JE: Neuropsychiatric illness and the metabolism of aromatic amino acids, trace amines and substitute neurotransmitters. Chapt 6 in *Neuroregulators and Psychiatric Disorders*, Barchas JD, Hamburg D, Usdin E (eds). Oxford University Press, New York, 1977, pp 46–56.
37. Baldessarini RJ, Lipinski JF: The schizophrenia syndrome and related psychoses. Chapt 346 in *Harrison's Principles of Internal Medicine*, eighth edition, McGraw Hill, New York, 1977, pp 1964–1970.
38. Baldessarini RJ: Chemotherapy, Chapt 18 in *Nicholi AM Jr, editor. Harvard Guide to Modern Psychiatry*, Harvard University Press, Cambridge, MA, 1978, pp 387–432.
39. Baldessarini RJ: The clinical pharmacology and toxicology of antipsychotic drugs: Part I: Introduction, clinical use and general toxicology. *Weekly Psychiatry Update Series* 1978; 2:(39): 1–8.

40. Baldessarini RJ: The clinical pharmacology and toxicology of antipsychotic drugs: Part II, Actions and neurological side-effects. *Weekly Psychiatry Update Series* 1978; 2 (40): 1–8.
41. Baldessarini RJ: The pathophysiologic basis of tardive dyskinesia. *Psychopharmacology Bull* 1978; 14: 79–81.
42. Baldessarini RJ, Tarsy D: Tardive dyskinesia. In Lipton ME, Dimascio A, Killam KF, editors. *Psychopharmacology—A Generation of Progress*. Raven Press, New York, 1978, pp 993–1004.
43. Granacher RP, Baldessarini RJ, Messner E: Physostigmine treatment of delirium induced by anticholinergics. In Hodge HC, editor. *Clinical Toxicology*. California Syllabus Co., Oakland, CA, 1978, pp 205–208.
44. Baldessarini RJ: The "neuroleptic" antipsychotic drugs: 1. Mechanisms of action. *Postgraduate Medicine* 1979; 65: 108–119.
45. Baldessarini RJ: The "neuroleptic" antipsychotic drugs: 2. Neurologic side-effects. *Postgraduate Medicine* 1979; 65: 123–128.
46. Baldessarini RJ: Neurological toxicology of antipsychotic drugs. *McLean Hosp J* 1979; 4: 2–19.
47. Baldessarini RJ: The pathophysiologic basis of tardive dyskinesia. *Trends in the Neurosciences (TINS)* 1979; 1: 133–135.
48. Baldessarini RJ: Status of psychotropic drug blood level assays and other biochemical measurements in clinical psychiatry. *Am J Psychiatry* 1979; 136: 1177–1180.
49. Baldessarini RJ: The use of chemotherapy in outpatient psychiatry, Chapt 42 in Lazare A, editor. *Outpatient Psychiatry, Diagnosis and Treatment*, Williams & Wilkins, Baltimore, MD, 1979, pp 563–595.
50. Baldessarini RJ, Tarsy D: Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. *Intl Rev Neurobiol* 1979; 21: 1–45.
51. Baldessarini RJ: Clinical application of blood drug-level assays and other biochemical measurements in psychiatry. *Weekly Psychiatry Update Series* 1980; 3 (28): 1–8.
52. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. Chapt. 19 in Gilman AG, Goodman LS, Gilman A, editors. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, sixth edition, MacMillan Co., New York, 1980, pp 391–447.
53. Baldessarini RJ (Chairman), Cole JO, Davis JM, Gardos G, Preskorn S, Simpson G, Tarsy D: Tardive dyskinesia: Summary of the findings of an American Psychiatric Association (APA) Task Force. *Am J Psychiatry* 1980; 137: 1163–1172.
54. Baldessarini RJ, Tarsy D: Pathophysiologic basis of neurologic side-effects of antipsychotic drugs. *Ann Rev Neurobiology* 1980; 3: 23–41.
55. Baldessarini RJ, Tarsy D: Pathophysiologic basis of tardive dyskinesia. Chapt 59 in Cattabeni F, Racagni G, Spano PF, Costa E, editors. *Long-Term Effects of Neuroleptics: Advances in Biochemical Psychopharmacology*, Vol. 22, Raven Press, New York, 1980, pp 451–455.
56. Baldessarini RJ, Tarsy D: Pathophysiologic basis of tardive dyskinesia. Chapt 17 in Fann WE, Smith, RC, Davis JM, Domino EF, editors. *Tardive Dyskinesia*. Spectrum Publications, Jamaica, NY, 1980, pp 181–186.
57. Baldessarini, R.J.: Does biological research lead to clinical progress or does clinical progress lead to biological research? A psychopharmacologist's perspective. In Matthyse S, editor. *Psychiatry and the Biology of the Human Brain*, Elsevier-North Holland, Inc., Amsterdam, 1981, pp 257–265.
58. Baldessarini RJ: The dopamine neurotransmission system in the brain and the biology and treatment of the psychoses (text to accompany an educational tape). Postgraduate Education Program, McLean Hospital, Belmont, MA and Audio-Visual Marketing, Inc., New York, 1981, 12 pp.
59. Baldessarini RJ: Recent advances in antidepressant pharmacology and pharmacotherapy. *Directions in Psychiatry* 1981; 1 (2): 1–8.
60. Baldessarini RJ: A summary of biomedical aspects of mood disorders. *McLean Hospital J* 1981; 6: 1–34.
61. Neumeyer JL, Lal S, Baldessarini RJ: Historical highlights of the chemistry, pharmacology and early clinical use of apomorphine. In Corsini GU, Gessa G, editors. *Apomorphine and Other Dopaminomimetics*, Vol 1, Basic Pharmacology, Raven Press, New York, 1981, pp 1–17.
62. Baldessarini, R.J.: Biomedical aspects of mood disorders. Lesson 10 in Flach FF, editor. *Guidelines for the Management of the Depressed Patient*, Life Sciences Advisory Group, CIBA Company and Rutgers Medical School, Newark, NJ, 1982, pp 12–24.
63. Baldessarini RJ: Overview of recent advances in antidepressant pharmacology (Part I). *McLean Hospital J* 1982; 7: 1–27.
64. Baldessarini RJ: Overview of recent advances in antidepressant pharmacology (Part II). *McLean Hospital J* 1982; 7: 99–101.

65. Baldessarini RJ: Clinical pharmacology and side-effects of antipsychotic and mood-stabilizing drugs used in the treatment of psychiatric patients with chronic or recurrent illnesses. Chapt 13 in Barofsky I, Budson RD, editors. *The Chronic Psychiatric Patient in the Community: Principles of Treatment*, Spectrum Publications, Jamaica, NY, 1983, pp 321–381.
66. Baldessarini RJ: How do antidepressants work? Chapt 17 in Frazier S, editor. *Issues in Psychiatry: Affective Disorders*. American Psychiatric Association Press, Washington, DC, 1983, pp 243–260.
67. Donaldson S, Gelenberg AJ, Baldessarini RJ: Update on new treatments for schizophrenia. *Schizophrenia Bull* 1983; 9: 504–527.
68. Baldessarini RJ: Antipsychotic agents, in Karasu TB, editor. *The Psychiatric Therapies, Part I, The Somatic Therapies*. American Psychiatric Press, Washington, DC, 1984, pp 119–170.
69. Baldessarini RJ: Risk rates for depression. *Arch Gen Psychiatry* 1984; 41: 103–104.
70. Baldessarini RJ: Course syllabus: Introduction to biological psychiatry. Postgraduate course in Comprehensive Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, March, 1984, pp 126–186.
71. Baldessarini RJ: Treatment of depression by altering monoamine metabolism: Precursors and metabolic inhibitors. *Psychopharmacol Bull* 1984; 20: 224–239.
72. Baldessarini, R.J.: Course syllabus: Introduction to psychopharmacology. Postgraduate course in Psychopharmacology, Harvard Medical School and Massachusetts General Hospital, Boston, October 1984, pp 20–80.
73. Baldessarini RJ: Course syllabus: Psychopharmacology of antidepressant agents. Postgraduate course in Depression: Psychobiology, Psychodynamics and Therapy, Harvard Medical School and Massachusetts General Hospital, Boston, October, 1984, pp 188–207.
74. Tarsy D, Baldessarini RJ: Tardive dyskinesia. *Ann Rev Medicine* 1984; 35: 605–623.
75. Baldessarini RJ: Clinical and epidemiologic aspects of tardive dyskinesia. *J Clin Psychiatry* 1985; 46 (4:2): 8–13.
76. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. Chapt 19 in Gilman AG, Goodman LS, Rall TW, Murad F, editors. *Goodman and Gilman's the Pharmacological Basis of Therapeutics*, seventh edition, MacMillan Co., New York, 1985, pp 387–445.
77. Baldessarini RJ: Course syllabus: Pharmacologic treatment of mood disorders. Department of Psychiatry, Harvard Medical School, Boston, March, 1985, 98 pp.
78. Baldessarini, R.J.: Workshop Syllabus: Psychopharmacology. Enoch and Sheppard Pratt Hospital, Towson, MD, March, 1985, 150 pp.
79. Baldessarini RJ, Arana GW: Does the DST have clinical utility in psychiatry? *J Clin Psychiatry* 1985; 46 (2, Section 2): 25–29.
80. Baldessarini RJ: Syllabus: Introduction to preclinical psychopharmacology, Course in Psychopharmacology, Hackett TP, Gelenberg AJ, Rosenbaum JF, Beresin EV, editors. Massachusetts General Hospital and Harvard Medical School, Boston, October, 1985, pp 14–75.
81. Cohen BM, Baldessarini RJ: Blood neuroleptic levels as a guide to clinical treatment. *Directions in Psychiatry* 1985; 4 (37): 1–8.
82. Baldessarini RJ: Syllabus: Pharmacologic treatment of major affective disorders, for Course in Psychopharmacology. Continuing Education Program, McLean Hospital, Belmont, MA, March 1986, 32 pp.
83. Baldessarini RJ: Syllabus: Pharmacologic treatment of major psychiatric disorders, for a Course in Contemporary Psychiatric Treatment. Postgraduate Education Program, Hospital Corporation of America and Vanderbilt University Medical School, Nashville, TN, April, 1986, 45 pp.
84. Baldessarini RJ: Course syllabus: Psychopharmacology of the major psychiatric disorders in the 1980's. Institute of Living, Hartford, CT, April, 1986, 78 pp.
85. Baldessarini RJ: Postgraduate symposium syllabus: Psychopharmacology of the major psychiatric disorders in the 1980s. The Education Center, Sheppard-Pratt Hospital, Towson, MD, May, 1986, 49 pp.
86. Baldessarini RJ: Syllabus: Psychopharmacology and psychobiology of major mood disorders, for a Course on Major Depression. National Institute of Mental Health, Bethesda, MD, June 1986, 35 pp.
87. Baldessarini RJ: Syllabus: Biomedical aspects of depression, for a Course on Major Depression. Harvard Medical School and Massachusetts General Hospital, Boston, October 1986, 45 pp.
88. Baldessarini RJ, Teicher MH, Cohen BM: The importance of dose in neuroleptic treatment. *Directions in Psychiatry* 1986; 6 (9): 1–8.

89. Donaldson S, Gelenberg AJ, Baldessarini RJ: Alternative treatments for schizophrenic psychoses, Chapt 19 in Berger P, Brodie HKH, editors. *American Handbook of Psychiatry*, Vol. 8, Academic Press, New York, 1986, pp 513–535.
90. Tarsy D, Baldessarini RJ: Clinical and pathophysiologic features of movement disorders induced by psychotherapeutic agents, Chapt 19 in Shah N, Donald A, editors. *Movement Disorders*, Plenum Press, New York, 1986, pp 365–389.
91. Arana GW, Baldessarini RJ: Development and clinical application of the dexamethasone suppression test in psychiatry. In Halbreich U, editor. *Hormones and Depression*, Raven Press, New York, 1987, pp 113–133.
92. Arana GW, Baldessarini RJ: The development and use of the dexamethasone suppression test in psychiatry, in Meltzer H, editor. *Psychopharmacology: The Third Generation of Progress*, American College of Neuropsychopharmacology (ACNP), Raven Press, New York, 1987, pp 609–615.
93. Arana GW, Baldessarini RJ, Brown WA, Carroll BJ, Davis JM, Glassman A (Chairman), Kupfer D, Shader RI, Schildkraut JJ: The DST: An overview of its current status in psychiatry. *Am J Psychiatry* 1987; 144: 1253–1262.
94. Arana GW, Baldessarini RJ, Brown WA, Carroll BJ, Davis JM, Glassman A (Chairman), Kupfer D, Shader RI, Schildkraut JJ: The DST: An overview of its current status in psychiatry. *American Psychiatric Association Task Force Report*, Washington, DC, 1987, 100 pp.
95. Baldessarini RJ: Psychopharmacology at the MGH, Chapt 6 in Hackett TP, Weisman AD, Kucharski A, editors. *Psychiatry in a General Hospital: The First Fifty Years*, Littleton Press, Littleton, MA 1987, pp 41–49.
96. Baldessarini RJ: Syllabus: Pharmacotherapy in depression, for Symposium on Treatment of Depression. Continuing Medical Education, Inc.: Santa Ana, CA, 1987, 42 pp.
97. Baldessarini RJ: Clinical use of antipsychotic agents. *Massachusetts Mental Health Legal Advisors Committee Advisor* 1987; 32 (12): 5–6.
98. Baldessarini RJ: Course syllabus: Preclinical and clinical psychopharmacology of antipsychotic antidepressant, and mood-stabilizing drugs, for Postgraduate Course in Modern Psychiatric Drug Therapy. New Brunswick Medical Association, Edmundston, NB, Canada, May, 1987, 47 pp.
99. Baldessarini RJ: Symposium Syllabus: Modern Psychopharmacological Treatment of Major Affective Disorders. Hall-Brooke Foundation, Westport, CT, June 5, 1987, 25 pp.
100. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology. New England Educational Institute, Inc., Pittsfield and Eastham, MA, July, 1987, 54 pp.
101. Teicher MH, Baldessarini RJ: Developmental pharmacodynamics, Chapt 3 in Popper C, editor. *Psychiatric Pharmacosciences of Children and Adolescents*, American Psychiatric Press, Washington, DC, 1987, pp 45–80.
102. Baldessarini RJ: Antipsychotic agents. *The Psychiatric Times* 1988; 5 (1): 38–42.
103. Baldessarini RJ: Postgraduate Course Syllabus: Psychopharmacology of the Major Psychiatric Disorders in the 1980s. Sheppard and Enoch Pratt Hospital, Baltimore, MD, April, 1988, 49 pp.
104. Baldessarini RJ: Course Syllabus: Clinical Pharmacology of Antipsychotic Agents. Menninger Foundation, Topeka KS, June 1988, 20 pp.
105. Baldessarini R.J.: Course Syllabus: Biomedical aspects of depression, Massachusetts General Hospital and Harvard Medical School, Boston, July, 1988, 34 pp.
106. Baldessarini RJ: Course Syllabus: Psychopharmacology. New England Educational Institute, Pittsfield and Eastham, MA, July, 1988, 42 pp.
107. Baldessarini, RJ: A summary of current knowledge of tardive dyskinesia. *L'Encephale (Paris)* 1988; 14: 363–368.
108. Baldessarini RJ: Recent advances in antidepressant pharmacology and pharmacotherapy, Chapt 7 in Flach FF, editor. *Psychobiology and Psychopharmacology*. WW Norton Co., New York, 1988, pp 90–108.
109. Baldessarini RJ: Update on antipsychotic agents. *Harvard Medical School Mental Health Letter* 1988; 4 (10): 4–6.
110. Baldessarini RJ, Cole JO: Psychopharmacology. In Nicholi AM Jr, editor. *The Harvard Guide to Modern Psychiatry*, second edition, Harvard University Press, Cambridge, MA, 1988, pp 481–533.
111. Baldessarini, RJ, Finklestein SP, Arana GW: Predictive power of diagnostic tests, Chapt 13 in Flach FF, editor. *Psychobiology and Psychopharmacology*, WW Norton, New York, 1988, pp 177–192.
112. Cohen BM, Baldessarini RJ: Blood neuroleptic levels as a guide to clinical treatment, Chapt 9 in Flach FF, editor. *Psychobiology and Psychopharmacology*, WW Norton Co., New York, 1988, pp 121–136.

113. Baldessarini RJ: Update on pharmacology and treatment with antidepressants. *J Clin Psychiatry* 1989; 50: 117–126.
114. Baldessarini RJ: Psychopharmacology of the major psychiatric disorders in the 1980s (Postgraduate Course Syllabus). Sheppard and Enoch Pratt Hospital, Baltimore, MD, June 1989, 49 pp.
115. Baldessarini RJ: Clinical psychopharmacology (Course Syllabus). Menninger Foundation, Topeka, KS, June, 1989, 30 pp.
116. Baldessarini RJ: Clinical psychopharmacology (Course Syllabus). New England Educational Institute, Pittsfield and Eastham, MA, July, 1989, 42 pp.
117. Baldessarini RJ: Update on antipsychotic and antimanic treatments (Course Syllabus). Symposium on Psychopharmacology. Berkshire Mental Health Center, Pittsfield, MA, November, 1989, 34 pp.
118. Baldessarini RJ: The future of psychiatric research and academic psychiatry. *McLean Hospital J* 1990; 15: 53–68.
119. Baldessarini RJ: Syllabus: Pharmacology of mood-altering agents. Continuing Medical Education Program, Massachusetts General Hospital and Harvard Medical School, Boston, March, 1990, 99 pp.
120. Baldessarini RJ: Pharmacology of antipsychotic agents (Course Syllabus). Continuing Medical Education Program, McLean Hospital, April, 1990, 25 pp.
121. Baldessarini RJ: Course Syllabus: Update on Clinical Psychopharmacology. Menninger Foundation, Topeka, KS, June 1990, 25 pp.
122. Baldessarini RJ: Clinical Psychopharmacology (Course Syllabus). New England Educational Institute, Pittsfield and Eastham, MA, July, 1990, 40 pp.
123. Baldessarini RJ: Basic and clinical pharmacology of mood-altering agents (Syllabus). Continuing Medical Education Program, Massachusetts General Hospital & Harvard Medical School, Boston, October, 1990, 25 pp.
124. Baldessarini RJ: Clinical Pharmacology and treatment with antidepressants. *Harvard Medical School Mental Health Letter* 1990; 6 (7): 4–6.
125. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. Chapt 18 in Gilman, AG, Goodman LS, Rall TW, Murad F, editors. *Goodman and Gilman's The Pharmacologic Basis of Therapeutics*, eighth edition, Pergamon Press, New York, 1990, pp 383–435.
126. Baldessarini RJ, Cohen BM, Teicher MH: Pharmacological treatment. Chapt 4 in Levy ST, Ninan PT, editors. *Schizophrenia: Treatment of Acute Psychotic Episodes*, American Psychiatric Press, Washington, DC, 1990, pp 61–118.
127. Baldessarini RJ: Clinical Psychopharmacology (Course Syllabus), Killington, VT Symposium. New England Educational Institute, Pittsfield, MA, February, 1991, 20 pp.
128. Baldessarini RJ: Practical review of basis neurotransmission and psychopharmacology: Emerging views (course syllabus and review). Syllabus Fifth U.S. Psychiatric Congress, Chicago, IL, November, 1992. CME Inc.: Santa Ana, CA, pp 111–120.
129. Baldessarini RJ: Improved long-term treatment with mood-altering agents (Course Syllabus and Review). Syllabus Fifth US Psychiatric Congress, Chicago, IL, November, 1992. CME Inc.: Santa Ana, CA, pp 142–151.
130. Baldessarini RJ: (editorial contributor): Holm A-C, Edsman I, Olind B, Lundberg T: Tolerability of remoxipride in the long-term treatment of schizophrenia: An overview. *Drug Safety* 1993; 8: 445–456.
131. Baldessarini RJ: Clinical Psychopharmacology (Syllabus). Psychiatric Residency Training Program. Massachusetts General Hospital, Boston, July 1993, 10 pp.
132. Baldessarini RJ: Clinical Psychopharmacology (Syllabus). Psychiatric Residency Training Program, McLean Hospital, Boston, September 1993, 10 pp.
133. Baldessarini RJ, Cohen, BM, Teicher, MH: Clinical dosing of antipsychotic agents. In Gram LF, Balant JP, Meltzer HY, Dahl SG, editors. *Strategies in Psychotropic Drug Development*, Clinical Pharmacology in Psychiatry Series. Heidelberg: Springer-Verlag, 1993, pp 138–148.
134. Baldessarini RJ: Mood-altering agents (syllabus) For Comprehensive Review and Update in Psychiatry, Mass. General Hospital, March, 1993, 6 pp.
135. Goff D, Baldessarini RJ: Interactions of drugs with antipsychotic agents. *J Clin Psychopharmacol* 1993; 13: 57–67.
136. Baldessarini RJ: Preventing relapses and recurrences of major depression. In Herbert CP, editor. *Past Pitfalls and New Expectations in the Treatment of Depression*. AgenScience Publishers, Montréal, 1993, pp 44–51.

137. Baldessarini RJ: Enhancing treatment with psychotropic medicines. *Bull Menninger Clinic* 1994; 58: 224–241.
138. Baldessarini RJ: Clinical psychopharmacology update-1994 (CME Course Syllabus). Sheppard and Enoch Pratt Psychiatric Hospital, Towson, MD, April 1994, 10 pp.
139. Baldessarini RJ: Treatment with mood-altering agents (Syllabus). Massachusetts General Hospital Comprehensive Review of Psychiatry CME Program, Boston, September, 1994, 69 pp.
140. Popli A, Baldessarini RJ, Cole JO: Interactions of serotonin-reuptake inhibitors with tricyclic antidepressants. *Arch Gen Psychiatry* 1991; 51: 666–667.
141. Baldessarini RJ: Commentary: Risks and implications of discontinuing maintenance psychotropic drug therapy. *Psychother. Psychosomatics* 1995; 63: 137–141.
142. Baldessarini RJ: Clinical psychopharmacology review and update: Antipsychotic and mood-altering treatments–1995 (Syllabus). Menninger Clinic, March, 1995, 10 pp.
143. Baldessarini RJ: Clinical psychopharmacology update: Advances in the Psychopharmacology of Major Psychiatric Disorders (Syllabus). Oklahoma Psychiatric Association Symposium, April, 1995, 14 pp.
144. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (CME Course Syllabus). Cape Cod Symposia. New England Educational Institute, Pittsfield, MA, July, 1995, 14 pp.
145. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (Syllabus). Santa Fe Symposia, New England Educational Institute, Pittsfield, MA, October, 1995, 11 pp.
146. Baldessarini RJ, Suppes T, Tondo L, Faedda G, Viguera A, Tohen M: Risks of interrupting maintenance therapy with psychotropic drugs. *Directions in Psychiatry* 1995; 15: 1–8.
147. Baldessarini RJ, Teicher MH: Dosing of antipsychotic agents in pediatric populations. *J Child Adolesc Psychopharmacol* 1995; 5: 1–4.
148. Goff D, Baldessarini RJ: Interactions of other drugs with antipsychotic agents. In Ciraulo D, Shader RI, Greenblatt DJ, Creelman W, editors. *Drug Interactions in Psychiatry*. Williams & Wilkins, Baltimore, 1995, pp 129–174.
149. Popli A, Baldessarini RJ, Cole JO: Commentary: Interactions of serotonin-reuptake inhibitors with tricyclic antidepressants. *Arch Gen Psychiatry* 1995; 52: 784–785.
150. Baldessarini RJ: Clinical Psychopharmacology: Review and Update–1996 (Symposium Syllabus). Department of Community Mental Health, University of South Florida, Tampa, FL, March, 1996, 14 pp.
151. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: Antipsychotic and anti-anxiety agents. Chapt 18 in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, ninth edition, McGraw-Hill Press, New York, 1996, pp 399–430.
152. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: Antimanic and antidepressant agents. Chapt 19 in Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, ninth edition. McGraw-Hill Press, New York, 1996, pp 431–459.
153. Baldessarini RJ: First-episode psychosis: Effect of duration of hospitalization on outcome. *Current Approaches to Psychoses* 1996; 5: 1–6.
154. Baldessarini RJ: Clinical psychopharmacology review and update: 1996 (CME Syllabus). Oklahoma Psychiatric Association, Tulsa, OK, March 1996, 18 pp.
155. Baldessarini RJ: Clinical psychopharmacology update-1996 (CME Syllabus). Sheppard & Enoch Pratt Psychiatric Hospital, Towson, MD, April 1996, 12 pp.
156. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology. Cape Cod Symposia. New England Educational Institute, Inc., Pittsfield and Eastham, MA, July, 1996, 14 pp.
157. Baldessarini RJ: Clinical psychopharmacology (Course Syllabus). Santa Fe Symposia IV. New England Educational Institute, Inc., Pittsfield, MA and Santa Fe, NM, October, 1996, 14 pp.
158. Baldessarini RJ, Centorrino F: Results and limits of antipsychotic pharmacotherapy. *Nóos: Aggiornamenta in Psichiatria (Rome)* 1996; 4: 249–273.
159. Baldessarini RJ, Tarazi FI: Brain dopamine receptors: A primer on their current status, basic and clinical. *Harvard Rev Psychiatry* 1996; 3: 301–325.
160. Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Tohen M: Pharmacological treatment of bipolar disorder throughout the life-cycle. In Shulman KI, Tohen M, Kutcher S, editors. *Mood Disorders Across the Life Span*. John Wiley & Sons, New York, 1996, pp 299–338.
161. Tondo L, Baldessarini RJ, Floris G, Silvetti F, Rudas N: Lithium maintenance treatment reduces risk of suicidal behavior in bipolar disorder patients. In Gallicchio VS, Birch NJ, editors. *Lithium: Biochemical and Clinical Advances*. Weidner Publishing Group, Cheshire, CT, 1996, pp 161–171.

162. Tondo L, Baldessarini RJ, Ruda N: Pharmacological treatment with lithium salts in mood disorders. In Altamura, AC, editor. *Clinica e Farmacoterapia delle Psicosi Maggiori*. McGraw-Hill, Milan, 1996, pp 201–211.
163. Baldessarini RJ: Dopamine receptors and clinical medicine. In Neve KA, Neve RL, editors. *The Dopamine Receptors*. Totowa, NJ: Humana Press, 1997, pp 457–498.
164. Baldessarini RJ: *Clinical Psychopharmacology: Overview with Recent Advances (Course Syllabus)*. Cape Cod Symposia. New England Educational Institute, Pittsfield, MA, June, 1997, 15 pp.
165. Baldessarini RJ: *Clinical pharmacology of antidepressants (Course Syllabus)*. Mass. General Hospital CME Program, September, 1997, 51 pp.
166. Baldessarini RJ: *Clinical pharmacology of antimanic and mood-stabilizing agents (Course Syllabus)*. Mass. General Hospital CME Program, September, 1997, 44 pp.
167. Baldessarini RJ: *Recurrence risk after discontinuing maintenance treatment in major affective and psychotic disorders (Course Syllabus)*. Mass. General Hospital CME Program, September, 1997, 31 pp.
168. Baldessarini RJ: *Biopsychiatry & Psychopharmacology: Antipsychotics I: Basic Pharmacology of Antipsychotic Agents (Course Syllabus)*. Mass. General/McLean Hospitals, October, 1997, 25 pp.
169. Baldessarini RJ: *Biopsychiatry & Psychopharmacology: Antipsychotics II: Introduction to the Clinical Pharmacology of Antipsychotic Agents (Course Syllabus)*. Mass. General/McLean Hospitals, October, 1997, 21 pp.
170. Baldessarini RJ: *Basic Pharmacology of Antipsychotic Agents (Course Syllabus)*. Mass. General Hospital CME Program, October, 1997, 12 pp.
171. Baldessarini RJ: *Clinical Pharmacology of Antipsychotic Agents (Course Syllabus)*. Mass. General Hospital CME Program, October, 1997, 25 pp.
172. Baldessarini RJ: *Course Syllabus: Clinical psychopharmacology*. Santa Fe Symposia V. New England Educational Institute, Inc., Pittsfield, MA and Santa Fe, NM, October, 1997, 15 pp.
173. Baldessarini RJ: *Pharmacology and clinical use of lithium in major affective disorders (Course Syllabus)*. Mass. General/McLean Hospitals, October, 1997, 20 pp.
174. Baldessarini RJ, Tondo L: Effects of lithium treatment and its discontinuation in bipolar disorders. *American Society of Clinical Psychopharmacology Progress Notes* 1997; 8 (2): 21–26.
175. Keabian JW, Tarazi FI, Kula NS, Baldessarini RJ: Compounds selective for dopamine receptor subtypes. *Drug Discovery Today* 1997; 2: 333–340.
176. Lasser RA, Baldessarini RJ: Thyroid hormones in depressive disorders: Reappraisal of clinical utility. *Harvard Rev Psychiatry* 1997; 4: 291–305.
177. Neumeyer JL, Baldessarini RJ: Apomorphine: New uses for an old drug. *Pharmaceut News* 1997; 4: 12–16.
178. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Neumeyer JL: S(+)-N-n-propylnorapomorphine ([+]-NPA): A novel atypical antipsychotic agent with clozapine-like effects. *Schizophrenia Res* 1997; 24: 82–82.
179. Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera A: Risks of discontinuing maintenance treatment with psychotropic medicines. In Rush J, editor. *Modern Problems of Pharmacopsychiatry*, vol. 25: Mood disorders: Systematic Medication Management. S Karger, Basel, Switzerland, 1997, pp 235–254.
180. Baldessarini RJ: The National Institute of Mental Health Career Scientist Awards: Commentary. *Arch Gen Psychiatry* 1998; 55: 19–20.
181. Baldessarini RJ: *Clinical use of antipsychotic agents (Syllabus)*. McLean Hospital CME Program, January, 1998, 28 pp.
182. Baldessarini RJ: *Overview of contemporary clinical psychopharmacology (Syllabus)*. Phillippe Pinel Psychiatric Institute of Montréal, Québec, February, 1998, 25 pp.
183. Baldessarini RJ: *Treatment of bipolar disorders (Syllabus)*. Vanderbilt University, Nashville, TN, April, 1998, 21 pp.
184. Jacobs DG, Baldessarini RJ: *National Depression & Manic-Depression Screening Day Syllabus*. National Mental Illness Screening Program, Wellesley, MA, May, 1998, 12 pp.
185. Baldessarini RJ: *Clinical Psychopharmacology: Overview and Update (Syllabus)*. Cape Cod Symposia. New England Educational Institute, Pittsfield, MA, June, 1998, 16 pp.
186. Baldessarini RJ: *Clinical psychopharmacology of antipsychotic agents (Syllabus)*. MGH/McLean Residency Training Seminars, September, 1998, 20 pp.

187. Baldessarini RJ: Treatment of psychotic disorders (Syllabus). MGH–McLean Residency Training Program, September, 1998, 10 pp.
187. Baldessarini RJ: Bipolar disorder (manic-depressive illness) (Syllabus). MGH–McLean Residency Training Program, September, 1998, 14 pp.
189. Baldessarini RJ: Psychopharmacology of drugs for major affective disorders (Syllabus). Massachusetts General Hospital CME Program, September, 1998, 76 pp.
190. Baldessarini RJ: Psychopharmacology: Where have we been; where are we; we are we going? (Syllabus). Massachusetts General Hospital CME Program, September, 1998, 10 pp.
191. Baldessarini RJ, Tarazi FI. Dopamine Receptors. In Watling KJ, editor. *The RBI Handbook of Receptor Classification and Signal Transduction*. RBI Inc, Natick, MA, 1998, pp 20–21.
192. Baldessarini RJ, Tondo L: Antisuicidal effect of lithium treatment in major mood disorders. In Jacobs D, editor. *The Harvard Medical School Guide to Assessment & Intervention in Suicide*. Jossey-Bass, San Francisco, 1998, pp 355–371.
193. Baldessarini RJ, Viguera AC: Medication removal and research in psychotic disorders. *Arch Gen Psychiatry* 1998; 55: 281–282.
194. Tarazi FI, Baldessarini RJ: Dopamine receptors. In Adelman G, Smith BH, editors. *Encyclopedia of Neuroscience CD-ROM edition*. Elsevier-Science Press, Amsterdam, Netherlands, 1998, 6 pp.
195. Baldessarini RJ, Tondo L, Viguera LC: Forty years of lithium treatment: Commentary. *Arch Gen Psychiatry* 1998; 55: 92–93.
196. Siegel A, Baldessarini RJ, Klepser MB, McDonald JC: Primary and drug-induced disorders of water homeostasis in psychiatric patients: Principles of diagnosis and management. *Harvard Rev Psychiatry* 1998; 6: 190–200.
197. Shelton RC, Thase ME, Kowatch R, Baldessarini RJ: Update on the management of bipolar illness. *J Clin Psychiatry* 1998; 59: 484–495.
198. Viguera AC, Baldessarini RJ: Update on the clinical use of lithium. *Atlantic Psychopharmacol Quart* 1998; 1 (1): 1–2.
199. Baldessarini RJ: Psychopharmacology of lithium and proposed antimanic or mood-stabilizing agents (Syllabus). Massachusetts General /McLean Hospital Residency Training Program, January, 1999, 30 pp.
200. Baldessarini RJ: Psychopharmacology of antidepressants (Syllabus). MGH/McLean Residency Training Program, March, 1999, 46 pp.
201. Baldessarini RJ: Psychopharmacology, Chapt. 21 in *The Harvard Guide to Modern Psychiatry*, third edition, Nicholi AM Jr (ed). Harvard University Press, Cambridge, MA, 1999, pp 444–496.
202. Baldessarini RJ: Clinical Psychopharmacology Review & Update: Antipsychotic and Mood-Altering Treatments—1999 (Syllabus). Menninger Foundation, Topeka, KS, March, 1999, 16 pp.
203. Baldessarini RJ: Overview of contemporary clinical psychopharmacology (Syllabus). Good Shepherd Center, Baltimore, MD, May, 1999, 29 pp.
204. Baldessarini RJ: Overview of bipolar disorder and its treatment with lithium and proposed mood-stabilizing agents (Syllabus). School of Allied Health Professions, Northeastern University, Boston, MA, May 1999, 42 pp.
205. Baldessarini RJ: Myths about bipolar disorders and their treatment (Syllabus). Proceedings of Lilly/Neuroscience symposium on Mood Stabilization in Affective Disorders. Eli Lilly Laboratories, Indianapolis, IN, June, 1999, 20 pp.
206. Baldessarini RJ: Clinical Psychopharmacology: Overview and Update (Syllabus). Cape Cod Symposia. New England Educational Institute, Pittsfield, MA, July, 1999, 86 pp.
205. Baldessarini RJ: Psychopharmacology of antipsychotic drugs (Syllabus). McLean Hospital CME Program, September, 1999, 31 pp.
208. Baldessarini RJ, Jamison KR: Effects of medical interventions on suicidal behavior: Summary and conclusions. *J Clin Psychiatry* 1999; 60 (Suppl. 2): 117–122.
209. Baldessarini RJ: Clinical pharmacology of antidepressants and mood-stabilizers (CMS Syllabus). Massachusetts General Hospital, September 14, 1999, 75 pp.
210. Baldessarini RJ: Update on lithium in bipolar disorders (CMS Syllabus). Massachusetts General Hospital, September 16, 1999, 10 pp.

211. Baldessarini RJ: Psychopharmacology: Where have we been; where are we; where are we going? (CME Syllabus). Massachusetts General Hospital, October 7, 1999, 12 pp.
212. Baldessarini RJ: Clinical psychopharmacology of antipsychotic agents: Summary (CME Syllabus). Massachusetts General Hospital, October 7, 1999, 24 pp.
213. Baldessarini RJ: Clinical psychopharmacology of antipsychotic drugs (Syllabus). MGH/McLean Residency Training Program, December, 1999, 48 pp.
214. Jamison KR, Baldessarini RJ: Effects of medical interventions on suicidal behavior: Introduction. *J. Clin. Psychiatry* 60 (Suppl. 2): 4–6, 1999.
215. Tarazi FI, Baldessarini RJ: Dopamine receptors. In Adelman G, Smith BH (eds.): *Encyclopedia of Neuroscience*. Elsevier Press, 2nd Ed, New York, 1999, pp 561–565.
216. Baldessarini RJ: Pharmacotherapy of psychotic disorders: A perspective on current developments. Chapt. 2.1 in Maj M, Sartorius N (eds): *Evidence and Experience in Psychiatry, Vol. 2, Schizophrenia*. New York: John Wiley and Sons., 1999, pp 108–112.
217. Kelleher JP, Centorrino F, Apicella A, Baldessarini RJ: Treatment of psychotic disorders. McLean Hospital Internet Site, 1999.
218. Siegel A, Baldessarini RJ, Klepser MB, McDonald JC: Primary and drug-induced disorders of water homeostasis in psychiatric patients: Principles of diagnosis and management (Greek translation). *Harvard Rev Psychiatry* 1999; 1: 33–45.
219. Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Database of Abstracts and Reviews of Effectiveness (DARE-983602). University of York, York, UK, 1999.
220. Baldessarini RJ: American biological psychiatry and psychopharmacology 1944–1994. Chapt 16 in Menninger RW, Nemiah JC, editors. *American Psychiatry After World War II (1944–1994)*, a volume celebrating the 150th anniversary of the founding of the American Psychiatric Association. Washington DC: APA Press, 2000, pp 371–412.
221. Baldessarini RJ: Psychopharmacology of lithium salts (Syllabus). MGH/McLean Residency Training Program, January, 2000, 36 pp.
222. Baldessarini RJ: Psychopharmacology: Where have we been, where are we, and where are we going? Status report at the millennium (Syllabus). New England Educational Institute Killington Psychiatry Conference, Woodstock Vt, January, 2000, 14 pp.
223. Baldessarini RJ: Psychopharmacology of lithium salts (Syllabus). MGH/McLean Residency Training Program, January, 2000 (50 pp).
224. Baldessarini RJ: Psychopharmacology of lithium and other antimanic or mood-stabilizing agents: Part II, Alternatives to lithium (Syllabus). Mass. General–McLean Hospital Residency Training Program, Boston, January, 2000, 20 pp.
225. Baldessarini RJ: Psychopharmacology of lithium and other antimanic or mood-stabilizing agents: Part I, Lithium (Syllabus). Mass. General–McLean Hospital Residency Training Program, Boston, January, 2000, 30 pp.
226. Baldessarini RJ: Clinical psychopharmacology of antidepressants (Syllabus). MGH/McLean Residency Training Program, February, 2000, 24 pp.
227. Baldessarini RJ: Basic psychopharmacology of antidepressants (Syllabus). MGH/McLean Residency Training Program, February, 2000, 20 pp.
228. Baldessarini RJ: Pharmacology of antidepressants: I. Basic Pharmacology (Syllabus). Massachusetts General Hospital, February, 2000, 26 pp.
229. Baldessarini RJ: Pharmacology of antidepressants: I. Clinical Pharmacology (Syllabus). Massachusetts General Hospital, February, 2000, 23 pp.
230. Baldessarini RJ: Bipolar Disorder (Syllabus). Course on Psychotic Disorders, Massachusetts General Hospital, April, 2000, 69 pp.
231. Baldessarini RJ: Treatment of bipolar disorder (Syllabus). CME Program, McLean Hospital, June, 2000, 46 pp.
232. Baldessarini RJ: Effects of treatment on suicidal behavior in bipolar disorder (Syllabus). CME Program, McLean Hospital, June, 2000, 55 pp.
233. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology for psychotic and major affective disorders. Cape Cod Symposia. New England Educational Institute, Inc., Pittsfield and Eastham, MA, July, 2000, 136 pp.

234. Baldessarini RJ: Preclinical pharmacology of DHA-clozapine (Syllabus). Symposium on Fatty Acid Derivatives of Drugs. Protarga Laboratories, Inc., Conshohocken, PA, August, 2000, 14 pp.
235. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology. Santa Fe Symposia. New England Educational Institute, Inc., Pittsfield, MA, October, 2000, 136 pp.
236. Baldessarini RJ: Long-term antipsychotic treatment (Syllabus). Massachusetts General–McLean Hospital Residency Training Program, Boston, October, 2000, 30 pp.
237. Baldessarini RJ: Long-term mood-stabilizing treatment (Syllabus). Massachusetts General–McLean Hospital Residency Training Program, Boston, October, 2000, 30 pp.
238. Baldessarini RJ: Long-term antidepressant treatment (Syllabus). Massachusetts General–McLean Hospital Residency Training Program, Boston, October, 2000, 30 pp.
239. Baldessarini RJ: Role of psychopharmacology in shortening hospitalization in psychotic patients (Syllabus). McLean Hospital, November, 2000, 30 pp.
240. Baldessarini RJ: Basic pharmacology of antipsychotic agents (Syllabus). Massachusetts General–McLean Hospital Residency Training Program, Boston, November, 2000, 50 pp.
241. Baldessarini RJ: Clinical pharmacology of antipsychotic agents (Syllabus). Massachusetts General–McLean Hospital Residency Training Program, Boston, November, 2000, 50 pp.
242. Baldessarini RJ, Tondo L: Treatment of bipolar disorder. *CNS News*, June 2000, pp 1–2.
243. Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz D: Pediatric-onset bipolar disorder: A neglected clinical and public health problem (from *Harvard Rev. Psychiatry* 3: 171–195, 1995). Reprinted in *Child & Adolescent Bipolar Disorder Foundation Website* (<http://www.bpkids.org/learning/references/018.htm>), Chicago, 2000, 19 pp.
244. Papolos D, Papolos J, Baldessarini RJ: Atypical antipsychotics: Their emerging role in the treatment of early-onset bipolar disorder. *The Bipolar Child Newsletter* 2000; 5 (10): 1–10.
245. Tondo L, Baldessarini RJ: Bipolar disorder. *International Encyclopedia of the Social & Behavioral Sciences*. Elsevier Press, Oxford, 2000, pp 130–135.
246. Baldessarini RJ: Is lithium still worth using? (Syllabus). Proc. Solvay Corporation National Meeting. Orlando, FL, January, 2001, 30 pp.
247. Baldessarini RJ: Clinical pharmacology of antidepressants (Syllabus). MGH/McLean Residency Training Program, January, 2001, 52 pp.
248. Baldessarini RJ: Antisuiicidal effects in long-term lithium treatment (Abstract & Syllabus). CME Symposium, Orange County, California, March, 2001, 24 pp.
249. Baldessarini RJ: Antisuiicidal effects in long-term lithium treatment (Abstract & Syllabus). Proc. Psychopharmacology CME Symposium, Stanford University, March, 2001, 24 pp.
250. Baldessarini RJ: Treatment of bipolar disorder (Syllabus). CME Program, McLean Hospital, March, 2001, 55 pp.
251. Baldessarini RJ: Clinical Psychopharmacology of Psychotic and Major Affective Disorders: Overview & Update (Syllabus). Brightside Seminar Series, Northampton, MA, March, 2001, 20 pp.
252. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: Antidepressant and anti-anxiety agents. Chapt 19 in Hardman JG, Limbird LE, Gilman AG, editors. *McGraw Goodman and Gilman's The Pharmacological Basis of Therapeutics*, tenth edition, McGraw-Hill Press, New York, 2001, pp 447–483.
253. Baldessarini RJ, Tarazi FI: Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents. Chapt 20 in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, tenth edition, Hardman JG, Limbird LE, Gilman AG (eds). McGraw-Hill Press, New York, 2001, pp 485–520.
254. Baldessarini RJ: Reduced suicide risk during long-term maintenance treatment with lithium. *Suicide Risk and Bipolar Disorder* (Symposium Syllabus), J.J. Mann, editor. American Psychiatric Association Annual Meeting, New Orleans, LA, May, 2001, pp 46–52.
255. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology for psychotic and major affective disorders. Cape Cod Symposia. New England Educational Institute, Inc., Pittsfield and Eastham, MA, July, 2001, 136 pp.
256. Baldessarini RJ: Clinical pharmacology of antipsychotic agents (Syllabus). Mass. General & McLean Hospitals Residency Training Program, July, 2001, 44 pp.
257. Baldessarini RJ: Clinical pharmacology of antimanic agents (Syllabus). Mass. General & McLean Hospitals Residency Training Program, July, 2001, 40 pp.

258. Baldessarini RJ: Clinical pharmacology of antidepressant agents (Syllabus). Mass. General & McLean Hospitals Residency Training Program, July, 2001, 40 pp.
259. Baldessarini RJ: Clinical pharmacology of antidepressant agents (Syllabus). Mass. General Hospital CME Program (COPE), September, 2001, 38 pp.
260. Baldessarini RJ: Clinical update on lithium (Syllabus). Mass. General Hospital CME Program (COPE), September, 2001, 38 pp.
261. Baldessarini RJ: Long-term outpatient treatment of major depression patients (Syllabus). Mass. General & McLean Hospitals Residency Training Program, October, 2001, 35 pp.
262. Baldessarini RJ: Suicide risk: Effects of psychiatric treatment (Syllabus). Department of Psychiatry, Emory University, Atlanta, GA, October, 2001, 20 pp.
263. Baldessarini RJ: Suicide risk: Effects of lithium treatment (Syllabus). National Advisory Committee meeting, GlaxoWellcome Corporation, Williamsburg, VA, November, 2001, 20 pp.
264. Baldessarini RJ: Long-term outpatient treatment of bipolar disorder patients (Syllabus). Mass. General & McLean Hospitals Residency Training Program, November, 2001, 40 pp.
265. Baldessarini RJ: Pharmacology of Antipsychotic Agents I: Basic Neuropharmacology (Syllabus). Mass. General & McLean Hospitals Residency Training Program, November, 2001, 25 pp.
266. Baldessarini RJ: Pharmacology of Antipsychotic Agents II: Clinical Psychopharmacology (Syllabus). Mass. General & McLean Hospitals Residency Training Program, November, 2001, 46 pp.
267. Baldessarini RJ: Bipolar Disorder (Syllabus). Mass. General & McLean Hospitals Residency Training Program, November, 2001, 15 pp.
268. Baldessarini RJ: Antipsychotic Agents in Bipolar Disorder (Syllabus). Proceedings Canadian Psychiatric Assoc. Montréal, Québec, November, 2001, 25 pp.
269. Baldessarini RJ: Clinical Use of Antidepressants (Syllabus). Mass. General & McLean Hospitals Residency Training Program, November, 2001, 30 pp.
270. Baldessarini RJ: Treatment of Bipolar Disorder with Lithium (Syllabus). Mass. General & McLean Hospitals Residency Training Program, December, 2001, 34 pp.
271. Baldessarini RJ, Tondo L, Hennen J, Viguera AC: Is lithium still worth using? An update of selected recent research. McLean Hospital Website, 2001.
272. Baldessarini RJ: "Atypical" antipsychotics: How far have we come? (commentary) Trends in Pharmacological Sciences (TIPS) 2001; 22: 49–50.
273. Baldessarini RJ, Tondo L: Bipolar disorder, including hypomania and mania. In Smelser NJ, Baltes PB (editors): International Encyclopedia of the Social & Behavioral Sciences. Oxford: Pergamon Press, 2001, pp 1240–1245.
274. Huxley NA, Baldessarini RJ: Psychosocial treatments in psychotic disorders. Psychiatric Times Website; <http://www.mhsource.com/schizophrenia/psychosoc.html>; 2001, pp 1–4.
275. Tondo L, Baldessarini RJ: Suicide: An overview of history and epidemiology. Medscape Internet Publications (<http://www.medscape.com/Medscape/psychiatry/ClinicalMgmt/CM.v03/public/index-C>), 2001, pp 1–8.
276. Tondo L, Baldessarini RJ: Suicide: An overview of treatment and clinical management. Medscape Internet Publications (<http://www.medscape.com/Medscape/psychiatry/ClinicalMgmt/CM.v03/public/index-C>), 2001, pp 9–18.
277. Baldessarini RJ: Bipolar disorder. Foreword to Yatham LN, Kusumakar V, Kutcher S, editors. Bipolar Disorder: A Clinician's Guide to Biological Treatments. Brunner-Routledge, New York, 2002, pp 13–16.
278. Baldessarini RJ: Clinical psychopharmacology of antimanic-mood stabilizers (Syllabus). Boston: McLean Hospital CME Program, June, 2002, 37 pp.
279. Baldessarini RJ: Historical evolution of Kraepelin's Manic-Depressive Illness concept: A brief overview (Syllabus). Cambridge Hospital Group for the History & Philosophy of Behavioral Science, Cambridge, MA, June, 2002, 15 pp.
280. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology for psychotic and major affective disorders. Cape Cod Symposia. New England Educational Institute, Inc., Pittsfield & Eastham, MA, July, 2002, 269 pp.
281. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antipsychotic agents. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, July 24, 2002, 25 pp.

282. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antimanic and mood-stabilizing agents. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, July, 2002, 25 pp.
283. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of the antipsychotic agents. PGY-III Residency Training Program, Massachusetts General–McLean Hospitals, September, 2002, 30 pp.
284. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of the antipsychotic agents. Psychiatry Board Review Syllabus. McLean Hospital, Belmont, MA, September, 2002, 14 pp.
285. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antimanic and mood-stabilizing agents. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, September, 2002, 25 pp.
286. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of the antipsychotic agents. CME Program, McLean Hospital, September, 2002, 36 pp.
287. Baldessarini RJ: Course and morbidity in bipolar disorders: An historical perspective (Syllabus). CME Program, McLean Hospital, September, 2002, 28 pp.
288. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antidepressants. PGY-II Residency Training Program, Massachusetts General & McLean Hospitals, Boston, September, 2002, 25 pp.
289. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antidepressants. PGY-III Residency Training Program, Massachusetts General & McLean Hospitals, Boston, September, 2002, 36 pp.
290. Baldessarini RJ: Seminar Syllabus: Basic neuropharmacology of antipsychotics. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, October, 2002, 25 pp.
291. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antipsychotics. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, October, 2002, 25 pp.
292. Baldessarini RJ: Seminar Syllabus: Clinical psychopharmacology of antipsychotics. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, October, 2002, 25 pp.
293. Baldessarini RJ: Seminar Syllabus: Risks and Challenges of Discontinuing Medication (Syllabus). CME Program, Massachusetts General Hospital, Boston, October, 2002, 10 pp.
294. Baldessarini RJ: Seminar Syllabus: Psychopharmacological treatments for bipolar disorder. Residency Training Program, Massachusetts General & McLean Hospitals, Boston, November, 2002, 34 pp.
295. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of antimanic and mood-stabilizing agents. CME Program, Baystate Medical Center, Springfield, MA, November, 2002, 42 pp.
296. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of antidepressants. CME Program, Baystate Medical Center, Springfield, MA, November, 2002, 42 pp.
297. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology of mood-stabilizing and antipsychotic drugs. CME Program, Baystate Medical Center, Springfield, MA, November, 2002, 36 pp.
298. Baldessarini RJ, Tondo L: Bipolar disorder, including hypomania and mania (electronic version). In Smelser NJ, Baltes PB, editors. *International Encyclopedia of the Social & Behavioral Sciences*. Pergamon Press, Oxford, UK, 2002, pp 1240–1245.
299. Baldessarini RJ: Pharmacological treatment of bipolar disorder. In Chapt. 3: Pharmacological Treatment, in Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N, editors. *Evidence and Experience in Psychiatry, Vol 5: Bipolar Disorder*, John Wiley & Sons, New York, 2002, pp 247–248.
300. Jacobs D, Baldessarini RJ, Rosenbaum J: Management of depression in general medical practice, a guideline for physicians. National Depression Screening Program, Wellesley Hills, MA, 2002, 10 pp.
301. Tarazi FI, Baldessarini RJ: Dopamine receptors. Adelman G, Smith BH, editors. *Encyclopedia of Neuroscience*, 3rd edition. Elsevier-Science Press, Amsterdam, Netherlands, 2002, pp 200–204.
302. Zhang K, Baldessarini RJ, Tarazi FI, Neumeyer JL: Selective dopamine D₄ receptor antagonists: Review of structure-activity relationships. *Curr Med Chem CNS Agents* 2002; 2: 259–274.
303. Baldessarini RJ: Course and morbidity in bipolar disorder: New insights (Abstract-Syllabus). Department of Psychiatry, Cambridge Health Alliance, Cambridge, MA, February 2003, 12 pp.
304. Baldessarini RJ: Sections on genetics and therapeutics of suicide. In Jacobs D, editor. *Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors (Part B)*. *Am J Psychiatry* 2003; 160 (11 Suppl): 1–44.
305. Baldessarini RJ: Course and outcome in first-episode bipolar disorder (Abstract & Syllabus). Department of Psychiatry, University of Iowa Grand Rounds series, Iowa City, IO, April 8, 2003, 10 pp.

306. Baldessarini RJ: Neuropharmacological studies of an animal model of ADHD (Abstract & Syllabus). Department of Psychiatry, University of Iowa research seminar series, Iowa City, IO, April 8, 2003, 10 pp.
307. Baldessarini RJ: Course and outcome in first-episode bipolar disorder (Abstract & Syllabus). Department of Psychiatry, University of Minnesota Grand Rounds series, Minneapolis, MN, April 9, 2003, 10 pp.
308. Baldessarini RJ: Pharmacological treatment of bipolar disorder (Syllabus). CME Program, McLean Hospital, Cambridge, MA, June, 2003, 38 pp.
309. Baldessarini RJ: Overview of clinical psychopharmacology (Syllabus). Vertex Pharmaceuticals, Inc., Cambridge, MA, June, 2003, 33 pp.
310. Baldessarini RJ: Course Syllabus: Clinical psychopharmacology for psychotic and major affective disorders. Cape Cod Symposia. New England Educational Institute, Inc., Pittsfield & Eastham, MA, July, 2003, 271 pp.
311. Baldessarini RJ: Long-term outpatient treatment with antipsychotic agents (Syllabus). MGH-McLean Residency Training Program, October, 2003, 20 pp.
312. Baldessarini RJ: Long-term outpatient treatment with mood-stabilizing agents (Syllabus). MGH-McLean Residency Training Program, October, 2003, 20 pp.
313. Baldessarini RJ: Long-term outpatient treatment with antidepressants (Syllabus). MGH-McLean Residency Training Program, October, 2003, 20 pp.
314. Baldessarini RJ: Risks and Challenges of Discontinuing Medication (Syllabus). CME Program, Massachusetts General Hospital, Boston, October, 2003, 10 pp.
315. Baldessarini RJ, Baethge C: Clinical Pharmacology of Antipsychotic Agents (Syllabus). Massachusetts General-McLean Hospital PGY-III Residency Training Program, Boston, October, 2003, 50 pp.
316. Baldessarini RJ, Baethge C: Seminar Syllabus: Preclinical Pharmacology of Antipsychotic Agents. Massachusetts General-McLean Hospital PGY-II Residency Training Program, Boston, October, 2003, 50 pp.
317. Baldessarini RJ: Pharmacological treatment of bipolar disorder (Syllabus). CME Program, Cambridge Health Alliance, Cambridge, MA, November, 2003, 25 pp.
318. Baldessarini RJ: Psychopharmacology Update (Syllabus). Brattleboro Retreat CME Program, Brattleboro, VT, November, 2003, 50 pp.
319. Baldessarini RJ, Baethge C: Clinical Pharmacology of Antipsychotic Agents (Syllabus). Mass. General-McLean Hospital PGY-II Residency Training Program, Boston, November, 2003, 52 pp.
320. Baldessarini RJ: Clinical Pharmacology of Antidepressants (Syllabus). Massachusetts General-McLean Hospital PGY-III Residency Training Program, Boston, December, 2003, 50 pp.
321. Baldessarini RJ: Surviving Depression (Syllabus). Kansas State Psychiatric Association Public Lecture. Topeka, KS, December, 2003, 10 pp.
322. Baldessarini RJ: Psychopharmacology Update (Syllabus). Kansas State Psychiatric Association. Topeka, KS, December, 2003, 50 pp.
323. Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Animal models of attention-deficit hyperactivity disorder. *Brain Res Rev* 2003; 42: 1-21.
324. Neumeyer JL, Booth RG, Baldessarini RJ: Therapeutic and diagnostic agents for Parkinson's disease. Chapt 12 in Vol. 6, Abraham D, editor. *Burger's Medicinal Chemistry and Drug Discovery*, 6th Edition. New York: John Wiley & Sons, 2003, pp 711-741.
325. Tohen M, Baldessarini RJ: Treatments for Bipolar Disorder: Introduction and overview. *Bipolar Disorders* 2003; 5 (3): 153-155.
326. Baldessarini RJ, Tondo L: Suicide risk and treatments for patients with bipolar disorder. *JAMA* 2003; 290: 1717-1519.
327. Baldessarini RJ: Expert consultant for Kane JM, Leucht S, Carpenter D, Docherty JP: Optimizing pharmacologic treatment of psychotic disorders. *J Clin Psychiatry* 2003; 64 (Suppl 12): 1-100.
328. Baldessarini RJ: Clinical psychopharmacology of antimanic and mood-stabilizing agents (Syllabus). MGH-McLean Residency Training Program, Belmont, January, 2004, 48 pp.
329. Baldessarini RJ: Clinical Psychopharmacology-2004: An Update (Syllabus). Brightside Medical System CME Program, Springfield, MA, April, 2004, 50 pp.
330. Baldessarini RJ: Clinical Psychopharmacology-2004: An Update (Syllabus). Brightside Medical System CME Program, Springfield, MA, April, 2004, 50 pp.

331. Baldessarini RJ: Clinical Psychopharmacology–2004: An Update (Syllabus). Brightside Medical System CME Program, Drexel Hill, PA, May, 2004, 50 pp.
332. Baldessarini RJ: Clinical Psychopharmacology-2004 (Syllabus). Cape Cod Symposia, Eastham, MA, July 2004, 285 pp.
333. Baldessarini RJ: Current status of lithium products for treatment of bipolar manic-depressive disorders: Expert report. Instituto Farmacoterapico Italiano (IFI) SpA, Rome, September, 2004, 27 pp.
334. Baldessarini RJ: Clinical Psychopharmacology-2004 (Syllabus). Philippe Pinel Institute of Psychiatry, Montréal, Québec, October, 2004, 225 pp.
335. Baldessarini RJ: Psychopharmacology of Antipsychotic Drugs-2004 (Syllabus). Massachusetts General–McLean Hospitals Residency Training Program, Boston, MA, October 2004, 72 pp.
336. Baldessarini RJ: Clinical Psychopharmacology of antipsychotic drugs-2004 (Syllabus). Massachusetts General–McLean Hospitals Residency Training Program, Belmont, MA, October, 2004, 72 pp.
337. Baldessarini RJ: Clinical Psychopharmacology-2004 (Syllabus). New England Educational Institute, Santa Fe, NM, October 2004, 275 pp.
338. Baldessarini RJ: Psychopharmacology of Mood-Stabilizing Drugs-2004 (Syllabus). Massachusetts General–McLean Hospitals Residency Training Program, Belmont, MA, November 2004, 76 pp.
339. Baldessarini RJ: Course and morbidity in bipolar disorder: New insights (Abstract and syllabus). Dartmouth-Hitchcock Medical Center, Hanover, NH, November 2004, 21 pp.
340. Baldessarini RJ: Clinical Psychopharmacology of Lithium & Other Mood-Stabilizers (Syllabus). Massachusetts General–McLean Hospitals Residency Training Program, Boston, MA, November 2004, 76 pp.
341. Bratti IM, Baldessarini RJ, Baethge C, Tondo L: Pretreatment episode count and response to lithium treatment in manic-depressive illness (Greek translation). *Harvard Rev Psychiatry* 2004; 11 : 29–39.
342. Tarazi FI, Zhang, Baldessarini RJ: Review: Dopamine D₄ receptors: Beyond schizophrenia *J Recept Sig Transduct* 2004; 24: 131–142.
343. Baldessarini RJ: Clinical Psychopharmacology of Antidepressants–2005 (Syllabus). Mass. General–McLean Hospitals Residency Training Program, Belmont, MA, January, 2005, 58 pp.
344. Baldessarini RJ: Clinical Psychopharmacology-2005 (Syllabus). Mental Health Association of New Brunswick, Edmunston, NB, April, 2005, 275 pp.
345. Baldessarini RJ: Relationships of antidepressant to suicidal behavior (Syllabus). Symposium on antidepressants and suicide. Eli Lilly Research Center, Indianapolis, IN, June, 2005, 15 pp.
346. Baldessarini RJ: Update on treatment of bipolar disorder (Syllabus). McLean Hospital CME program, Cambridge, MA, June 2005, 70 pp.
347. Baldessarini RJ: Epidemiology and clinical characteristics of bipolar disorder (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, June 28, 2005, 70 pp.
348. Baldessarini RJ: Update on treatment of bipolar disorder (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, June 28, 2005, 70 pp.
349. Baldessarini RJ: Epidemiology and clinical characteristics of bipolar disorder: IIA (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, June 28, 2005, 70 pp.
350. Baldessarini RJ: Clinical Psychopharmacology-2005 (Syllabus). New England Educational Institute, Eastham, MA, July, 2005, 275 pp.
351. Baldessarini RJ: Clinical Psychopharmacology of antipsychotic drugs-2005 (Syllabus). Massachusetts General–McLean Hospitals Residency Training Program, Belmont, MA, October, 2005, 72 pp.
352. Baldessarini RJ: Update on treatment of bipolar disorder IIB (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, July, 2005, 70 pp.
353. Baldessarini RJ: Update on clinical characteristics and epidemiology of bipolar disorder (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, October, 2005, 25 pp.
354. Baldessarini RJ: Update on treatment of bipolar disorder (Syllabus). Boston University School of Medicine Psychiatry CME program, Boston, MA, October, 2005, 30 pp.
355. Baldessarini RJ: Update on treatment of psychotic disorders (Syllabus). MGH-McLean Residency Training Program, Belmont, MA, October 2005, 30 pp.

356. Baldessarini RJ: Update on treatment of bipolar disorder (Syllabus). MGH-McLean Residency Training Program, Belmont, MA, October 2005, 23 pp.
357. Baldessarini RJ: Update on treatment of major depressive disorder (Syllabus). MGH-McLean Residency Training Program, Belmont, MA, October 2005, 25 pp.
358. Baldessarini RJ: Opening of the modern antipsychotic era: The lithium story. *Aretaeus News (Rome)* 2005; 1 (2): 1–3.
359. Baldessarini RJ: Drug therapy of depression and anxiety disorders. Chapt 17 in Brunton LL, Lazo JS, Parker KL, editors. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, eleventh edition, McGraw-Hill Press, New York, 2005, pp 429–459.
360. Baldessarini RJ, Goodwin FK: Antisuioidal efficacy of lithium products: Citizen's petition to the United States Food and Drug Administration, Washington, DC, September, 2005, 50 pp. Available at www.fda.gov/ohrms/dockets/dockets/05p0402/05p-0402-cp00001-001-vol1.pdf; 10-17-2005.
361. Baldessarini RJ, Tarazi FI: Drugs for psychosis and mania. Chapt 18 in Brunton LL, Lazo JS, Parker KL, editors: *Goodman and Gilman's Goodman and Gilman's The Pharmacological Basis of Therapeutics*, eleventh edition, McGraw-Hill Press, New York, 2005, pp 461–500.
362. Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic agents: A critical overview. *Can Med Assoc J* 2005; 172: 1703–1711.
363. Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon FK, Meltzer HY, Ryan ND, Shaffer D, Wagner KD: ACNP Task Force Report on SSRIs and Suicidal Behavior in Youth. *Neuropsychopharmacology* 2005; 30: 1–20.
364. Tondo L, Albert MJ, Koukopoulos AE, Baethge C, Baldessarini RJ: Bipolar disorder. Chapt. 11 in Tarazi FI, Schatz JA, editors. *Manual of Neurological and Psychiatric Disorders*. Totowa, NJ: Humana Press, 2005, pp 205–227.
365. Viguera AC, Cohen LS, Nonacs RM, Baldessarini RJ: Management of bipolar disorder during pregnancy and the postpartum period: Weighing the risks and benefits. Chapt 3 in Cohen LS, Nonacs RM, editors. *Mood and Anxiety Disorders During Pregnancy and Postpartum*. Review of Psychiatry Series, No. 24. APA Press, Arlington, VA, 2005, pp 53–76.
366. Zhang K, Baldessarini RJ: Attention-deficit/hyperactivity disorder (ADHD). Chapt. 12 in Tarazi FI, Schatz JA, editors. *Manual of Neurological and Psychiatric Disorders*. Totowa, NJ: Humana Press, 2005, pp 229–250.
367. Baldessarini RJ: Clinical Psychopharmacology-2006 (Syllabus). New England Educational Institute, Eastham, MA, July, 2006, 275 pp.
368. Baldessarini RJ, Pompili M, Tondo D: Suicide in bipolar disorder: Risks and management. *CNS Spectrums* 2006; 11: 465–471.
369. Baldessarini RJ, Pompili M, Tondo L: Bipolar disorder. Chapter 13 in Simon RI, Hales RE, editors. *Textbook of Suicide Assessment and Management*, Washington, DC: American Psychiatric Press, 2006, pp 277–299.
370. Baldessarini RJ, Tondo L: Pharmacology of suicide prevention. In Tatarelli R, Pompili M, Girardi P, editors: *Suicide in Psychiatric Disorders*. New York: Nova Publishers, Inc., 2007, pp 193–213.
371. Baldessarini RJ, Tondo L, Faedda GL, Viguera AC, Baethge C, Bratti I, Hennen J: Latency, discontinuation, and re-use of lithium treatment. Chapter 38 in: Bauer M, Grof P, Müller-Oerlinghausen B, editors. *Lithium in Neuropsychiatry: The Comprehensive Guide*. London: Taylor & Francis, 2006; pp 465–481.
372. Zhang A, Zhang Y, Branfman A, Baldessarini RJ, Neumeyer JL: Advances in the development of dopaminergic aporphinoids. *J Med Chem* 2007; 50: 1–11.
373. Zhang A, Neumeyer JL, Baldessarini RJ: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutic agents for neurological and psychiatric disorders. *Chem Reviews* 2007; 107: 274–302.
374. Baldessarini RJ: Clinical Psychopharmacology-2007 (Syllabus). New England Educational Institute, Eastham, MA, July, 2007, 275 pp.
375. Baldessarini RJ, Tondo L: Pharmacology of suicide prevention. In Pompili M, editor: *Suicide in Psychiatric Disorders*. New York: Nova Publishers, Inc., 2007, pp 193–213.
376. Baldessarini RJ: Suicide in psychiatry: risks and treatments (Syllabus). Pri-Med CNE Institute. Boston, January, 2008, 8 pp.

377. Baldessarini RJ: Update on clinical psychopharmacology: a one-week course (Syllabus). New England Educational Institute, Marco Island, FL, February 2008, 250 pp.
377. Baldessarini RJ, Leon A: Basis and impact of the FDA “black-box” warning of an association of suicidal ideation and behavior during treatment with antidepressant drugs in juveniles and young adults: an overview and symposium report. Website of the International Society for CNS Drug Trials and Methodology (ISCTM), February, 2008.
378. Baldessarini RJ: Update on clinical psychopharmacology: a three-day course (Syllabus). New England Educational Institute, Santa Fe, NM, October 2008, 250 pp.
380. Baldessarini RJ: Update on clinical psychopharmacology: a one-week course (Syllabus). New England Educational Institute, Santa Fe, New Mexico, October, 2008, 200 pp.
381. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. *Epidemiol Psi Soc (Rome)* 2009; 18: 179–183.
382. Baldessarini RH: How do doctors select psychotropic medicines? Toward evidence-based psychiatry (Keynote Syllabus and PowerPoint presentation, 25 pp). Proc World Psychiatr Assoc, Florence, Italy, May, 2009.
383. Baldessarini RJ: Epidemiology and therapeutics of bipolar disorder (Syllabus & PowerPoint Presentation; 50 pp). Proc Master Class in Psychopharmacology, Massachusetts Mental Health Center, Boston, MA, May, 2009.
384. Baldessarini RJ: Il Disturbo da Deficit di Attenzione/Iperattività (ADHD). *Medicina delle Tossicodipendenze* 2009; 16 (61): 9–17.
385. Baldessarini RJ: Epidemiology and therapeutics of bipolar disorder (Syllabus & PowerPoint Presentation; 50 pp). Proc CME Program in Psychiatry, McLean Hospital, Boston, MA, May, 2009.
386. Baldessarini RJ: Overview of modern clinical psychopharmacology: positive and negative impact on mental health professions (Keynote Syllabus & PowerPoint presentation, 50 pp). Proc Symposium on Psychopharmacology, Am Psychiatr Nursing Assoc, Reston, VA, June, 2009.
387. Fawcett JA, Baldessarini RJ, Coryell WH, Silverman MM, Stein DJ. Defining and managing suicidality in patients taking psychotropic medications. *J Clin Psychiatry* 2009; 70: 1–8.
388. Baldessarini RJ: Psychopharmacology and Clinical Practice (Syllabus & PowerPoint). Proc Ann Meeting Am Psychiatric Nursing Assoc, Reston, VA, June, 2009, 8 pp (25 slides).
389. Baldessarini RJ: Update on clinical psychopharmacology: a five day course (Syllabus/Powerpoint). New England Educational Institute, Eastham, MA, July, 2009, 250 pp.
390. Viguera AC, Varkula M, Donovan K, Baldessarini RJ: Managing health outcomes of women with schizophrenia during pregnancy and breastfeeding. Chapt 15 in Meyer JM, Nasrallah HA, editors. Washington, DC: American Psychiatric Publishing, Inc., 2009, pp 415–433.
391. Baldessarini RJ (with the Editor). Drugs for depression and bipolar disorder. *Treatment Guidelines from the Medical Letter* 2010; 8: 35–42.
392. Baldessarini RJ, Tondo L. Psychopharmacology for suicide prevention. Chapt 14 in Pompili M, Tatarelli R, editors. *Evidence-Based Practice in Suicidology: A Sourcebook*. Gottingen: Hogrefe Publishing, GmbH, 2010, pp 243–264.
393. Baldessarini RJ, Tondo L. Rate of discontinuation of psychotropic drugs. *Brown University Psychopharmacology Update (Providence, RI)*, 2010.
394. Baldessarini RJ. Clinical Psychopharmacology (Syllabus, PowerPoints). New Engl Ed Institute, Eastham, MA, July, 2010 (250 pp).
394. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Chapt 43 in *Hyperkinetic Movement Disorders* (Weiner WJ, Tolosa E, editors). In *Handbook of Clinical Neurology* (Aminoff MJ, Boller F, Swaab DF, series editors). Edinburgh: Elsevier Press, 2010, pp 601–616.
396. Baldessarini RJ, Vázquez GH, Tondo L. Treatment of cyclothymic disorder: overview and commentary. *Psychother Psychosomat* 2011; 60:131–135.
397. Tondo L, Baldessarini RJ. Antisuicidal effects of lithium-treatment. *Psychiatric Times* 2011; 28[2]:22–26.

398. Baldessarini RJ. The current state of psychopharmacology and psychiatry. *Rev Psiquiatr Salud Ment* 2011; 4 [1]:5–8.
399. Baldessarini RJ. Clinical Psychopharmacology (Syllabus, PowerPoints). New Engl Ed Institute, Eastham, MA, June, 2011 (250 pp).
400. Baldessarini RJ, Tondo L. Psychopharmacology for suicide prevention. Chapt 9 in Pompili M, editor. *Suicide: A Global Perspective*. Sarjah, UAE: Bentham Science Publishers, 2012, pp 114-127.
401. Baldessarini RJ, Pompili M, Tondo L. Bipolar disorder. In Simon RI, Hales RE, editors. *Textbook of Suicide Assessment and Management*, second edition, Washington, DC: American Psychiatric Press, 2012, pp 159–175.
402. Baldessarini RJ. Transcribed interview of Ross J. Baldessarini by David Healy, MD. In Chapt 10, Vol 5: Gershon S, editor. *An Oral History of Neuropsychopharmacology: The First Fifty Years*. Nashville, TN: American College of Neuropsychopharmacology (ACNP), 2011, pp 13–35.
403. Baldessarini RJ. Clinical Psychopharmacology (Syllabus & PowerPoints). New Engl Ed Institute, Eastham, MA, June, 2012 (250 pp).
404. Baldessarini RJ. Psychopharmacology–2012 (Syllabus & Powerpoints). 23rd Cape Cod Summer Seminars. Harvard Medical School, July 2012, 150 pp.
405. Baldessarini RJ. Major Affective Disorders: Overview & Update (Syllabus & PowerPoints). New Engl Ed Institute, Eastham, MA, July, 2012 (283 pp).
406. Baldessarini RJ, Faedda GL, Offidani E, Vázquez GH, Marangoni C, Serra G, Tondo L. Diagnostic changes from major depressive to bipolar disorder and pathological mood-elevation during treatment with antidepressants. *Psychiatric Times* 2013 (8 Nov); 1–2.
407. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye, Malhi, GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin J-M, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Özerdem A, McElroy SL, Girardi P, Bauer M, Yatham YN, Zarate CA Jr, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Eduard Vieta E. International Society for Bipolar Disorders (ISBD) task-force report on antidepressant use in bipolar disorders. *Am J Psychiatry* 2013; 170:1249–1262.
408. Reginaldi D, Koukopoulos A, Baldessarini RJ, Faedda GL, Fazzari G, Girardi P, Kotzalidis G, Manfredi G, Minnai GP, Pascchiarotti I, Raja M, Sani G, Serra G, Tondo L, Vieta E. Transitions: Athansios Koukopoulos (1831–2013). *Int J Bipolar Disord* 2013; 1:17.
409. Ye N, Neumeyer JL, Baldessarini RJ, Zhen X, Zhang A. Recent progress in development of dopamine receptor subtype-selective agents—potential therapeutics for neurological and psychiatric disorders: update. *Chem Rev* 2013; 113:123–178.
410. Gardner D with Baldessarini RJ. Competent psychopharmacology. *Can J Psychiatry* 2014; 59:406–411.
411. Vázquez GH with Baldessarini RJ. Impact of psychopharmacology on contemporary clinical psychiatry. *Can J Psychiatry* 2014; 59:412–516.
412. Baldessarini RJ. Antipsychotics. Chapter 15.2 in Alpert J, Schlozman S (editors). *Introduction to Psychiatry: Preclinical Foundations and Clinical Essentials*. New York: Cambridge University Press, 2015; in press.
413. Baldessarini RJ. Mood-stabilizers. Chapter 15.3 in Alpert J, Schlozman S (editors). *Introduction to Psychiatry: Preclinical Foundations and Clinical Essentials*. New York: Cambridge University Press, 2015; in press.
414. Baldessarini RJ, Pérez J, Salvatore P, Trede K, Maggini C. History of bipolar manic-depressive disorder. Chapt 1 in Yildiz A, Nemeroff C, Ruiz P (editors). *Bipolar Disorder: Millennium Update*, New York: Oxford University Press, 2015, in press.
415. Baldessarini RJ, Tondo L. Lithium in psychiatry. *Rev Neuro-Psiquiatria (Lima)* 2013; 76:189–203.

416. Faedda GL, Marangoni C, Serra G, Savatore P, Sani G, Vázquez GH, Tondo L, Girardi P, Baldessarini RJ, Koukopoulos A. Clinical risk factors for bipolar disorders: a review. PROSPERO Register, York University, UK, 2013; review number CRD42013004613.
417. Tondo L, Baldessarini RJ: Bipolar disorder. International Encyclopedia of the Social & Behavioral Sciences, second edition. Elsevier Press, Oxford, 2015, in press.
418. Vázquez GH, Baldessarini RJ, Tondo L. Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview. *Depression Anxiety* 2014; 31:196–206.
419. Tondo L, Baldessarini RJ. Reduction of suicidal behavior in bipolar disorder patients during long-term treatment with lithium. Chapt 26 in Koslow SH, Ruiz P, Nemeroff CB (editors): *A Concise Guide to Understanding Suicide*. Cambridge, UK: Cambridge University Press, 2014, pp 217–228.
420. Tondo L, Baldessarini RJ. Suicide in bipolar disorder. Chapt 37 in Yildiz A, Nemeroff C, Ruiz P (editors). *Bipolar Disorder: Millennium Update*, New York: Oxford University Press, 2015, in press.
421. Tondo L, Vázquez GH, Baldessarini RJ. Treatment-resistant depression in bipolar disorder. *Curr Psychiatry Rep* 2015; in press.
422. Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Nature and management of co-occurring psychiatric illnesses in bipolar disorder patients: focus on anxiety syndromes. In *Bipolar Disorder*, edited by Yildiz A, Nemeroff C, and Ruiz P. New York: Oxford University Press, 2014, in press.
423. Ventriglio A, Baldessarini RJ. Impact of early life stress on psychiatric disorders: searching new biomarkers and innovative pharmacological targets. *Curr Ther Design* 2014; in press.

BOOKS

1. Baldessarini RJ: An Architectural History of North Adams, Massachusetts (thesis). Williams College, Williamstown, MA and North Adams Public Library, North Adams, MA, 1958, 100 pp.
2. Baldessarini RJ: Antivitamin Compounds of Biotin (thesis). Williams College, Williamstown, MA, 1959, 117 pp.
3. Baldessarini RJ: Chemotherapy in Psychiatry. Harvard University Press, Cambridge, MA, 1977, 201 pp.
4. Baldessarini RJ: Mood Drugs. *Disease-a-Month*, New York, November, 1977, 65 pp.
5. Baldessarini RJ, Maffei F, Andreoli V: Farmacoterapia in Psichiatria. Masson-Italia, Milan, Italy, 1978, 160 pp.
6. Reichlin S, Baldessarini RJ, Martin, editors: The Hypothalamus, Association for Research in Nervous and Mental Diseases (ARNMD) Series, No. 56. Raven Press, New York, NY, 1978, 490 pp.
7. Baldessarini RJ, Aoba A: Chemotherapy in Psychiatry (Japanese language edition). Igaku-Shoin, Tokyo, Japan, 1980, 193 pp.
8. Baldessarini RJ (Chairman-Editor), Cole JO, Davis JM, Gardos G, Simpson G, Tarsy D: Tardive Dyskinesia, American Psychiatric Association Task Force Report No. 18. American Psychiatric Association, Washington DC, 1980, 205 pp.
9. Baldessarini RJ: Chemotherapy in Psychiatry (Spanish language edition). Fondo de Cultura Economica, Mexico DF, Mexico, 1981, 226 pp.
10. Baldessarini RJ: Biomedical Aspects of Depression and Its Treatment. American Psychiatric Press, Inc., Washington, DC, 1983, 163 pp.
11. Baldessarini RJ (ed): Movement Disorders and Tardive Dyskinesia (special issue). *J Clin Psychiatry* 1985; 46 (4:2): 1–53.
12. Baldessarini RJ: Chemotherapy in Psychiatry: Principles and Practice (second edition). Harvard University Press, Cambridge, MA, 1985, 354 pp.
13. Baldessarini RJ, Tohen M: Las Bases Biomedicas de la Depression y Su Tratamiento (Spanish language edition). LaPrensa Medica Mexicana, Mexico City DF Mexico, 1986, 147 pp.
14. Baldessarini RJ, Maffei F, Andreoli V: Farmacoterapia in Psichiatria (second Italian edition). Masson et Cie., Milan, Italy, 1987, 375 pp.
15. Baldessarini RJ, Fleischhacker W, Sperk G: Pharmakotherapie in der Psychiatrie (first German edition). Georg Thieme Verlag, Stuttgart, Germany, 1991, 223 pp.
16. McDonald JC, Zarate CA Jr, Siegel AJ, Baldessarini RJ: McLean Hospital Formulary, Belmont, MA: McLean Division of Massachusetts General Hospital, 1995, 117 pp.

17. McDonald JC, Zarate CA Jr, Siegel AJ, Baldessarini RJ, Douglas C: McLean Hospital Formulary. McLean Hospital, Belmont, MA, 1997, 96 pp.
18. Shelton RC, Thase ME, Kowatch R, Baldessarini RJ: Update on the management of bipolar illness. *J. Clin. Psychiatry* 59: 1–12, 1998.
19. Baldessarini RJ, Jamison K, editors: Effects of Medical Interventions on Suicidal Behavior (Special Supplemental Issue). *J Clin Psychiatry* 1999; 60 (Suppl 2), 122 pp.
20. Centorrino F, Baldessarini, RJ, editors: Treatment of Bipolar Disorder. *Noös–Aggiornamenti in Psichiatria* Rome, 2000, 120 pp.
21. Tohen M, Baldessarini RJ, editors: Treatments for Bipolar Disorder. Special issue of *Bipolar Disorders* 2003; 5 (3): 153–225.
22. Jacobs DG, Baldessarini RJ, Fawcett JA, Horton L, Meltzer HY, Pfeffer CR, Simon RI: Practice Guideline for the Assessment and Treatment of Patients with Suicidal Behaviors. *Am J Psychiatry* 2003; 160 (11 Suppl): 1–60.
23. Baldessarini RJ: Psychiatric treatments vs. suicidal risk. In Mann J, editor. Task Force Report on Treatment and Suicide Risk. American College of Neuropsychopharmacology, Nashville, TN, June, 2004, 20 pp.
24. Baldessarini RJ. *Chemotherapy in Psychiatry: Pharmacologic Basis of Treatments for Major Mental Illness*, third edition. New York: Springer Press, 2013.
25. Baldessarini RJ. *Chemotherapy in Psychiatry: Pharmacologic Basis of Treatments for Major Mental Illness*, third edition. On-line edition, 2013. Accessible at <<http://dx.doi.org/10.1007/978-1-4614-3710-9>>.
26. Baldessarini RJ. *Chemotherapy in Psychiatry: Pharmacologic Basis of Treatments for Major Mental Illness*, third edition. Paperback edition, 2013.

PATENTS

1. Neumeyer JL (with Baldessarini RJ, Szabo S): (–)10,11-Methylenedioxy-N-n-propylnorapomorphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers. US Patent: 4,543,256, September 24, 1985.
2. Neumeyer JL, Baldessarini RJ: (+)N-n-propylnorapomorphine and selective limbic activity. US Patent 4,617,773, August 18, 1987.
3. Baldessarini RJ, Campbell A: Method of dopamine inhibition using *l-threo*-methylphenidate. US Patent 6,221,883-B1, April 24, 2001.
4. Baldessarini RJ, Zhang K, Tarazi FI: Dopamine D₄ receptor antagonists as treatment for Attention Deficit-Hyperactivity disorder (ADHD). US Patent 6,747,029, June 8, 2004.
5. Neumeyer JL, Baldessarini RJ: R(–)-11-hydroxyaporphine derivatives [amides] and uses thereof. US Patent 7,648,995, January 19, 2010.
6. Neumeyer JL, Baldessarini RJ: R(–)-11-hydroxyaporphine derivatives [esters] and uses thereof. US Patent 8,063,060-B2 November 22, 2011.

FILMS, TAPES & CDs

1. Baldessarini RJ: Biogenic Amine Theories of Depression (educational videotape). Network for Continuing Medical Education, New York, NY, 1975.
2. Baldessarini RJ: Neurological Side Effects of Antipsychotic Drugs (educational audiotape) for Abernathy R (ed): Continuing Education Program, Vol. 1 (Tape 1), Educational Reviews, Inc., Leeds, AL, 1976.
3. Baldessarini, R.J.: Basis for Amine Hypotheses in the Affective Disorders (educational film, based on a symposium in Miami, FL). American Psychiatric Association, Washington, DC, May, 1976.
4. Tarsy D, Granacher RP, Baldessarini, RJ: Cases of Tardive Dyskinesia (educational film). Massachusetts General Hospital and Boston Veterans Administration Hospital, Boston, 1976.
5. Baldessarini RJ: Use of Antidepressants (educational audiotape). Sandoz Laboratories, New York, 1977.
6. Baldessarini RJ: Neurologic aspects of psychotropic drugs, in *The Autonomic Nervous System* (set of educational audiotapes). American Academy of Neurology and Educational Marketing Corp., Minneapolis, 1977.
7. Baldessarini RJ: Mood Drugs (educational audiotape). Year Book Publishers, Chicago, 1977.

8. Baldessarini RJ, Granacher RP: Toxicity of Antidepressants (educational audiotape). Pfizer Laboratories, New York, 1977.
9. Baldessarini RJ: Lithium: Part I: Pharmacology (educational audiotape). Educational Reviews, Inc., Leeds, AL, 1978.
10. Baldessarini RJ: Lithium: Part II: Clinical Use and Toxicity (educational audiotape). Educational Reviews, Inc., Leeds, AL, 1978.
11. Baldessarini RJ: Neurotransmitters (educational audiotape), in Woods B (ed): Biological Aspects of Psychiatry. Audiovisual Medical Marketing, Inc., New York, 1981.
12. Baldessarini RJ: Schizophrenic Disorder (educational videotape), in Interviewing Techniques in Psychiatry, Tape 4A. Audiovisual Marketing, Inc., New York, NY, 1983.
13. Baldessarini RJ: Clinical Pharmacology of Antipsychotic Drugs (educational audiotape), in Abernathy R, editor. Practical Reviews in Psychiatry 7(8). Educational Reviews, Inc., Leeds, AL, 1983.
14. Baldessarini RJ, Michels R: Clinical Evaluation of Hospitalized Psychiatric Patients (educational videotape), Jacobs D, editor. Hospital Corporation of America, Nashville TN, 1986.
15. Baldessarini RJ: The Essence of Inpatient Psychiatry (educational videotape; 4 reels). Jacobs D, Brouillette D, editors. HCA Psychiatry Company, Nashville, TN, 1986.
16. Baldessarini RJ: Recent Advances and Future Prospects in Psychopharmacology (educational audiotape, 90 min.). Psychiatric Times Co., Santa Ana, CA, 1987.
17. Baldessarini RJ: Understanding Mental Illness: Biomedical Aspects of Contemporary Psychiatry (educational videotape, 60 min). "Talk About the Mind" Program, Dreyfus JE (Host). Milton Cablesystems, Milton, MA, December 1988.
18. Baldessarini RJ: Clinical pharmacology of antidepressants and mood stabilizing agents (educational videotape, 2 hours), Ballenger J, editor. Medical University of South Carolina, Charleston SC, June, 1989.
19. Baldessarini RJ: Update on Antidepressants (educational audiotape), Abernathy R, editor. Educational Reviews, Inc., Birmingham, AL, 1989.
20. Baldessarini RJ, Tohen M: Review of the Psychosis Program of McLean Hospital (educational videotape), Hillgren K, moderator. Sadra sjukvirdsomridet, Stockholm, Sweden, September, 1989.
21. Baldessarini RJ: Long-Term Treatment with Antipsychotic and Mood-Altering Agents (educational videotape, 2 hours). Psychiatry Update Series, Medical University of South Carolina, Charleston SC, June 1990.
22. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (10 one-hour audiotapes). New England Educational Institute, Pittsfield, MA, July, 1992.
23. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1993.
24. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1994.
25. Baldessarini RJ: Treatment of mania through the life-cycle (1 hour of audiotape). Healthlink Communications, Inc., Toronto, Ontario, October, 1994.
26. Baldessarini RJ: Risks of interrupting maintenance therapy with psychotropic medications. Directions in Psychiatry Audio Tape Series (vol. 15:11); Hatherleigh Company, New York: 30 min, June, 1995.
27. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1995.
28. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1996.
30. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1997.
31. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1998.
32. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 1999.
33. Baldessarini RJ: Lithium and suicide risk in bipolar disorder (12 nationwide audioconferences, 90 min each). Interactive Network for Continuing Education (INCE), Monmouth Junction, NJ, March-April, 2000.
34. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 2000.
35. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 2001.

36. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 2002.
37. Goodwin FK, Baldessarini RJ, Dunner DL: The use of lithium in treating bipolar disorder (12 pp teaching CD). MBL Communications for CNS Spectrums, New York, 2003.
38. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audiotapes). New England Educational Institute, Pittsfield, MA, July, 2003.
39. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2004.
40. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2005.
41. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2006.
42. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (15 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, October, 2006.
43. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2007.
44. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2008.
45. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2009.
46. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2010.
47. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2011.
48. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2012.
49. Baldessarini RJ: Clinical Psychopharmacology: Recent Advances (20 hours of audio-CDs). New England Educational Institute, Pittsfield, MA, July, 2013.

Ross J. Baldessarini
June 11, 2015

[1018 Additional abstracts, syllabi & brief reports are not shown]